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Abstract

SPECIFIC LEVELS OF THERAPEUTIC ULTRASOUND STIMULATE THE
RELEASE OF INFLAMMATORY AND ANGIOGENIC MEDIATORS FROM
MACROPHAGES IN CULTURE
By Thomas Todd Turner, P.T, Ph.D
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Sheryl D. Finucane
Assistant Professor, Department of Physical Therapy

Therapeutic ultrasound (TUS) is a treatment modality that is used to accelerate
tissue healing. TUS is thought to affect cellular processes of tissue healing, especially
those that occur in the inflammatory and early proliferative phases. TUS can be applied
using various parameter selections including intensity, wavelength, duty cycle and
treatment duration and no clear consensus exists on optimal parameters for healing
enhancement. Macrophages are important mediators of inflammation and their actions are
critical to normal progression into the proliferative phase of healing. They complete many
functions during these periods of tissue healing, among those being release of cytokines
and growth factors. These paracrine factors affect other inflammatory cells, resident cells
xv

of the healing tissue, including fibroblasts and endothelial cells that are necessary for
restoration of damaged tissue. The hypothesis of this investigation is that TUS enhances
early healing, in part, through stimulation of macrophage release of paracrine factors
involved in coordination of the cellular aspects of tissue healing and that specific levels of
TUS are most stimulatory for macrophages. This study examined macrophage release of
interleukin-1 (IL-1 ), vascular endothelial growth factor (VEGF), transforming growth
factor- 1 (TGF- 1) and fibroblast mitogens, in response to varied levels of TUS.
Fibroblasts incubated up to 48-hours in media conditioned by TUS-stimulated
macrophages were not induced to proliferate regardless of the parameters sets of TUS
applied. TUS (1 MHz, 400mW/cm2 SATA, 20% duty cycle, 10-minute exposure) induced
macrophage release of VEGF and IL-1 within 10-minutes post-TUS, without any
additional release being stimulated at 1-hour post-insonation. No other combination of
TUS parameters studied induced release of IL-1 and VEGF. TUS did not induce release
of TGF- 1 at either time point post-TUS. VEGF and IL-1 release occurred in
conjunction with lactate dehydrogenase (LDH) release from treated macrophages,
indicating non-specific cell membrane permeabilization was involved in the cellular
response. For IL-1 , TUS-stimulated release was inhibited at lower exposure
temperatures. Inhibition of TUS-induced release at lower temperatures indicates that a
cellular metabolic process, most likely exocytosis, was also stimulated by TUS. Based on
these results, it appears that TUS exposure at 1 MHz, 400mW/cm2 SATA, 20% duty cycle
induces non-specific and cell-mediated release of secretory proteins. Thus, enhanced

xvi

release of cytokines and growth factors from macrophages is a possible mechanism by
which TUS enhances tissue healing.

This document was created in Microsoft Word 2007.

xvii

Chapter 1
Therapeutic Ultrasound and Tissue Healing: Review of
Literature

Introduction
Therapeutic ultrasound (TUS) has been utilized for over sixty years in the clinical
setting and continues to be widely used to treat a variety of conditions. Typical clinical
rationale for its use include; reduction of edema and pain, acceleration of tissue repair, and
modification of scar formation 1,2. Despite frequent clinical use, there is a deficiency in the
understanding of the mechanism of action of TUS on various tissues, and also a dearth of
scientifically generated treatment parameters for achieving the optimal effect of TUS.
As will be discussed in the following review, TUS has been studied using various
experimental methods: 1) in vitro cell culture experiments, 2) in vivo animal experiments,
and 3) clinical trials. Many in vivo and in vitro studies have noted beneficial effects of
TUS on healing of injured tissues namely, integument, ligaments, tendons and bone 3-12.
This enhanced tissue healing, appears to be greatest when TUS is applied during the
inflammatory phase of healing 13-16.

1

Much of the research on TUS effects on fracture healing has utilized a common set
TUS treatment parameters: 1.5 MHz, 30 mW/cm2, 20% pulsed wave (PW), 20-minute
treatments. Experimental investigations using these TUS exposure parameters have
generated data that demonstrate the benefit of TUS on fracture healing in various research
models 17-22. Use of a standardized parameter set allows direct comparison of findings
among a variety of studies. In addition, identification of a consistently effective TUS dose
creates a comparison point for other TUS parameter sets for clinical effectiveness and
cellular effects.
Among the body of investigations on soft tissue healing, many variant TUS
application parameters have been reported to generate beneficial effects 4,23-27. However,
definition of optimal TUS application parameters has not been accomplished. The
following will examine the molecular, biochemical and mechanical effects of TUS on cells
and tissues and how those effects relate to enhanced healing.

Ultrasound Parameters
Ultrasound consists of high frequency sound waves generated by conversion of
electrical energy into mechanical energy, utilizing a piezoelectric crystal 28.
Piezoelectricity is a material property of natural and synthetic crystals and it defines the
process by which a crystal produces an electrical voltage when compressed and produces
an electrical voltage of opposite polarity when expanded 29. Using a reverse piezoelectric
effect TUS transducers create an alternating voltage across a crystal, which causes the
crystal to expand and contract and results in the establishment of high frequency waves of
2

pressure within the ultrasound spectrum. These ultrasound waves are propagated through a
medium at the same frequency as the alternating current, and this propagating pressure
wave can produce a mechanical force when applied to biological tissues 30-32. Wave
propagation through tissues occurs via molecular collision and vibration, and the induced
molecular vibration results in energy absorption and heating of tissue 31. As the sound
wave propagates through tissue, a progressive loss of energy occurs due to absorption and
scattering of the wave. This process, known as attenuation, results in a decrease in the
intensity of the sound wave as it penetrates deeper into tissue 33. Different tissues absorb
ultrasound energy to varying degrees, based mainly on protein content 34. Bone, followed
by ligaments and tendons, absorb energy most readily. By comparison, skin and muscle
absorb intermediate amounts, with adipose tissue absorbing the least 31.
Ultrasound is typically applied therapeutically in the frequency wavelength range
of 0.75 to 3.0 MHz 35. Higher frequency (3 MHz) sound waves are thought to cause more
rapid movement of molecules resulting in greater attenuation of ultrasound energy at more
superficial levels and a reduced depth of penetration into tissue when compared to lower
frequency sound waves (1 MHz) 31. TUS exposure at 1 MHz has been shown to produce
tissue heating to a depth of 5 cm while 3 MHz is attenuated at more superficial levels with
heating confined to < 2 cm below the treated surface in human lower extremities 36.
Energy emitted from the transducer is not uniform across the crystalline surface of
the TUS transducer; rather, hot spots of intense energy can develop along portions of the
transducer during sonication 28,32. Two methods are used to reduce the heating effect of
TUS. Constant slow, gentle movement of the transducer over the target site eliminates
3

heat buildup generated by the hot spots that would otherwise remain over one site for the
full duration of treatment. This moving applicator method is most often employed when
treating tissues with a continuous wave (CW) application, which has a greater propensity
to result in heating. The second method to reduce the heating effect is to apply TUS in a
pulsed-wave (PW) mode in which “off” periods interrupt the sound waves. The percentage
of total treatment time during which US energy is being emitted is referred to as the duty
cycle. A 20% duty cycle is used most often clinically and in research reports, however,
duty cycles of 10%, 25%, 33%, and 50% are available on most TUS generators 1,33,37.
Beyond reduced tissue heating, the effect of different duty cycles on the overall efficacy of
TUS is unknown.
The intensity of applied ultrasound is defined as the rate of energy delivery per unit
area of the transducer (watts/cm2), with typical therapeutic values of 30-2000 mW/cm2 2.
The total amount of energy delivered to a specific site by TUS varies as a function of the
tissue location, the types and numbers of tissue interfaces, the TUS intensity and duty
cycle utilized, and the total duration of treatment. TUS exposure dosage is often reported
as the “spatial average, temporal average” (SATA). Multiplying the duty cycle by the
intensity of exposure generates the SATA value. The resultant SATA value can then be
used to compare more directly, the overall TUS dosage between different investigations.
For example, the different treatment parameters below result in an identical SATA value of
400 mW/cm2 (with treatment duration remaining the same for each set):
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2000 mW/cm2 at 20% duty cycle is: 2000 mW/cm2 x 20% = 400 mW/cm2 SATA
800 mW/cm2 at 50% duty cycle is: 800 mW/cm2 x 50% = 400 mW/cm2 SATA
400 mW/cm2 at 100% duty cycle is: 400 mW/cm2 x 100% = 400 mW/cm2 SATA

Given the variance in available TUS intensities and wavelength frequencies (0.75
to 3 MHz), the disparity between the depth and amount of energy absorption among tissue
types, measurement of the TUS energy that is imparted to tissues is inexact. In addition,
many of the studies discussed in this review utilized different intensities, frequencies,
durations, and repetitions of TUS exposure. Therefore conclusions and generalizations
about TUS effects in relation to dosage are often limited and additional study is needed to
identify optimal TUS parameters for specific effects. The next section of the review will
focus on cellular and tissue processes affected by TUS, with emphasis on the biological
effects on healing tissues.

Proposed Biophysical Mechanism of TUS: Thermal
The physical mechanism(s) of TUS that generate cellular responses are typically
divided into two classifications, thermal and nonthermal. Thermal effects are believed to
create increased metabolic activity due to elevated temperature as TUS propagates through
tissues. Propagation of the ultrasound wave results in absorption of energy by tissues, via
molecular vibration and friction in sonicated tissue, with the extent of energy absorbed
being dependent on the physical characteristics of the intervening tissues 31,38. In general,
increased temperature (> 1ºC) is believed to increase metabolic activity in cells and
5

tissue 39. According to Lehman, temperature increases of 2-3 C and > 4 C produce
increased blood flow and increased collagen extensibility, respectively 40.
The ability of TUS to increase tissue temperature has been demonstrated
experimentally. Using hogs, TUS applied to knee joints at 1 MHz, 1500 mW/cm2 SATA,
CW for 5 minutes has been reported to result in a temperature increase of 4-8 C at 5 cm
below the sonication surface 41. Measuring at fixed tissue depths (2.5 and 5.0 cm for 1
MHz) and (0.8 and 1.6 cm for 3 MHz) Draper et al investigated tissue heating in humans
following TUS and reported average temperature elevation of 3-4 C in calf musculature of
subjects measured at a depth of 5 cm when treated with TUS (1 MHz, 1500 mW/cm2
SATA, CW, 10 minutes) 36,42. Sonication at lower intensities (500 mW/cm2 or 1000
mW/cm2 SATA) resulted in heating of 0.4 C and 1.6 C, respectively at a depth of 5 cm.
TUS application at 3 MHz, CW at intensities between 500-2000 mW/cm2 SATA resulted
in temperature increases of 3-6 C at 1.6 cm tissue depth 36. These results appear to
confirm the correlation between TUS frequency and depth of tissue heating. However, by
measuring at fixed depths for each frequency, the depth limit of heating was not
completely investigated. Using cadaveric specimens, Cambier et al reported increased
temperature of nearly 5 C at a depth of 3 cm, following 10-minute sonication (1MHz,
1000-2000 mW/cm2 SATA) of the legs of human cadavers while Demmink et al reported
tissue heating of 4 - 8 C in pig hind limbs treated with varying CW TUS frequencies (0.86,
2.0 and 3.0 MHz) for 5 minutes at 2000 mW/cm2 SATA 43,44.
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In rats, CW TUS was reported to accelerate restoration of joint motion following
experimentally induced knee-joint contractures. The authors attributed the increased
motion to increased extensibility of peri-articular structures due to TUS-induced heating 45.
The effect of TUS on tissue extensibility in humans has been reported for healthy subjects
only and with conflicting results. In separate studies using healthy female subjects, triceps
surae extensibility was increased due to TUS application, however, medial collateral
ligament extensibility was not influenced by TUS 46,47. The importance of these findings
in humans is questionable given that the increasing extensibility of healthy connective
tissue is not a rationale for TUS application. Furthermore, increased extensibility of
healthy tissues may create laxity of supporting structures (i.e. ligaments) and be
detrimental to the supportive role of connective tissues.
The overall evidence supports the ability of TUS to heat tissues to therapeutic
levels (temperature rise of at least 1 and up to 5 C) given a high enough intensity and long
enough treatment duration. Thus, it is reasonable to conclude that TUS can have a thermal
affect on tissues. However, TUS dose necessary to heat tissues to therapeutic levels, and
the effect of TUS-induced tissue heating on healing, tissue mechanics or metabolic
properties remains undefined.

Proposed Biophysical Mechanism of TUS: Nonthermal
Beyond the effects generated through heating, TUS also affects treated tissue via
nonthermal actions. These non-thermal mechanisms are typically divided into acoustic
cavitation and acoustic streaming. Both mechanisms are theorized to create shearing
7

forces along membranes of cells and organelles, subsequently altering membrane
permeability 31,32,48. Furthermore, alterations in ion flux, especially calcium (Ca2+) are
thought to result in extracellular matrix molecule (ECM) production, secretion of growth
factors and cytokines, cell proliferation and changes in cell motility 7,49-54. All of these
TUS-stimulated cellular functions occur during normal tissue healing processes and
provide a theoretical framework for investigation of TUS and tissue healing.

Acoustic Cavitation.
Cavitation describes the formation and activity of gas or vapor filled cavities when
a medium (fluid) is exposed to an ultrasonic field 29. These phenomena are separated into
inertial and stable cavitation. Inertial cavitation describes gas bubbles that grow in size
then collapse violently, generating locally high temperatures and pressures and this form of
cavitation has been shown to induce cellular damage in mammalian cells and in general its
effects are believed to be detrimental to cells 55,56. Inertial cavitation has been shown to
occur as a result from exposure of fluid media to ultrasound, particularly in response to
high intensity, pulsed ultrasound (> 3 W/cm2) 29. These high intensity ultrasound
exposures have been investigated as a method for gene delivery and are not typical of TUS
parameters. The effectiveness of these treatments are reported to be directly associated
with acoustic cavitation, but the high intensities are greater than what is considered to be
TUS (< 2000 mW/cm2) 57,58.
Stable cavitation differs from inertial cavitation in that the gas bubbles oscillate in
size as a result of ultrasonically induced pressure changes without any collapse occurring.
8

Ultrasound-induced pressure waves enable production of high velocity gradients of
oscillating bubbles at membrane-medium interfaces, and these gradients are hypothesized
to generate shear forces on cell membranes and subsequently change membrane
characteristics, most notably, permeability 29,31. Stable cavitation induced by TUS has
been reported in a number of in vitro models, but its relationship to cellular response has
not been clarified. Cavitation during TUS exposures has been associated with membrane
permeability changes in epithelial cells, and increased collagen synthesis by fibroblasts
treated with TUS 59,60.
Evidence of cavitation following in vivo TUS is limited and contradictory. Stable
bubble formation has been measured in guinea pig hind limbs treated with a single, 5minute TUS exposure (0.75 MHz, 80-680 mW/cm2 SATA, 25% PW) 61,62. The authors
reported that development of cavitation bubbles was directly proportional to increasing
TUS intensity. However, the authors admitted difficulty in interpretation of their images
due to artifact when using a pulse-echo ultrasound imaging to detect cavitation. In
contrast, Gross et al applied TUS to canine left ventricles for 2 to 5 minutes (0.51 MHz 1.61 MHz, 125 - 16,000 mW/cm2 SATA) and reported no bubble formation at any
frequency, intensity or duration tested 63. Given the unique composition of the fluid-filled
heart and unique characteristics of the moving fluid compared to tissues typically treated
with TUS (i.e., ligaments, tendons, integument, bone), it is difficult to generalize their
findings to other tissues.
Based on the available evidence it appears that cavitation can occur during in vitro
TUS exposures. However, the link between cellular responses and TUS-induced cavitation
9

has not been identified. Regarding in vivo exposures, additional evidence to support TUSinduced cavitation in the hind limbs of guinea pigs has not been reported. Given this
limited evidence for in vivo cavitation and the unclear relationship between in vitro
cavitation and cellular response, it is premature to conclude that TUS effects are mediated
by cavitation.

Acoustic Streaming
Acoustic streaming is referred to as movement of fluid in a propagating ultrasonic
wave and is classified as either bulk streaming or microstreaming 31. Microstreaming is
the result of eddies of fluid flow around TUS-induced vibrating gas bubbles. By
definition, the occurrence of microstreaming is dependent on cavitation, since movement
of gas bubbles in the media is necessary to create fluid flow. Bulk streaming describes
propagation of unidirectional fluid flow by an ultrasound pressure wave.
Microstreaming due to TUS exposure has not been reported, but bulk streaming has
been measured during in vitro sonication of human bone cells 64. The authors found
measurable bulk streaming at intensities of 130, 480 and 1770 mW/cm2 SATA when TUS
was applied at 3 MHz, CW for 10 minutes. In addition, gene expression of transforming
growth factor- (TGF- ) was up-regulated at all three TUS intensities, which suggests a
possible role of bulk streaming in generating a cellular response. No other evidence has
been reported to support the role of either type of acoustic streaming as a mechanism of
action of TUS. This may be due to the difficulty in measuring these phenomena given the
available experimental models and monitoring equipment.
10

Free Radicals
Formation and activity of free radicals following TUS exposure is another proposed
mechanism to explain the action of TUS. Because free radicals are capable of disrupting
cell membranes, via peroxidation of lipid components, their formation has been
hypothesized to be responsible for permeability changes and subsequent alterations in
cellular activity following TUS application 65. Free radical formation has also been
reported in cultured frog skin exposed to TUS 66. The sonicated tissue (1 MHz, 300
mW/cm2 SATA, CW, 4 minutes) exhibited increased ionic conductance that was
eliminated by adding free radical scavengers to the bathing media. Ultrasound exposure at
various intensities 500-3000 mW/cm2 SATA and variable duty cycles (15% to 100%) has
also been reported to induce free radical production in sonicated tap water 67. To date
however, no evidence of TUS-induced free radical production has been reported in vivo.
Free radicals do exist in tissues, but free radical scavengers often limit their
actions 66. Proponents of a free radical mechanism of action of TUS suggest that
scavengers protect membranes from damage, but do allow some reactions to occur that
would account for increased permeability 32. On the other hand, an increase in free
radicals could exceed the ability of tissue to control oxidizing reactions, thereby resulting
in cell membrane damage rather than enhancement of cellular activities.

Conclusion: Nonthermal Mechanisms of Action
It is unclear which, if any, of the proposed non-thermal mechanisms have a role in
the actions of TUS. The preponderance of evidence does not indicate the most likely
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candidate mechanism, and it may be that the final response to TUS exposure occurs due to
components of each mechanism. The findings of Harle et al, in which the authors reported
measurement of cavitation and bulk fluid streaming during in vitro TUS treatment of
human osteoblasts appear to support the hypothesis of multiple mechanisms being
responsible for TUS effects64.

TUS and Tissue Healing
TUS enhancement of healing is supported for many injured tissues, but the nature
and extent of its effect on healing, much like the mechanism of action, is not fully
understood. The effects of TUS on tissue healing have been described in numerous models
and tissue types including dermal wounds, ligaments, tendons, and bone as well as for a
variety of cell types involved in the healing process. The overall body of evidence
provides a strong basis for enhancement of healing following exposure to TUS.
A variety of TUS treatment parameters have shown an ability to improve numerous
aspects of tissue healing, with the greatest support for the benefits of TUS being reported
for acceleration of fracture healing. Fibroblasts, chondrocytes, osteoblasts, muscle satellite
cells, Schwann cells, endothelial cells, monocytes, macrophages, spleenocytes, and
thymocytes have demonstrated responsiveness to TUS exposure with in vitro and in vivo
models. The following sections will describe the relevant findings regarding TUS effects
on tissues and cells. Where appropriate, differential responses based on the exposure
parameters will be discussed. Lastly, evidence describing TUS affects on the early phases
of healing, especially the inflammatory phase, will be presented in an effort to clarify the
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hypothesis that the most beneficial aspects of TUS occur when exposures are given during
early stages of the healing process.

Fracture Healing
The ability of TUS to enhance fracture healing is strongly supported by various
investigations. Clinical trials, as well as numerous in vivo and in vitro models, have
consistently generated results indicating that TUS positively alters processes that occur
during fracture healing. Unlike studies of TUS effects on soft tissue healing discussed
later, a majority of reports investigating TUS effects on fracture healing have utilized the
same set of TUS parameters (1.5 MHz, 30 mW/cm2 SATA, 20% PW, 20 minutes). An
ultrasound generator designed to transmit TUS energy at these specific settings for
acceleration of fracture healing is available clinically and is referred to as the “Sonic
Accelerated Fracture Healing System” (SAFHS) 68. Development and use of this TUS
device permits more liberal inter-study comparison and generalization of results.
In vivo studies utilizing rabbits, rats, dogs and sheep have demonstrated TUSenhanced healing of experimentally induced fractures. At 21 days post-injury, healing
femoral fractures in rats had increased maximum torque to failure and torsional stiffness
compared to untreated fractures after daily TUS exposures (0.5 MHz, 50 and 100 mW/cm2
SATA, 20% PW, 15 minute treatments) 69. The increased callus strength coincided with
increased expression of aggrecan mRNA, up to two weeks post-injury. Azuma et al
reported increased strength of healing femoral fractures in rodents following sonication at
SAFHS parameters 22. TUS exposures were given in varied interval schedules post-injury:
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days 1-8, 9-16, 17-24, and 1-24. Overall the effect of repeated TUS exposures appeared to
be additive such that 24 consecutive treatments post-injury resulted in the greatest
improvement in fracture strength compared to controls and the other treatment intervals.
TUS exposures during the post-injury interval days 1-8, 9-16 and 17-24 enhanced fracture
strength significantly more than controls, but significantly less than fractures treated from
days 1-24. No difference in fracture strength was reported among any of the eight-day
treatment intervals. Based on this study, it appears that the additive effects of TUS, rather
than early treatment initiation, is the most important factor for improving fracture healing.
This finding is inconsistent with the theory of greatest effect on the inflammatory phase of
healing.
Daily application of SAFHS improved tibial osteotomy healing in sheep, noted by
reduction in healing time from 103 days to 79 days, compared to untreated controls 70. In
this study, the authors used a transosseous application of TUS, utilizing a stainless steel pin
to transmit ultrasound energy directly on the bone surface. Given the ability of noninvasive, transcutaneous ultrasound application to improve fracture healing, there seems to
be no clear indication at this time for use an invasive, possibly infection-generating TUS
application protocol.
In addition to the osteotomy fracture models noted above, TUS enhancement of
healing of nonunion fractures and fractures in diabetic rodents has been demonstrated.
Nonunion tibial fractures in rats exposed to SAFHS daily for 6 weeks demonstrated a 50%
healing rate compared to 0% healing in untreated tibial fractures 17. Femoral fractures in
diabetic rats had improved torque to failure and stiffness after only 1 week of SAFHS
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exposures 20. TUS exposures 6 days per week for 5 months (1 MHz, 50 mW/cm2 SATA,
20% PW, 15 minutes) to canine ulnas accelerated healing and reduced non-unions from
60% to 0% compared to controls 6.
TUS has also been effective for enhancing healing in spinal fusion models. Six
weeks of daily SAFHS exposures improved the rate of healing and the histological quality
of bone following lumbar spinal fusion in rabbits, compared to untreated controls 71. In
addition, sonication reduced pseudoarthroses, a common complication of spinal fusion,
from 35% to 7%, increased stiffness and load to failure of healing bone compared to sham
treatment 72. Lumbar spinal fusion in canines exposed to SAFHS 6 days a week for 12
weeks exhibited increased mechanical stiffness and accelerated rate of bony fusion when
compared to untreated controls 73.
In an investigation of rabbit mandibular fracture, daily SAFHS exposures for 3
weeks accelerated endochondral ossification and increased failure load and stiffness of
healing mandibles, compared to sham 74. Sakurakichi et al reported accelerated bone
formation using a distraction osteogenesis model in rabbit tibiae treated with SAFHS 75.
TUS exposures resulted in increased bone mineral density, maximal torque at failure and
stiffness 4 weeks post-injury.
Randomized, placebo-controlled clinical trials have reported enhanced fracture
healing in the tibia, distal radius, scaphoid and metatarsals after SAFHS exposures.
Radiographically assessed healing of fresh fractures of the tibia treated with SAFHS was
accelerated by 28 days, with cast discontinuation improved by 26 days and complete
cortical bridging improved by nearly 70 days over placebo 76. For distal radius fractures,
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SAFHS accelerated healing by 37 days, as assessed by radiographic evidence of complete
bridging of the cortex of the fracture site 18. Leung et al reported on complex tibial
fractures, classified as open shaft or comminuted fracture, treated with SAFHS for 90
consecutive days 77. SAFHS improved bone mineral content, alkaline phosphatase activity
and reduced time to removal of external fixator and the time to full weight bearing
compared to sham treatment. Alkaline phosphatase, an enzyme that contributes to
processes involved with bone formation, is considered a marker of fracture healing 78.
Enhanced fracture healing in patients with compromised healing has also been
reported. Nonunion fractures, defined as fracture gaps bridged with soft tissue and
exhibiting lack of healing for 6-8 months post-injury, represent a major problem for some
patients 78. Non-union fractures generally require some type of intervention, often invasive
surgery, to promote healing and allow patients to return to premorbid function 68. Based
on clinical and radiographic assessment, SAFHS induced full healing of nonunions in 86%
(25 of 29 cases) and 85% (57 of 67 cases) of subjects, with average time to healing of 22 24 weeks 79,80. Both studies included a variety of fracture sites including tibia, femur,
radius, ulna, scaphoid, humerus, metatarsal, and clavicle, with all sites being responsive to
TUS.
In addition to nonunions, TUS has been shown to improve delayed fracture healing
associated with cigarette smoking. Cigarette smoking is directly related to poor healing
generally and delayed fracture healing specifically. Cook et al reported that healing time
was reduced for fractures of the tibia by 72 days (41% reduction in healing time) and the
radius by 50 days (51% reduction) in smokers receiving SAFHS compared to sham 19.
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Given the evidence of TUS benefits on compromised fracture healing, the question
of TUS effects on intact osteoporotic bone has been investigated 81. Rat hind limbs made
osteoporotic through bilateral ovariectomy were exposed to 12 weeks of daily SAFHS. In
a similar investigation, rat hind limbs made osteoporotic by sciatic neurectomy, were
exposed to 4 weeks of daily TUS (1 MHz, 125 mW/cm2 SATA, CW, 15-minutes) 82. TUS
had no effect on restoration of bone mineral content or bone mineral density. Taken
together, these reports do not support improvement of osteoporotic bone loss following
SAFHS exposures. Beneficial effects of TUS on tissues generally involve injured, healing
tissue and it might be expected that no benefit would occur for intact, non-injured tissues,
such as osteoporotic bone.
Accelerated fracture healing following TUS exposure has been verified using a
variety of in vivo markers of bone healing as discussed above. The cellular mechanisms
that are affected by TUS have been investigated utilizing in vitro assays. Much of this area
of research has focused on chondrocyte and osteoblast response to TUS, with bone marrow
stromal cells and in vitro bone tissue culture models also being employed.
Tissue culture models of isolated bone tissue from fetal mice metatarsals have been
used to analyze cellular responsiveness to TUS 83,84. Metatarsal rudiments from fetal mice
exposed to daily TUS for 1 week (1 MHz, 154 mW/cm2 SATA, 20% PW, 5 minutes)
increased total longitudinal growth and length of the proliferative zone of cartilage as
compared to untreated controls, suggesting that TUS enhanced chondrocyte
proliferation 83. Sonication at lower intensities (20, 66 and 98 mW/cm2 SATA, 20% PW,
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and 100 and 500 mW/cm2 CW, 5 minutes) was reported to have no effect on length of the
proliferative zone or total bone rudiment length 84.
In contrast, SAFHS has been reported to increase the length of the calcified
diaphysis of metatarsal bone rudiments from fetal mice following 7 consecutive days of
exposures, without any changes in the length of the proliferative zone of cartilage or in
total bone rudiment length 84. The authors suggested that the lower intensity (30 vs. 154
mW/cm2), in comparison to Wiltink et al84 affected the hypertrophic zone, specifically
chondrocyte hypertrophy and matrix calcification, rather than chondrocyte proliferation in
the proliferative zone. However, Wiltink et al included sonication at intensities
comparable to SAFHS intensities (20 and 66 mW/cm2 SATA) and did not report
alterations in the hypertrophic zone. The variance in treatment duration (5 vs. 20 minutes)
may provide a better explanation for the difference in findings between these two studies,
since TUS dose may influence the overall tissue response to sonication 12. These reports
indicate chondrocytes in regions of endochondral ossification are stimulated by TUS.
Also, it appears that different TUS intensities may differentially affect processes in the
bone-healing continuum. Findings from these similar experimental models of developing
bone treated with different TUS exposure parameters illuminate the difficulty in
identifying optimal TUS doses. However, the ability of non-SAFHS exposure parameters
to alter bone formation indicates that a range of TUS exposure parameters may affect bone
healing and regeneration.
Concomitant with studies examining the effect of TUS on chondrocytes of fetal
bone, osteoblast response to TUS has been investigated using in vitro models 9,85. Sun et al
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treated bone defects in isolated rat femora with daily TUS (1.5 MHz, 320 or 770 mW/cm2
SATA, 20% PW, 15-minutes) for 2 weeks and found accelerated healing and enhanced
trabecular regeneration compared to sham 85. In a follow-up study, Sun et al co-cultured
mouse osteoblasts and osteoclasts and exposed them to 2 weeks of daily TUS (1 MHz, 68
mW/cm2 SATA, 20% PW, 20-minutes) 9. Osteoblasts were induced to proliferate, while
osteoclast numbers declined. Increased levels of tumor necrosis factor- (TNF- ),
alkaline phosphatase and prostaglandin E2 (PGE2) were also measured in the culture media
following sonication. TNF- is an inflammatory cytokine that is believed to have a role in
regulation of bone repair via stimulation of endochondral ossification and osteoclast
function 86,87. PGE2 is a lipid compound considered to be a potent inflammatory regulator
of bone repair 78,88,89. These combined findings indicate that TUS stimulated aspects of the
inflammatory phase (i.e. TNF- and PGE2) and the reparative phase (i.e. osteoblast
proliferation and alkaline phosphatase production).
Release of other cytokines related to bone healing has also been related to TUS
exposure. Rat osteoblasts treated with TUS (1 MHz, 120 mW/cm2, 20% PW, 15-minutes)
had altered cytokine release following sonication 90. The authors found increased release
of transforming growth factor- 1 (TGF- 1) after two exposures, while release of TNFand interleukin-6 (IL-6) was reduced after two and three exposures, respectively. IL-6 acts
to enhance osteoclast function in bone as well as promoting angiogenesis and extracellular
matrix (ECM) synthesis 78,87, while TGF- 1 is a signaling peptide involved in recruitment
and stimulation of ECM producing cells, including osteoblasts 86,87,91.
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In addition to TUS induction of cytokine, protein and inflammatory mediator
release, in vitro models have been used to identify the effects of TUS on gene expression
in osteoblasts. Using osteoblastic cells exposed to a single SAFHS treatment, investigators
have reported induction of mRNA expression of cyclooxygenase-2 (COX-2), c-fos,
alkaline phosphatase, osteocalcin, bone sialoprotein and insulin growth factor-1
(IGF-1) 92,93,94. Bone sialoprotein and osteocalcin are non-collagenous matrix bone
proteins, and IGF-1 promotes cellular activity associated with bone growth 86,,87. c-fos is a
proto-oncogene that is thought to influence osteoblast proliferation and differentiation and
to regulate constituents of the bony matrix 91. COX-2 is an enzyme that appears to be
involved in regulating bone formation and remodeling through stimulation of
prostaglandin synthesis by osteoblasts 92,95.
Utilizing SAFHS, Sena et al showed induction of immediate early response genes
(c-jun, c-myc, COX-2, Egr-1, TSC-22) and bone differentiation marker genes (osteonectin,
osteopontin) 3 hours after a single sonication of bone marrow stromal cells 96. These
results suggest that in addition to effects on osteoblasts, osteoclasts and chondrocytes, TUS
enhances differentiation and maturation of progenitor cells involved in fracture healing.
In two separate studies of single TUS exposures, Harle et al exposed osteoblastic
cells to continuous TUS at 3 MHz for 5 or 10 minutes at varying intensities (140-1770
mW/cm2 SATA) 64,97,98. Sonication altered ECM protein production in a dose-dependent
manner 97. Specifically, TUS intensities of 140 and 990 mW/cm2 SATA reduced levels of
osteonectin, while intermediate intensities 230 and 540 mW/cm2 had no effect on this
ECM protein. Osteopontin levels were reduced following 990 mW/cm2 exposures but not
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at lower intensities. TGF- gene expression was also reported to have a dose-dependent
relationship to TUS 64. A single TUS application at varying intensities (3 MHz, 130-1770
mW/cm2 SATA, CW, 10-minutes) induced TGF- gene expression that was dosedependent, with the highest intensity (1770 mW/cm2) inducing the greatest expression.
According to the overall results by Harle et al, it is apparent that TUS intensities can affect
cellular activities differentially. These investigations indicate a transcriptional response to
TUS exposure in addition to a secretory or more general release response. In addition, this
trio of investigations utilized TUS exposure parameters different from SAFHS parameters,
strengthening the hypothesis that many different TUS exposure parameters can be effective
in altering cellular function.
Similar to the findings of Harle et al, dose-response relationships between TUS and
cell function have been reported utilizing SAFHS. Osteoblastic cells exposed to SAFHS
have been reported to generate differential expression of genes associated with
osteogenesis (alkaline phosphatase, osteopontin, and bone morphogenic protein-7
(BMP-7), based on the number of daily TUS exposures (1, 3, 5 or 7 exposures), with 3
exposures inducing the greatest up-regulation 99. Production of alkaline phosphatase,
osteocalcin and vascular endothelial growth factor (VEGF) were dependent on the number
of TUS treatments in human periosteal cells exposed to SAFHS parameters 10. VEGF is a
cytokine that has a critical role in angiogenesis during tissue repair 86,100,101. The response
of periosteal cells suggests that they may also have a role in TUS-enhanced fracture
healing.

21

The evidence that supports enhancement of fracture healing by TUS is extensive. Based
on the overall findings on fracture healing with in vivo and in vitro models, it appears that
TUS enhances bone healing by: alterations in ECM protein production (by chondrocytes,
osteoblasts, and periosteal cells), release of inflammatory mediators and cytokines, and
through the enhancement of cell proliferation and differentiation. TUS-induced alteration
of gene expression appears to be the mechanism for some of these effects. Therefore, it is
plausible to suggest that TUS-enhanced fracture healing occurs through stimulation of
some, if not all, of these processes. However, given that nearly all in vivo and clinical
reports of TUS-enhanced fracture healing have utilized the 30 mW/cm2 intensity, it is
difficult to determine which of the reported in vitro responses noted at intensities above 30
mW/cm2 actually contribute to the fracture healing process.

Hyaline Cartilage
Articular cartilage is an avascular tissue and resident chondrocytes have a minimal
capacity for tissue repair, especially in comparison to resident cells of other connective
tissues (bone, ligament, tendon and dermis). Among the postulates generated to explain
the poor healing of articular cartilage is the hypothesis that the avascular nature results in
the inability to recruit stem cells to aid healing 12,102. Many surgical techniques and
medical treatments have been employed by orthopedic surgeons in efforts to improve
articular cartilage healing, but none have generated consistent success 102. In an effort to
discover other treatment options, several authors have undertaken studies to determine
whether TUS can enhance healing of cartilage 12,103,104.
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In a pair of investigations, Huang et al treated chemically induced osteoarthritis
(OA) in rat knee joints with TUS (1 MHz, 500 or 625 mW/cm2 SATA, 20% or 25% PW, 7
minutes, 3x/wk for 4 weeks)104. They found TUS exposures improved repair of arthritic
cartilage with superficial damage and prevented further arthritic deterioration in more
severely damaged cartilage at 2-months post-injury (one month after cessation of TUS
treatment) 103. In addition, articular cartilage healing was correlated with increased
chondrocyte proliferation and with increased production of stress proteins in treated
joints 104. Stress proteins, also known as heat shock proteins, can be produced by and then
protect cells exposed to trauma as a result of arthritis, autoimmune disease, heat and
ischemia 105,106. Huang et al theorized that the stress proteins protected chondrocytes and
allowed them to proliferate and modulate cartilage repair via increased ECM production.
Stress protein production following TUS exposure and their relation to enhanced healing
has not been confirmed by other investigations.
Full-thickness osteochondral defects in rabbit knee joints treated with SAFHS have
been induced toward earlier and better morphological and histological repair 12. SAFHS
treatment for 12 weeks (6 days per week) resulted in fewer degenerative changes up to 52
weeks post-injury compared to untreated controls. Additional TUS treatments beyond 12
weeks (18, 24, and 52 weeks of TUS) did not result in any additional benefit in the quality
of healing defects. The authors also reported that daily 40-minute treatments improved the
histological appearance of healing deficits compared to 20-minute treatments up to 18
weeks post-injury. When TUS exposure time was reduced to 5 or 10 minutes, there was
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no difference in healing compared to the 20-minute exposures. This duration-dependent
improvement in healing cartilage indicates a dose-dependent response to TUS.
In vitro studies have also been utilized to demonstrate the ability of TUS to affect
chondrocyte function, supporting in vivo findings and indicating these cells can be
stimulated to improve healing of articular cartilage 11,107,108. Parvizi et al exposed isolated
rat chondrocytes to five daily TUS treatments (1 MHz, 50 and 120 mW/cm2 SATA, 20%
PW, 10 minutes) and reported increased aggrecan gene expression at both intensities and
increased proteoglycan synthesis at the higher intensity 11. Isolated rabbit chondrocytes
embedded in three-dimensional collagen gel matrices treated with SAFHS twice weekly
for 3 weeks increased chondroitin-6-sulfate production 107. Chondroitin-6-sulfate is an
important matrix protein in articular cartilage.
Chondrocyte response to TUS has been related to the state of cellular
differentiation. Chondrocytes within sternal cartilage explants from chick embryos
exhibited variable responsiveness following exposure to 1 week of daily SAFHS 109.
Sonication of explants from the proximal sternum, cartilage that is destined for terminal
differentiation and endochondral ossification, resulted in stimulation of hypertrophic
chondrocytes and subsequent maturation of bony tissue. Chondrocytes in the explants
from the distal sternum, cartilage that retains its hyaline cartilage characteristics in the
adult, were stimulated to increase production of ECM molecules aggrecan and type II
collagen without further cellular differentiation.
In a subsequent investigation, Zhang et al applied a single TUS treatment (1.5
MHz, 2 or 30 mW/cm2 SATA, 20% PW, 20 minutes) to chicken chondrocytes isolated
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from hyaline cartilage and reported alterations in cell proliferation, and gene expression of
ECM proteins 108. Compared to untreated controls, TUS at 2 mW/cm2 SATA increased
cell proliferation, but TUS at 30 mW/cm2 SATA did not. Both TUS intensities induced
elevated gene expression of type II collagen and reduced aggrecan gene expression. The
differences between 2 and 30 mW/cm2 SATA further illustrates an apparent dosedependent response to TUS.
TUS enhancement of chondrocyte ECM production has been reported to involve
growth factor production 110. Epiphyseal chondrocytes isolated from distal femora of
neonatal rats were sonicated with SAFHS for 5 or 10 consecutive days and responded by
increased gene expression for type II collagen, aggrecan and TGF- 1, as well as increased
cell proliferation, when compared to sham exposures. Addition of human recombinant
TGF- 1 to control cells resulted in increased type II collagen and aggrecan mRNA
expression comparable to TUS treatment effects. Pretreatment with anti-human TGF- 1
antibody prior to TUS application cancelled the increases in cell proliferation, type II
collagen and aggrecan mRNA expression, indicating that chondrocyte response to TUS
was likely mediated through TGF- 1 production and its ensuing effect on cellular
metabolism.
The reported benefits of TUS on articular cartilage healing and chondrocyte
function have led some investigators to explore the ability of TUS to enhance healing of
intervertebral disc (IVD) injury, which includes nucleus pulposus (NP) and annulus
fibrosus (AF) cell types. Nucleus pulposus cells are considered to have chondrocyte-like
function, while those of the annulus fibrosus are believed to have a phenotype more closely
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related to fibroblasts 111. Both cell types isolated from bovine and rabbit annulus fibrosus
and nucleus pulposus have been shown to be responsive to TUS 52,112. SAFHS for 20
consecutive days increased collagen and proteoglycan synthesis by bovine cells, without
any effect on cellular proliferation 52. Daily TUS treatment for 5 or 12 days at variable
intensities (7.5, 15, 30, 60 or 120 mW/cm2 SATA) increased proliferation and
proteoglycan synthesis in a dose-dependent manner in rabbit cells 112. Compared to
untreated controls, TUS intensities 7.5 and 15 mW/cm2 increased chondrocyte
proliferation and TUS intensities ≥ 30 mW/cm2 increased proteoglycan content. The
proliferative response at intensity levels below SAFHS (< 30 mW/cm2) substantiates
findings by Zhang et al 108 of enhanced proliferation of chondrocytes following treatment
at sub-SAFHS intensities.
Cartilage and isolated chondrocytes have repeatedly demonstrated responsiveness
to TUS in research investigations. TUS exposure is related to enhancements of articular
cartilage healing, hyaline cartilage growth, and endochondral ossification. Strong evidence
exists to signifying that these responses are related to enhancement of chondrocyte
function, including matrix production, cellular proliferation and cytokine release.
Analyses of hyaline cartilage and fibrocartilage models suggest that chondrocyte
proliferation and protein synthesis are regulated by different TUS treatment intensities,
indicating differential response to varied doses of TUS energy. Chondrocytes from a
variety of species and tissue origins are responsive to TUS; therefore TUS may be a
plausible modality for enhancement of articular cartilage healing and chondrocyte
function.
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Tendons
Several investigators have examined the efficacy of TUS on tendon and ligament
healing in vivo, and have demonstrated benefits of TUS on numerous characteristics of
these tissues including collagen deposition, collagen fiber alignment, cell number, ultimate
tensile strength, ultimate load, stiffness, and energy absorption capacity. A variety of TUS
treatment parameters have been reported to improve the healing processes in surgically
transected tendons, up to 30 days post-injury. However, SAFHS parameters have not been
studied in relation to TUS enhancement of tendon healing.
TUS has been reported to enhance aspects of healing in partially ruptured rat
Achilles tendons. Frieder et al reported that TUS exposures for 3 weeks (1500 mW/cm2
SATA, CW, 3-minutes, 3x/wk, no reported TUS frequency) improved collagen fiber
density and alignment, and decreased overall cellular content at 3 weeks post-injury 113.
Similar TUS exposure parameters (1500 mW/cm2 SATA, CW, 4 minutes, daily, no
reported TUS frequency) resulted in increased collagen content and tendon breaking
strength by 5 days post-injury that remained elevated at 9, 15 and 21 days post-injury when
compared to sham treatments 114. TUS delivered at < 1000 mW/cm2 SATA has also been
reported to improve healing in partially ruptured rat Achilles tendons as 9 consecutive
daily TUS exposures (1 MHz, 500 mW/cm2 SATA, CW, 5-minutes) increased collagen
content and breaking strength of treated tendons up to 21 days post-injury 115.
Completely ruptured rat Achilles tendons treated with TUS (1 MHz, 1000 mW/cm2
SATA, CW, 5 minutes, 9 consecutive days) had greater ultimate tensile strength compared
to sham-sonicated controls at 9 days post-injury 116. In a follow-up study, Enwemeka et al
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utilized an identical protocol with the exception of reducing the TUS intensity from 1000
mW/cm2 to 500 mW/cm2 SATA and reported enhanced healing, as indicated by increased
tensile strength, tensile stress and energy absorption capacity 23. In comparing the data
between studies, Enwemeka et al noted that all three variables of tendon function (tensile
strength, tensile stress and energy absorption capacity) were greater in tendons sonicated at
500 than 1000 mW/cm2 SATA.
Other investigators using variable TUS intensities (1 MHz, 1000 and 2000
mW/cm2 SATA, CW, 4 minutes, 22 consecutive daily exposures) have reported conflicting
results between the two intensities in relation to the healing response 5,117. Ng et al
reported improved ultimate tensile strength in hemi-transected rat Achilles tendon at both
treatment intensities, compared to untreated injury controls 5. However, in an identical
tendon injury and TUS exposure model, Ng et al reported that 2000 mW/cm2, but not 1000
mW/cm2, improved ultimate tensile when each was compared to untreated controls 117.
The only reported difference among the biomechanical testing protocol was the
performance of load-relaxation testing prior to tendon strength testing 5 which was not
performed in the subsequent study 117. Otherwise, no explanation of the variable findings
is readily apparent.
In addition to a possible intensity-dependent effect, duty cycle has also been
reported to alter the healing benefit of TUS 118. Using a complete tendon rupture model,
TUS exposures (1 MHz, 500 mW/cm2 SATA, 5 minutes, 12 treatments) delivered in CW
or 20% PW were compared. Analysis of collagen fiber alignment revealed improved fiber
alignment in PW treated tendons compared to mock-sonicated tendons, while fiber
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alignment following CW exposures was significantly worse (more random fiber
alignment) than the controls and tendons treated with PW.
Since collagen fiber alignment is a factor in imparting strength to tendons, this
finding contrasts the reports of CW TUS enhancing tendon healing. However, the
enhanced tendon strength noted with CW TUS is likely related to the reported overall
increase in collagen deposition rather than orientation of collagen fibers, suggesting varied
treatment duty cycles affect different aspects of the healing response. Other researchers
have corroborated the finding of improved collagen fiber alignment in tendons treated with
PW TUS 119. Utilizing methods identical to Da Cunha et al 118, complete tendon
transection and TUS treatment regimen (1 MHz, 500 mW/cm2 SATA, 20% PW, 5minutes, 12 treatments), the authors reported improved collagen fiber alignment compared
to sham treatments 119.
While Da Cunha et al 118 reported that PW TUS, but not CW TUS, improved
collagen alignment, Frieder et al 113 reported that CW TUS does improve collagen fiber
alignment in healing tendons. The contradictory findings here are likely due to
experimental differences. Frieder et al utilized TUS treatment parameters that were quite
different than those of Da Cunha et al: treatment intensity (1500 vs. 500 mW/cm2 SATA),
treatment durations (3 minutes vs. 5 minutes), treatment frequency (3 treatments per week
vs. daily treatments), and overall treatments (9 vs. 12), respectively. Additionally, Frieder
et al employed a partial tendon rupture model compared to the full tendon rupture model of
Da Cunha et al.
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Despite the evidence discussed above, reports of limited or no benefit of TUS on
tendon healing have been published 120,121,122. These investigations of healing of
tenotomized chicken flexor tendons exposed to TUS have provided less promising results
in comparison to tendon healing studies in rat Achilles tendon. Chicken flexor tendons
treated with TUS (3 MHz, 750 mW/cm2 SATA, CW, 5 minutes, 20 daily treatments)
exhibited no enhancement of either collagen production or breaking strength at 10 weeks
post-injury, when treatments were initiated 28 days post-injury 121. Additionally,
sonication provided no improvement in breaking strength 6 weeks post-injury in TUStreated chicken flexor tendons, when treatments were initiated 7 days post-injury (3 MHz,
200 mW/cm2 SATA, 20% PW, 4 minutes, 3x/wk for 5 wks) 122. In a comparison study,
Gan et al applied TUS (3 MHz, 200 mW/cm2 SATA, 25% duty cycle, 3-minutes, 10 daily
treatments) to chicken flexor tendons, with TUS initiated 7 days or 42 days post-injury 120.
In agreement with the other investigations using chicken flexor tendons122, the authors
found no improvement in strength of the healing tendons, regardless of the timing of TUS
treatments.
The data regarding TUS enhancement of chicken flexor tendon healing appears to
conflict with reports involving rat Achilles tendon. Most notable in comparing
investigations among chicken and rat models, researchers utilizing rats initiated TUS
treatments on the day of surgery or on post-operative day one, rather than 7, 28 or 42 days
after injury. Following the hypothesis that TUS affects the early stages of healing
(inflammatory and early reparative phases), the lack of effect of TUS on chicken flexor
tendon healing compared to rat tendon healing are likely due to the inability of TUS to
30

affect early healing when initiated 7 days or later post-injury. Yet for bone TUS enhances
healing of delayed and non-union fractures, tissues that are not progressing through the
normal healing phases. This apparent discrepancy may indicate that the healing benefit
provided by TUS is tissue specific. Additionally, given the responsiveness of bone cells to
mechanical forces, including ultrasound 123,124,125, it may be that bone cells are better able
to transduce ultrasound energy into cellular activity compared to fibroblasts.
Although variable methodologies inhibit direct inter-study comparison, the overall
body of investigations into TUS effects on tendon healing indicates that CW and PW TUS
can enhance tendon healing in animals. These benefits appear to be related to
improvements in quantitative and qualitative deposition of collagen into the ECM. Further
research is needed to clarify the differential effect of TUS duty cycle on collagen
deposition and collagen fiber alignment, as well as clarifying the effect of the timing of
initiation of TUS-exposures on healing of tendons.

Ligaments
TUS effect on ligament healing has not been studied to the same extent as tendon
healing, but sonication of transected ligaments has demonstrated improved healing up to 6
weeks post-injury 4,13,126,127. Takakura et al reported enhanced healing of transected rat
medial collateral ligaments (MCL) after exposure to SAFHS 127. Specifically, ultimate
load, stiffness, energy absorption, and collagen fibril diameter were all increased in the
TUS treated MCLs at 12 days post-injury. No differences were noted at 21 days postinjury. Sparrow et al treated completely transected rabbit MCLs with TUS (1 MHz, 300
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mW/cm2 SATA, CW, 10 minutes, every other day for 6 treatments) and reported increased
energy absorption to failure, ultimate load and increased cross sectional area of sonicated
ligaments 6 weeks post-injury 4. Also, the proportion of type I collagen relative to the
amount of type III collagen was increased in MCLs at 3 and 6 weeks post-injury. During
healing, type I collagen, which provides greater tensile strength to ligaments compared to
type III collagen, replaces much of the initially deposited type III collagen 128,129. The
finding of an increased proportion of type I collagen suggests that TUS affects either the
normal replacement of type III collagen with type I collagen or that TUS enhances the
initial deposition of type I collagen.
TUS-enhanced MCL healing has been associated with the production of
TGF- 1 126. Transected MCLs treated with TUS (3 MHz, 460 mW/cm2 SATA, 20% PW,
5 minutes) had increased levels of the cytokine growth factor. TUS exposure (3 MHz, 100
mW/cm2 SATA, 20% PW, 5-minutes) had no effect on TGF- 1. Furthermore, 10 days of
TUS (3 MHz, 460 mW/cm2 SATA, 20% PW, 5-minutes) induced greater amounts of TGF1 compared to 1 and 5 days of treatment. As discussed previously, TGF- 1 activity
during healing enhances cellular recruitment, ECM production and angiogenesis 130, but
Leung et al 126 did not investigate any of these variables.
TUS (3 MHz, 460 mW/cm2 SATA, 20% duty cycle, 5 minutes, 10 daily treatments)
has also been shown to affect the levels of inflammatory mediators during healing of
completely transected rat MCLs 13. This experimental model was identical to that of
Leung et al 126. The authors reported increased PGE2 and decreased leukotriene B4 (LTB4)
from 2 to 11 days post-injury. These arachidonic acid derivatives are known mediators of
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the inflammatory response to wounding, with PGE2 being produced by endothelium,
monocytes, macrophages and fibroblasts, and LTB4 being released from neutrophils and
mast cells 88,131. TUS effect on inflammation has been hypothesized to be an acceleration
of the process 48. However, increased PGE2 and decreased LTB4 up to 11 days post-injury,
coupled with increases in TGF- 1 suggest that TUS effects on inflammation may be more
complicated than simply accelerating the cellular processes.
The limited data regarding TUS and healing ligaments indicates that TUS can
improve healing up to 6 weeks post-injury most notably through increased mechanical
strength of the treated ligaments. This benefit to healing appears to be the result of
enhancement of growth factor production, alteration of the inflammatory process and
modulation of collagen deposition, presumably via affect on fibroblast protein synthesis.
The effect of TUS on fibroblast proliferation has not been explored in these in vivo
models, but as will be discussed later, TUS has been reported to increase fibroblast
proliferation in vitro.

Integument
Healing integument wounds require connective tissue matrix deposition,
angiogenesis and regeneration of epithelium 131,132. In non-fetal tissues, this healing
process results in replacement tissue that is suboptimal (decreased tensile strength and
pliability) compared to the uninjured, original tissue. Studying the effect of TUS on fullthickness and incision wounds in animal models including pig, rat, and human, researchers
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have reported acceleration of the inflammatory phase and enhancement of the proliferative
phase of healing 3,24,133,134,135.
Using a pig model, Byl et al found that 5 daily exposures to TUS (1 MHz,
100-300 mWcm2 SATA, 20% PW) increased tensile strength and collagen deposition in
incision wounds, and accelerated full-thickness wound closure when compared to sham
controls assessed 1 week post-injury 3. Full-thickness wounds were sonicated for 5
minutes and incision wounds were sonicated for 10 minutes. All wounds were treated at
100 mW/cm2 SATA for the first 2 days, and at 300 mW/cm2 SATA for the final 3 days of
treatment.
In rats, incision wounds treated with 7 or 10 daily TUS exposures (1 MHz, 100
mW/cm2 SATA, 20% PW, 5 minutes) had increased fibroblast number 4 days postinjury 133, increased collagen deposition 7 days post-injury 133,134 and increased wound
breaking strength 25 days post-injury 133,134. Healing of full-thickness wounds in rats has
also been reported to be enhanced by TUS after 5 daily treatments (0.75 or 3 MHz, 100
mW/cm2 SATA, 20% PW, 5 minutes) when compared to sham 135. Five days post-injury
treated wounds had more extensive granulation tissue, increased fibroblast number, and
fewer macrophages and leukocytes, all of which suggest acceleration of the inflammatory
phase with earlier initiation of the proliferative phase. There were no differences in
healing characteristics between wounds treated with TUS at 0.75 MHz and 3 MHz.
Wound healing studies in humans have generated much less consistent results.
TUS-treated chronic human venous stasis ulcers (3 MHz, 200 mW/cm2 SATA, 20% PW,
5-10 minute treatments, 3x/wk for 4weeks) had decreased wound area after 4 weeks of
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sonication 136. However, Lundeberg et al reported that TUS treatments (1 MHz, 100
mW/cm2 SATA, 10% PW, 10-minutes, 3x/wk for 4wks) had no effect on the rate of
wound healing or wound closure for patients with chronic venous stasis ulceration
compared to sham TUS 137. Eriksson et al also found no improvement in wound closure or
wound healing rates following treatment of chronic venous stasis ulcers with TUS (1 MHz,
1000 mW/cm2 SATA, CW, 10 minutes, 2x/wk for 8wks) 138.
The effect of TUS on pressure ulcer healing has also been described 139,140.
McDiarmid et al 139 utilized TUS (3 MHz, 160 mW/cm2 SATA, 20% PW, 5-10 minutes,
3x/wk), while Ter Riet et al 140 utilized TUS (3.28 MHz, 100 mW/cm2 SATA, 20% PW, 48 minutes, 5x/wk for 12wks) to investigate enhancement of healing. Both studies reported
no effect on pressure ulcer healing compared to sham treated wounds, but McDiarmid et al
reported enhanced rate of healing of “infected” wounds treated with TUS. Because
infected wounds were classified by visualization and not bacteriological assay, and given
the small sample size of the groups, (TUS = 11 and placebo = 8) little can be inferred,
regarding the response of infected wounds to TUS exposure.
Based on the overall evidence, it appears that TUS does positively affect early
stages of healing of acute integument wounds. This benefit has been demonstrated in
animal models, but has not been established in treating wounds in humans. The
discrepancy between in vivo and clinical studies is likely due to differences in
methodology and types of wounds. In animal studies investigators treated acute wounds
daily, while investigators in clinical trials utilized TUS intermittently for treatment of
chronic wounds. The effect of consecutive versus non-consecutive TUS exposures has not
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been explored in relation to integumentary wound healing, but an additive effect of
repeated TUS exposures has been reported in articular cartilage 12. The clinical
investigations have focused on patients with compromised healing (i.e., chronic venous
stasis or pressure ulceration), while animal studies utilized acute wounds without healing
deficiencies. Chronic ulceration involves dysfunctional healing physiology, and it is
possible that TUS cannot influence inadequate or compromised wound healing states such
as chronic ulceration 130,141.
However, TUS has shown the ability to improve compromised fracture healing at
SAFHS parameters. Clinical studies discussed here have not reported use of SAFHS on
chronic ulceration. Based on the ability of SAFHS parameters to enhance inadequate
fracture healing, it is possible that specific parameters may be necessary to affect
compromised wound healing. Differences in the pathophysiology of chronic venous ulcers
and pressure ulcers compared to non-union and delayed union fractures might also be
related to the disparate findings of TUS benefit to tissue with compromised healing.
Furthermore, differences in the overall treatment regimens (3 to 4 months of treatment for
fractures compared to 4 to 8 weeks of treatment for chronic venous ulcers) might explain
the discrepancy in TUS effects on healing in these models.
The overall efficacy of TUS in clinical healing remains in question. Despite
positive in vivo evidence for enhanced healing of acute wounds in animal models reported,
clinical trials with traditional TUS (1-3 MHz, 0.03-2000 mW/cm2 SATA) have not
supported its use for chronic ulceration. Additional investigation using different
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parameters, such as SAFHS, are needed to determine if TUS can be beneficial for
enhancement of healing in chronic integumentary wounds.

In Vitro Fibroblast Response to TUS
In vitro models have been used to examine cellular response to TUS and to
associate the cellular response with demonstrated benefits for tissue healing in vivo 7,8,97.
Ramirez et al investigated fibroblast response to TUS in a matrix injury model using
collagenase to partially disrupt a monolayer of neonatal rat fibroblasts 8. Following a
single treatment of TUS (1 MHz, 400 mW/cm2 SATA, CW, 3 minutes), the fibroblasts had
increased collagen synthesis compared to untreated controls. Additionally, three and five
TUS exposures increased fibroblast proliferation compared to untreated controls.
Supporting the proposed proliferative and anabolic effect of in vitro TUS on
fibroblasts, a single dose of TUS (1 MHz, 20, 80, 140 or 200 mW/cm2 SATA, 20% PW, 5
minutes) increased proliferation of and collagen production by human gingival
fibroblasts 7. Most TUS intensities (20, 80, and 140 mW/cm2) resulted in elevated
collagen production, but only higher intensities (140 and 200 mW/cm2) increased cell
proliferation. These findings again indicate a dose-dependent relationship between TUS
intensity and cellular response.
In contrast to the two previous in vitro studies, a single dose of TUS (3 MHz, 140990 mW/cm2 SATA, CW, 5 minutes) did not increase cell proliferation in human ligament
fibroblasts, and TUS at several intensities (140, 230, 540 mW/cm2) decreased collagen
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production 97. However, in agreement with Doan et al 7, cell response to TUS appeared to
be dose-dependent.
Comparison of the studies by Doan et al 7 and Harle et al 97 demonstrate that
different TUS exposure conditions 1MHz, 20% PW and 3MHz, CW respectively,
influence fibroblasts in culture. Both studies utilized TUS doses that are commonly used
clinically and that are comparable to doses utilized in the in vivo tendon, ligament and
integument wound healing investigations. These contradictory results add to the
uncertainty of the effect of TUS parameters on cell proliferation and collagen production.
Whether the TUS frequency and duty cycle affected this result is not known and neither
study compared the effects of these parameters.
Overall, TUS has many positive effects on tendon, ligament and integument
healing. Evidence supports TUS enhancement of healing of these soft tissues, especially
when TUS treatments are initiated early in the post-injury phase. This enhancement
appears to be related to fibroblast function; specifically, cellular proliferation, as well as
collagen deposition and organization, all of which support enhanced in vivo healing
following TUS. These responses suggest that TUS can alter processes of the proliferative
phase of healing rather than simply affecting the inflammatory phase.
In spite of the convincing body of evidence supporting TUS benefit for soft tissue healing
in animal models, the differential effects of the TUS exposure parameters remains unclear.
Changes in frequency, intensity, duty cycle, and overall TUS dose (including overall
number and duration of TUS exposures) appear to alter TUS effects; however, no
consensus exists in the available literature in regard to effects of specific parameters.
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Additional comparison studies are critical to elucidate the parameter-response relationships
that appear to exist.

Muscle Healing
Unlike the vast number of investigations of TUS enhancement of healing of
integument, tendons, and ligaments, minimal experimentation has been undertaken in
regard to TUS effects on healing following skeletal muscle injury. Like most tissues,
muscle heals following a general, three-step progression of inflammation, repair and
remodeling. Unlike other tissues, muscle healing is dependent on activation of normally
dormant satellite cells. Satellite cells, and other immature mesenchymal cells differentiate
into myoblasts, which fuse together to form myotubes and eventually mature into
myofibers as replacement for the original, damaged regions of fibers 142. Resident
fibroblasts in the area of injury proliferate and secrete matrix molecules to replace the
connective tissue surrounding the muscle fibers. This fibroblastic activity must be
balanced with appropriate myotube formation. Maintaining the balance between satellite
cells and fibroblasts represents an additional obstacle to adequate healing of injured
muscle 143. Theoretically, proliferative enhancement of satellite cells would produce
improved muscle repair, while proliferative enhancement of fibroblasts would result in
increased scar formation. Thus, any modality altering cell number for muscle healing
needs specificity in the cells that it affects to provide an appropriate benefit to healing.
Given that TUS has been reported to induce proliferation in a number of experimental
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models and cell types, application of TUS to injured muscle could be expected to affect
cell proliferation and subsequent muscle repair.
Among the investigations of TUS on muscle healing, minimal evidence supports a
benefit to healing. Two TUS exposures (3 MHz, 300 mW/cm2 SATA, 20% PW, 6
minutes) increased satellite cell proliferation at 4 days post-injury and three or four TUS
exposures increased fibroblast proliferation at 7 days post-injury, in contusion-injured rat
muscle 144. By 10 days post-injury, neither variable was affected by TUS, nor was there
benefit for re-capillarization or myotube formation at any time point. Four consecutive
days of TUS exposure (3 MHz, 100 mW/cm2 SATA, CW, 5 minutes) did not affect muscle
mass, contractile protein concentration, fiber cross-sectional area, number and density of
myonuclei at 4 days post-injury compared to untreated muscle 145. However, these
variables are not likely to be increased within the 4-day time frame 143.
TUS treatment (1 MHz, 500 mW/cm2 SATA, CW, 5 minutes) given for 7
consecutive days post-injury has been reported to accelerate muscle repair following
contraction-induced muscle injury in rats 26. At 7 days post-injury, maximum isometric
tetanic force of injured muscles was greater following TUS in comparison to untreated,
injured controls. Analysis of force production in experimental muscle should be a superior
measure of the state of repair compared to cellular and molecular variables assessed by
Markert et al 145 and Rantanen et al 144, since force production directly relates to the overall
“health” of the muscle.
The evidence of TUS benefit to muscle healing reported by Karnes and Burton 26
may also be related to utilization of a contraction-induced injury; a mode of injury that
40

typically preserves the basal lamina so as to provide scaffolding for regenerating fibers,
unlike a contusion-injury which is more likely to destroy the basal lamina 142.
Furthermore, the reported benefit to healing could be a result of an increased number of
TUS exposures, 7 exposures compared to 3-4 days of treatment utilized by Markert et al 145
and Rantanen et al 144, given in vivo evidence of an additive effect of TUS on tissue
healing 13,24,126,146.
The data from investigations of muscle healing provide minimal evidence for
benefit of TUS, when assessed in the short term (< 2 weeks). However, TUS does appear
to have a proliferative effect on skeletal muscle fibroblasts and satellite cells, similar to its
mitogenic effect on cells of other healing tissues. Concerning TUS exposure parameters,
CW and PW, 1 and 3 MHz and intensities between 100-500 mW/cm2 have been employed,
without the emergence of any trend of effect of those sonication variables on muscle
healing. Furthermore, analysis of healing muscle has not been undertaken beyond 10 days
post-injury, leaving unanswered the long-term effect of sonication. As such, further
experimentation comparing types of muscle injury, TUS parameters, and assessment of
increased healing time points should be undertaken to clarify the question of TUS benefit
on skeletal muscle healing.

Peripheral Nerve Regeneration
Injury to peripheral nerves occurs as a result of crush, stretch, avulsion or
compression, with functional nerve repair often being incomplete 147. There have been
several reports of the effects of TUS on peripheral nerve regeneration. Using rat models of
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peripheral nerve injury, investigators have reported that TUS application improves
neuronal regeneration and functional outcomes for tissues innervated by the injured nerve.
Following TUS exposure (1.5 MHz, 16 mW/cm2 SATA, 20% PW, 20 minutes, 12
consecutive days), regenerating neurotomized sciatic nerves in rats had increased numbers
of A-type and B-type fibers, myelin sheath thickness and overall axon fiber area when
compared to sham treated nerves at 2 weeks post-injury 148. Functional recovery of crushinjured rat sciatic nerves was enhanced following TUS treatment for 10 consecutive days
(1 MHz, 80 mW/cm2 SATA, 20% PW, 10 minutes) compared to sham 149. Recovery of
hind limb function, recorded at weekly intervals, was accelerated from day 14 to day 21
post-injury, while nerve fiber density was increased in nerve segments distal to the injury
site 21 days post-injury. Also employing a crush-injury model of rat sciatic nerve, Mourad
et al reported that TUS exposures three times per week for 4 weeks (2.25 MHz, 250
mW/cm2 SATA, CW, 1 minute) improved functional recovery in hind limbs compared to
sham TUS 150. Over the 30-day time course of healing, recovery of hind limb function was
accelerated from day 16 to day 30. Despite the use of the exposure frequency of 2.25
MHz, an unusual treatment frequency not available on many clinical ultrasound generators,
and the brief treatment duration (1-minute), a positive influence of TUS on nerve
regeneration was demonstrated.
TUS has been reported to increase Schwann cell myelination in regenerating
peripheral nerves in rats 27. After excision of a 10 mm segment of the sciatic nerve,
investigators implanted nerve guidance conduits, some seeded with Schwann cells,
between the nerve stumps and exposed the nerves/conduits to 12 TUS exposures over 14
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days (1 MHz, 40 mW/cm2 SATA, 20% PW, 5 minutes). At 6 weeks post-injury, sonicated
nerve fibers within the seeded conduits had greater mean axonal area and myelination in
comparison to sham-treated specimens and when compared to treated conduits that were
not seeded. These findings are in concurrence with those of Crisci et al 148 in which
neurotomized sciatic nerves had greater axonal area and increased myelination following
TUS. Enhanced recovery of limb function noted by Raso et al 149 and Mourad et al 150 also
indicates that TUS improves nerve myelination and / or axonal growth.
Together, these investigations suggest that TUS enhances peripheral nerve
regeneration, apparently through alteration in Schwann cell activity. Schwann cells are
believed to have a predominant role in peripheral nerve regeneration through production of
neurotrophic factors, guidance of axonal growth and increased myelination 147. Thus it is
plausible to suggest that TUS directly affects Schwann cell function as well as the
regenerating axons. However, the cellular mechanisms involved in the TUS-enhanced
nerve regeneration via Schwann cells have not yet been investigated.

Angiogenesis
Angiogenesis is critical for repair of injured tissues, as adequate blood supply must
be present for appropriate healing. The process of angiogenesis begins soon after tissue
injury, in the inflammatory phase of healing, as endothelial cells proliferate and eventually
provide the base for new vasculature 151. The importance of this process of tissue healing
provides a basis for investigating angiogenesis as a potential target for the effects of TUS.
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Studies that have examined TUS effects on endothelium and angiogenesis have
shown positive results. Capillary density and arteriole blood flow were increased in
chronically ischemic rat cremaster muscle following TUS exposure for 3 weeks (1 MHz,
150 mW/cm2 SATA, 50% PW, 5 minutes, 3x/wk), when compared to sham treatments 152.
Full-thickness wounds in rats treated with TUS up to 7 consecutive days (0.75 MHz,
100mW/cm2 SATA, 20% PW, 5 minutes) had increased vascularity compared to sham
treated wounds after 5 days of treatment 153.
Investigation of TUS effects on angiogenesis following ischemic injury to rat hindlimb has provided additional evidence of the benefit of sonication 154. TUS exposure (2
MHz, 50 mW/cm2 SATA, CW, 5 minutes, 3 treatments) was initiated on the day of surgery
(injury) and concluded on day 3 post-injury. Histological analysis at 7 days post-injury
revealed increases in the number of proliferating endothelial cells, the overall number of
blood vessels and the average blood vessel diameter in TUS-treated muscle compared to
controls. At 3 weeks post-injury, angiography revealed sustained increase in blood vessel
number, while laser Doppler analysis showed increased tissue perfusion for treated limbs
compared to controls. The authors also reported a 38-fold increase in vascular endothelial
growth factor (VEGF) mRNA in treated limbs at 7 days post-injury compared to controls.
VEGF is a potent angiogenic factor and the authors hypothesized that its up-regulation
explains the improvement in vascularity, and endothelial proliferation. These results
support the findings of Hogan et al 152 and Young and Dyson 153, who reported a beneficial
effect of TUS on angiogenesis, and it appears to be the most complete analysis of TUS
effect on variables of angiogenesis.
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In vitro analysis of the effect of TUS on endothelial cells have been also been
reported. Release of nitric oxide (NO) and calcium ions (Ca2+) into culture media was
increased by TUS after 6 consecutive days of treatment (1 MHz, 200, 320, and 400
mW/cm2 SATA, 20% PW, 10 minutes) when compared to untreated controls 155. Nitric
oxide release was increased following TUS at 320 mW/cm2 SATA, while calcium release
was increased following TUS at each intensity. Nitric oxide is an important mediator of
vascular function, affecting vascular smooth muscle relaxation, leukocyte adhesion to
endothelium and inhibition of platelet aggregation 156,157. Changes in Ca2+ flux in cells
have been reported in other cell types treated with TUS, including chondrocytes,
fibroblasts, epidermis and this altered ion flux has been implicated by others as a
component of the mechanism of TUS effect on cells 49,50,65,158.
This body of research suggests that angiogenesis following injury is enhanced by
exposures to TUS, up to 3 weeks post-injury. Improvement in the angiogenic response
following tissue injury could accelerate overall tissue healing, although this has not been
directly investigated. The mechanism responsible for the enhancement of angiogenesis
appears to be related to endothelial cell function. Treatment intensities between 50 and
400 mW/cm2 SATA appear to be beneficial for an angiogenic effect, which follows the
current trend of utilization of intensities below 1000 mW/cm2 SATA to achieve TUSenhanced healing 35,37.
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Inflammatory Cells
As discussed previously, an appropriate inflammatory response is crucial for proper
tissue healing. The inflammatory phase of healing involves functions of a variety of cells
including mast cells, monocytes, macrophages, lymphocytes and neutrophils. TUS
enhancement of healing is hypothesized to be a function of enhancing the inflammatory
and proliferative phases of healing. The ability of TUS to alter the inflammatory phase has
been supported by in vivo and in vitro investigations that have directly explored the effect
of TUS on various inflammatory cells.
Sonication has been reported to affect mast cell function in vivo and in vitro.
Increased mast cell degranulation in rat ankle joints treated with a single TUS exposure
(0.75 MHz, 1.5 MHz, or 3.0 MHz, 500 mW/cm2 SATA, 20% PW, 1 minute) has been
demonstrated 159. No difference in induction of mast cell degranulation was found between
the variable frequencies. Byl et al reported increased mast cell degranulation in porcine
flank wounds following a single TUS exposure (1 MHz, 500 mW/cm2 SATA, 20% PW, 5
minutes) 3. During the inflammatory phase, mast cell degranulation results in release of
histamine, serotonin, and heparin, which serve to increase vascular permeability,
inflammatory cell recruitment and to enhance angiogenesis 160.
Monocytes and macrophages have been shown to be responsive to TUS in vitro.
Human macrophages exposed to TUS (0.75 MHz or 3 MHz, 500 mW/cm2 SATA, CW, 5
minutes) released a soluble mitogenic factor into culture media, evident by fibroblast
proliferation that was induced after fibroblasts were cultured in the macrophage
conditioned media 161. Based on the time of response, the authors hypothesized that TUS
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exposure at 0.75 MHz resulted in release of pre-formed products only, while 3 MHz
exposures resulted in synthesis and release of the fibroblast mitogenic factor. Doan et al
investigated the variable effects of TUS on human monocytes, the blood-borne precursor
to macrophages 7. Single 5-minute exposures at 1 MHz, 20% PW with variable intensities
(20, 80, 140, and 200 mW/cm2 SATA) were compared. The treated monocytes released
more vascular endothelial growth factor (VEGF) at each intensity except 140 mW/cm2
compared to sham. Release of interleukin-8 (IL-8), basic fibroblast growth factor (bFGF),
interleukin-6 (IL-6) and tumor necrosis factor- (TNF- ) was not affected by TUS
exposure. The authors did report increased release of IL-1 in response to TUS at 45 Hz,
but this very low frequency is not considered traditional TUS and needs to be validated
further for clinical usage.
Lymphocytes have also been reported to respond to TUS exposures. Cultured
spleenocytes exposed to TUS (1 MHz or 3 MHz, 100 or 500 mW/cm2 SATA, CW, 10
minutes) exhibited altered production of interleukin-2 (IL-2), interleukin (IL-4) and
interferon- (IFN- ) 162. Following TUS exposure, spleenocytes were cultured with
Concanavalin A (Con A), a lectin protein known to stimulate T-cell production of IL-2, IL4 and IFN- . These cytokines are considered inflammatory regulators because they control
activities of T and B-lymphocytes, macrophages, natural killer (NK) cells and mast
cells 163. Treatment at both frequencies and intensities, followed by addition of Con A to
the culture media, resulted in increased IL-2 production. Con A addition after TUS at 1
MHz also resulted in increased release of IL-4 and IFN- , while Con A addition after TUS
at 3 MHz resulted in decreased release of IL-4 and IFN- . This finding suggests that TUS
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can alter cellular response to subsequent stimuli rather than only affecting on-going
processes.
In vivo assessment of the effect of TUS on inflammatory cells has also been
reported among investigations of wound healing in rats 133,134,135. Full-thickness flank
wounds were exposed to TUS (0.75 MHz or 3 MHz, 100 mW/cm2 SATA, 20% PW, 5
minutes, 5 or 7 treatments) 135. At 5 days post-injury, quantitative histological analysis
demonstrated a reduced number of neutrophils in wounds treated with TUS at 0.75MHz
compared to sham treated wounds. Macrophage number was also reduced in wounds
treated at either intensity (0.75 MHz and 3 MHz). No difference in cellular content of
healing wounds was noted when assessed at 7 days post-injury. Demir et al treated
incision wounds with TUS (1 MHz, 100 mW/cm2 SATA, 20% PW, 5 minutes, 4 or 10
treatments) and reported reduction in the number of neutrophils at 4 and 10 days postinjury and reduced macrophage and mast cell number 10 days post-injury compared to
sham TUS 133. In addition, fibroblast number and hydroxyproline content were increased
at both time points. Taskan et al 134 used an experimental model and TUS exposure
parameters identical to Demir et al 133, and reported a decrease in mast cells at 4 and 7 days
post-injury. Contrary to the other inflammatory cell studies in rat wounds, Taskan et al
reported that macrophage number in the wounds was increased at both post-injury time
points.
Most of the changes noted among these rat wound studies are consistent with
progression from the acute inflammatory phase to the proliferative phase of healing. The
exception being an increase in macrophages reported in one study. Overall, these findings
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indicate that the inflammatory phase was affected, and the preponderance of evidence
suggests that the change was acceleration rather than exaggeration of the inflammatory
phase.
A study examining an indirect effect of TUS on inflammatory cells does provide
some evidence for actual enhancement of inflammation 54. Isolated bovine endothelial
cells were exposed to TUS (1 MHz, 1600 mW/cm2, CW, 15 minutes) and were then
incubated with freshly isolated human polymorphonuclear leukocytes (PMNLs). Adhesion
of PMNLs to the sonicated endothelial cells was increased from 1 to 240 minutes postsonication in comparison to sham-treated endothelial cells. Since the initial stages of
inflammation include increased migration of leukocytes (PMNLs) from the vasculature
into the interstitium, potentiation of this process could result in increased inflammatory
activity 163.
Considering evidence from these investigations, numerous cells involved in the
inflammatory phase of healing have demonstrated responsiveness to TUS indicating that
sonication can affect processes in these cells. Inflammatory cytokine and growth factor
release, mast cell degranulation and increased endothelial cell adhesion properties are all
activities normally associated with the inflammatory phase of healing. The limited in vivo
evidence, suggests that both the inflammatory and early proliferative phases can be
accelerated by TUS treatment.
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Conclusion
In spite of the vast amount of research on TUS and its effects on healing, many
questions about its effects remain, such as the cellular activities that are most responsive to
TUS, the long-term benefit for soft tissue healing, the timing of treatment initiation, the
optimal TUS exposure parameters for enhanced healing and the biophysical mechanism of
TUS effects on various cell types.
The thermal affect of TUS is hypothesized to create some of the reported cellular
and tissue responses. Using appropriate TUS parameters, there is little question that tissue
heating occurs and this heating effects molecular movement. However, many
investigations have demonstrated TUS effects without measurable changes in temperature
or using parameters that are not expected to produce temperature increases, thus it is clear
that thermal changes need not be present for TUS to be effective.
Regarding nonthermal mechanisms, the current body of investigations has not
clearly elucidated the biophysical mechanism of action of TUS on cells and tissues.
Research findings suggest that a number of different mechanisms could be responsible for
TUS action. However, minimal evidence supports a correlation between any one of the
proposed nonthermal mechanisms of action, acoustic cavitation, free radical production
and acoustic streaming, to altered cellular functions. The technical difficulty in accurately
measuring these phenomena presents a considerable challenge in evaluating the role of
these proposed mechanisms. Furthermore, these proposed mechanisms could be occurring
in combination rather than exclusively, further complicating understanding of the role each
might play in cellular responses.
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TUS enhancement of tissue healing is supported in various models and tissue types
including bone, tendon, ligament, cartilage and integument. In fractures, the processes
responsible for the acceleration of fracture healing appear to be related to enhancement of
matrix production, chondrocyte and osteoblast activity, and the ability to enhance
vascularity. Accelerated healing of soft tissues (ligaments, tendons, articular cartilage, and
dermal wounds) also appears to be enhanced by TUS exposure, although some conflicting
results exist. For soft tissue healing, TUS affects cellular activities of inflammatory and
reparative phases of healing, with the overall result being enhanced matrix production and
deposition through resident cell (fibroblast and chondrocyte) activity.
It is apparent that many different TUS protocols and treatment parameter sets are
effective in altering various aspects of cellular function and tissue healing. However,
limited research has investigated the exact nature of the effect of different ultrasound
parameters, presumably because so many different ones are available. Additional research
is needed to assist in identifying the relationships between TUS parameters, possible
mechanisms of action and cellular response.
Enhancement of processes of the inflammatory and proliferative phase, many of
which are regulated by macrophages, is a likely mechanism by which TUS exposure
improves healing of injured tissues. Indeed, TUS exposure has been reported to induce
release of growth factors, cytokines and inflammatory mediators, as well as enhance
angiogenesis and ECM production and deposition during healing. Macrophages,
coordinators of inflammation and the early proliferative phase of healing, play a vital role
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in all of these processes during tissue healing and without them, poor healing quality
results 142,164-166.
Thus, the following chapters will describe our attempts to characterize the
macrophage response to varied TUS parameter sets and how those responses might be
related to the acceleration of early healing. In addition, we will explore the possible
mechanism of TUS that is associated with the macrophage response.
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Chapter 2
Effect of Therapeutic Ultrasound on Macrophage Release of
Fibroblast Mitogens

Abstract
Macrophages coordinate the action of many different cells involved in tissue repair
following injury. One way macrophages do this is by releasing paracrine factors that can
induce proliferation of resident cells that are responsible for rebuilding damaged tissue.
Therapeutic ultrasound (TUS) has been associated with enhancing the early stages of tissue
repair, when macrophages are likely to be active. The objective of this study was to
examine the effect of varied TUS parameter sets on macrophage release of fibroblast
mitogens, as evidenced by proliferation of fibroblasts exposed to macrophage conditioned
media. Phorbol-12-myristate-13-acetate (PMA) was used to induce differentiation of
monocytic U937 cells into activated macrophages. Macrophages were exposed to TUS for
5 or 10 minutes at 0, 40 and 400 mW/cm2 SATA, using a 20% duty cycle delivered at 1
and 3 MHz wavelength frequency. Macrophage conditioned media was collected at 10minutes and 1-hour post treatment. Proliferation of human gingival fibroblasts (HGF-1)
was assessed after incubation in the macrophage conditioned media. Fibroblasts
proliferation was not affected by incubation in macrophage conditioned media for 24 or
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48-hours, regardless of the combination of TUS intensity, wavelength and treatment
duration utilized for macrophage insonation. Our results indicate that TUS at the
parameters studied does not induce release of preformed fibroblast mitogens from
activated macrophages. Mitogenic response of fibroblasts to TUS is either mediated
directly by fibroblast response to sonication or induced by TUS parameters not included in
this study.
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Introduction
Following tissue injury, macrophages perform numerous functions including
coordination of the inflammatory and reparative phases of healing. Functions of
macrophages within the wound environment, include: phagocytosis of cellular and
extracellular matrix (ECM) debris, neutrophil removal, cellular recruitment, induction of
cell proliferation, and stimulation of cells responsible for ECM deposition and
angiogenesis 164-168. Many of these functions require secretion of chemical mediators (i.e.
cytokines, growth factors) by macrophages that act as autocrine and paracrine mediators
for cells in the wound healing milieu 163,164. As such, any altered release of secretory
products from macrophages is likely to impact the overall healing process.
Health care practitioners utilize TUS to improve tissue repair. TUS has been
reported to enhance healing of many tissues and numerous studies suggest that TUS most
likely enhances healing by affecting the early phases of the healing process
3,5,13,114,118,127,134,135,153

. Data from in vitro analyses of osteoblasts, fibroblasts and

chondrocytes indicate that TUS can alter many cellular processes including: genetic
transcription, granule release, protein secretion, matrix molecule synthesis and deposition,
and cell proliferation 8,9,10,96-98,159. During normal tissue repair, macrophages provide
molecular signals that stimulate many of the aforementioned cellular responses. It is
possible that TUS-enhanced healing occurs, at least in part, via stimulation of macrophage
function. Thus, it is important to understand what role macrophages play in the TUSinduced enhancement of tissue healing. However, only a few investigations have assessed
the effects of TUS on macrophage function.
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In vitro analysis has demonstrated that macrophages respond to TUS by releasing
paracrine factors involved with tissue repair 7,161. Young and Dyson reported increased
fibroblast proliferation following incubation in conditioned-media from sonicated
macrophages 161. The authors surmised that the macrophages released a growth factor into
the culture media following sonication, and in this way macrophages contribute to the
enhancement of healing induced by TUS. Young and Dyson also reported in vivo findings
of an accelerated inflammatory phase, specifically noting increased neutrophil clearance
rate, earlier recruitment and proliferation of fibroblasts and increased rate of granulation
tissue formation in the first week of healing of full thickness dermal wounds in rats 135.
Following injury to integument, ligaments and tendons, fibroblasts are the primary
cell type responsible for restoration of the connective tissue matrix and structural integrity
of the healing tissue 116,129,169. Fibroblasts are recruited to the site of injury via chemotactic
agents, are induced to proliferate, and are responsible for deposition of collagen and other
ECM proteins necessary for tissue repair 157,170. These functions of fibroblast are
coordinated in part by macrophage-released products such as cytokines and growth factors
129,164,171,172,173,174

. Given the limited data regarding macrophage response to TUS and the

possibility that macrophages directly contribute to TUS-enhanced healing, the purpose of
this investigation was to explore TUS effects on macrophage release of paracrine
mediators that modify fibroblast proliferation and to identify difference in macrophage
response to TUS treatment parameters.
The ranges of TUS parameters were selected considering the difference in cellular
responses that have been previously reported among in vitro investigations, in order to
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identify optimal TUS parameters for macrophage response. The experimental hypothesis
was that sonication would result in macrophage release of a stimulatory factor(s) that
enhances fibroblast proliferation, a process consistent with progression of the
inflammatory phase toward the reparative phase of healing and that these effects on
macrophage function will be dose-dependent.

Material and Methods
Materials and Reagents. Phorbol 12-myristate 13-acetate (PMA), dimethyl
sulfoxide (DMSO), and lauryl sulfate (SDS) were obtained from Sigma Chemical Co., St.
Louis, MO. Tris and the DC Protein Assay Kit were obtained from BioRad Laboratories,
Hercules, CA. The bovine serum albumin (BSA) protein standard was purchased from
Pierce Biotechnology Inc, Rockford, IL. Recombinant human platelet derived growth
factor-bb (rhPDGFbb) was purchased from R & D Systems, Minneapolis, MN. Glycerol,
sodium hydroxide, hydrochloric acid, and sterile pipets were purchased from Fisher
Scientific, Pittsburgh, PA. Other sterile culture equipment: tissue culture plates and
centrifuge tubes were purchased from Corning Inc., Corning NY. Microtubes were
purchased from ISC Bioexpress, Kaysville, UT. Cell Proliferation Assay Kits were
purchased from Chemicon Intl., Temecula, CA. Cell types used in this investigation:
human monocytic cells (U937), and human gingival fibroblasts (HGF-1) purchased from
American Type Culture Collection, Manassas, VA. Cell culture media reagents including:
RPMI-1640 culture media and Dulbecco’s Modified Eagle’s Medium (DMEM), sodium
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pyruvate, sodium bicarbonate, HEPES, L-glutamine, 0.25% trypsin, fetal calf serum and
penicillin/streptomycin/amphotericin B were purchased from Invitrogen, Carlsbad, CA.

Cell Culture
U937 cells. All cell manipulations were conducted using sterile technique within a
standard biological safety cabinet (Forma Scientific, Waltham, MA). Upon receipt, U937
(human monocytic) cells were thawed, expanded in RPMI growth media (RPMI-1640
supplemented with 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/L
sodium bicarbonate, 10% heat-inactivated fetal calf serum (HIFCS), penicillin 100 U/ml,
streptomycin 100 μg/ml, and amphotericin B 250 ng/ml), and then stored under liquid
nitrogen in cryovials in 1.5 ml aliquots at 1.0 x 106 cells/ml in RPMI growth media with
10% DMSO. U937 cells from this stock batch were thawed and cells between passages
3-12 were utilized for all subsequent experimentation.
To begin experiments, U937 cells were thawed at 37 C, suspended in 20 ml of
RPMI growth media, and centrifuged for 5 minutes at 200 x g to pellet the cells. Cells
were then resuspended in 20 ml of RPMI growth media, placed in 75 cm2 culture flasks
and maintained in a humidified, water-jacketed incubator cabinet at 37 C with 95% air, 5%
CO2 mixture. Cell concentration was maintained between 1 x 105 and 2 x 106/ml, per
manufacturer instruction. Cells were passed every 2-3 days to sustain appropriate
concentration and to provide enough cells for each experiment. For cell passages, media
containing cells were collected in 50 ml polypropylene tubes and centrifuged for 5 minutes
at 200 x g. The supernatant was decanted, and the cells were resuspended in 30 ml of
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RPMI growth media. Next, cell concentration was assessed using a standard laboratory
hemacytometer (Fisher Scientific, Pittsburgh, PA). Cells were then resuspended in RPMI
growth media at a concentration of 1 x 105 cells/ml in 20ml aliquots and returned to 75 cm2
flasks for further propagation.
HGF-1 Cell Propagation. Upon receipt from the vendor, HGF-1 cells were
thawed, washed and suspended in 25ml of DMEM growth media (DMEM supplemented
with 4mM L-glutamine, 1mM sodium pyruvate, penicillin 100U/ml, streptomycin
100μg/ml, amphotericin B 250ng/ml and 10% fetal calf serum). Cells were placed in a
75cm2 culture flask and grown in a humidified, water-jacketed incubator with 95% air, 5%
CO2 mixture. DMEM growth media was replaced every 2-3 days until cells reached
confluence. At confluence, cells were detached from the culture flask with 0.25% trypsin,
collected in sterile 50ml polypropylene tubes and centrifuged at 200 x g for 10 minutes to
pellet the cells. The cells were resuspended in DMEM growth media and were split 1:4
into 75cm2 flasks and returned to the incubator for further propagation. HGF-1 cells were
passed another time and grown to confluence. At confluence, cells were trypsinized,
collected and suspended in DMEM growth media containing 10% DMSO. Cells at a
concentration of 2-4 x 105 cells/ml were placed in 1.5ml aliquots in cryovials and stored
under liquid nitrogen. Experiments were completed using fibroblasts from the initial stock
batch described above. All experiments with fibroblasts were conducted using cells
between passages 5-10.
U937 Differentiation and Preparation for TUS Exposure. U937 cells exhibit a
monocytic phenotype, but can be induced to differentiate into macrophages through the
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addition of phorbol 12-myristate 13-acetate (PMA) 175. Differentiation of U937 monocytes
into macrophages parallels the transformation of circulating monocytes into macrophages
upon tissue injury or infection 176. The newly differentiated macrophages are equipped to
fully participate in inflammatory and immune functions. To induce differentiation into
macrophages, the following processes were completed. U937 cells were collected in 50 ml
tubes, pelleted by centrifugation for 5 minutes at 200 x g, and resuspended in RPMI
growth media. Cell concentration was determined and adjusted to a final concentration of
0.5 x 106 cells/ml in 120ml total volume of fresh RPMI growth media. Following this
dilution, cell concentration was again verified to insure appropriate final concentration.
PMA was added to the cell suspension to a final concentration of 50 ng/ml. U937 cells
were plated on 60 x 15 mm polystyrene culture plates in 5ml aliquots and incubated for 24
hrs to allow cellular differentiation and adherence to the plates. Following differentiation,
RMPI growth media containing PMA was removed and discarded, and cells were rinsed
with serum-free RPMI growth media. Fresh, serum-free RPMI growth media (5ml) was
added to each plate, and macrophages were returned to the incubator for an additional 24
hours. After the second incubation period, macrophages were rinsed with 5ml serum-free
RPMI growth media, covered with 10ml of serum-free RPMI growth media, placed in the
sonication apparatus and exposed to TUS as described below.
TUS Treatment of U937 Macrophages. For all experimental TUS exposures,
culture plates (samples) containing cells were treated using a system similar to that
described by Reher et al 177(Fig 2.1). A thermostatically controlled, circulation water bath
maintained at 37.0 C (Thermo NESLAB Model EX17) was used to maintain temperature
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of samples during ultrasound exposure. To allow samples undergoing sonication to
maintain contact with the heated water, a custom-designed suspension platform, made of
Lexan plastic, was fabricated. Culture plates were set in a centrally placed opening (60mm
diameter) and secured to plastic support braces with thumbscrews such that the bottom
surface of the dish was submerged in the water bath. A laboratory stand and adjustable
clamp were used to hold the ultrasound transducer in place above the sample during
sonication. The water bath, platform and transducer stand were placed within the sterile
hood for experimentation. Prior to treatment of each sample, the emitting crystal of the
transducer was cleaned with de-ionized water and sterilized using 70% ethanol. Once the
sample was secured in the platform, the transducer was lowered directly into the media to a
set height of 5 mm from the surface of the dish. The sample was then exposed to TUS at
the chosen parameters for 5 or 10 minutes using a stationary delivery technique. For sham
controls, samples were secured in the platform and the transducer was placed in the sample
for 5 or 10 minutes, but the ultrasound generator was not turned on. Immediately
following treatment, the media was concentrated by removal of 5ml of media, and the cells
were returned to the incubator for 10 minutes or 1 hour. Following post-TUS incubation,
conditioned media were collected under sterile conditions, centrifuged for 5 minutes at
200 x g to remove any cellular debris, and dispensed into aliquots in sterile 1.7ml
microtubes and stored at -70 C.
TUS was applied at 1 or 3 MHz frequency, with a duty cycle of 20%, resulting in
SATA intensity levels of: 0 (sham TUS), 40, or 400 mW/cm2 SATA. Each
intensity/frequency combination was applied for 5 and 10 minutes (Table 2.1). Each
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experimental block (set of TUS treatments) included each TUS parameter group for a total
of 10 parameter sets per experimental block. The order of application of each TUS
parameter set was randomized for each experimental block to reduce the possibility of
experimenter bias. Samples for each experimental block were labeled 1-10 following
sonication, and recorded in a database along with the corresponding parameter set. All
subsequent assays of conditioned media were completed using the 1-10 code from each
experimental block. Samples were matched to their particular TUS parameters only after
all data collection was completed. Each experimental block was conducted on a single day
using cells from the same stock batch to reduce intra-assay variability. A total of n = 5
experimental blocks were completed.
Fibroblast Incubation with Macrophage Conditioned Media. HGF-1 aliquots were
thawed, washed in plain DMEM and resuspended in DMEM growth media and propagated
under humidified incubation conditions as described above. Once cells neared confluence,
they were prepared for exposure to macrophage conditioned media as follows. DMEM
growth media was removed and the monolayer of cells was rinsed briefly with 5ml of
0.25% trypsin. The rinse was discarded and 8ml of fresh trypsin was added to each flask.
Flasks were returned to the incubator for 3-5 minutes to allow full detachment of cells.
The cell suspension was transferred into a sterile 50ml polypropylene tube and cells were
pelleted by centrifugation for ten minutes at 200 x g. The pelleted cells were resuspended
in fresh DMEM growth media and quantified. Concentration was adjusted to 20,000
cells/ml creating a “batch” of fibroblasts and 100 l of the suspension was added to wells of
a 96-well culture plate (Corning, Inc., Corning, NY) for a final concentration of 2,000
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cells/well. This concentration was used to insure the monolayer of fibroblasts would be
preconfluent and able to expand. From each batch of fibroblasts, two separate 96-well
plates were seeded to allow for 24 and 48-hour incubations.
Cells were placed in the humidified incubator for 4 hours to allow adherence to the
culture plate. Following cell attachment, the growth media was removed and 100 l of
fresh, serum-free DMEM was added to each well and the plate returned to the incubator for
24 hours. The serum-free incubation period served to bring the fibroblasts to a quiescent
state of activity prior to experimentation. At the end of the incubation period in serum-free
DMEM, media was removed from each well and replaced with 100 l of macrophage
conditioned media. Each macrophage conditioned media sample was loaded in duplicate
wells on each of the two plates for a total of 4 wells per conditioned media sample.
In addition to experimental macrophage conditioned media, negative and positive
control samples were included in the proliferation assay. Negative controls consisted of
fibroblasts incubated in non-conditioned (fresh), serum-free RPMI growth media. To
insure that the experimental fibroblasts were capable of proliferating, of fibroblasts were
incubated in serum-free RPMI growth media supplemented with rhPDGF-bb, a known
mitogenic agent for fibroblasts 178,179,180. Control media were incubated with fibroblasts in
the same plates and for the same time periods as the experimental samples.
To reduce intra-assay variability, all conditioned media samples from a single TUS
experimental block were added to plates that contained fibroblasts plated from a single
batch. Plates with fibroblasts in conditioned media were returned to the incubator for 24 or
48 hours. At the end of each incubation period, fibroblast proliferation was assessed to
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determine the effect of varied levels of TUS on macrophage-release of mitogenic factors
for fibroblasts.
Fibroblast Proliferation Assay. Fibroblast proliferation following incubation in
macrophage conditioned media was analyzed using a Cell Proliferation Assay Kit
(Chemicon Intl., Temecula, CA). The assay is based on assessment of mitochondrial
dehydrogenase cleavage of tetrazolium salt (WST-1) to formazan dye, a process that
increases as cell number increases, due to increased mitochondrial enzymes. At the end of
the conditioned media incubation (24 or 48 hours), fibroblasts were removed from the
incubator and 10 l of WST-1 reagent was added to each well of the culture plate. The
plates were mixed for one-minute using a microplate shaker, and then returned to the
incubator for four hours to allow development of the formazan dye. Finally, optical
density (OD) of the samples was measured with a microplate reader (SpectraMax Plus,
Molecular Devices, Sunnyvale CA) set at 450nm, with 650nm serving as the reference
wavelength. For each incubation time point, OD values were obtained from duplicate
wells for each conditioned media sample and averaged together prior to data analysis.
Validation of WST-1 Assay for Cell Proliferation. The WST-1 assay measures
cellular mitochondrial enzymatic activity. A greater number of cells (e.g. due to
proliferation) correlates with an increase in the number of available mitochondrial
enzymes 181. Despite this, it is possible that mitochondrial enzyme activity could change
without a change in cell number. To insure that increased OD measurements were
consistent with increased cell number, a validation assay was performed.
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HGF-1 cells propagated in DMEM growth media as described above were seeded
onto 96-well microplates in 100μl volumes for end concentrations of: 0, 1, 2, 4, and
8 x 103cells/well. Each cell concentration was seeded in replicates of five, one set of five
for analysis using the WST-1 assay and one set of five for direct cell counting. Cells were
incubated 4 hours to allow adhesion, and then media was removed and replaced with 100μl
of serum-free DMEM growth media. Cells were incubated 24 hours, after which the
serum-free DMEM growth media was removed and replaced with 100μl of RPMI growth
media, identical to macrophage RPMI growth media utilized in the TUS exposure
experimentation. The cells were returned to the incubator for 24 or 48 hours. At the end
of the respective incubation periods, one set of serial dilutions was analyzed by completing
the WST-1 assay as described previously, and the other set was analyzed by direct cell
counting. For direct counting, cells were released from the microplate using 0.25% trypsin
and counted using a standard light microscope and laboratory hemacytometer. OD values
that were obtained for 0 x 103 cells/ml were used as background measures of the WST-1
assay and were subtracted from all other values for plated cells at 1, 2, 4, and
8 x 103 cells/well.

Data Analysis/Statistics
For the five TUS experimental blocks, data is reported as the mean± SEM. Overall
differences in conditioned-media induced fibroblast proliferation were analyzed by oneway ANOVA (Sigma Stat version 2.03; Systat Software, Inc., Point Richmond, CA). All
post hoc analysis of significant differences was performed using Tukey’s HSD test using
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Sigma Stat version 3.01. All statistical analyses used an a priori p-value < 0.05 to
determine significant differences. WST-1 assay validation was completed using a linear
regression analysis on the variables of OD and cell counts, and is reported as the
coefficient of determination (R2).
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Figure 2.1

A

B
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Figure 2.1. Sonication Apparatus. A) Custom-designed suspension platform for securing
culture plates in the water bath and B) Sonication apparatus including suspension platform,
water bath, laboratory stand and adjustable clamp holding the ultrasound transducer. This
apparatus was used for all TUS exposures.
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Table 2.1
5 minutes

0 mW/cm2 (sham)

1 MHz

3 MHz

40 mW/cm2

40 mW/cm2

400 mW/cm2

400 mW/cm2

10 minutes

0 mW/cm2 (sham)

1 MHz

3 MHz

40 mW/cm2

40 mW/cm2

400 mW/cm2

400 mW/cm2
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Table 2.1. TUS Exposure Parameters. Listing of the exposure parameter combinations
utilized for sonication of macrophages with subsequent 10-minute or 1-hour incubation
post-TUS. All intensity values are reported as SATA at 20% duty cycle. Sham treatments
were completed for 5 minute and 10 minute exposures.
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Results
HGF-1 Fibroblast Proliferation.

Differences in fibroblast proliferation following

24-hour or 48-hour incubation in macrophage-conditioned media were assessed using the
WST-1 assay and analyzed by one-way ANOVA. Fibroblasts were incubated for each
time period in media conditioned by macrophages that were treated with TUS and
incubated post-TUS for either 10-minutes or 1-hour. Negative control samples for
proliferation consisted of fibroblasts incubated in unconditioned RPMI macrophage growth
media and positive control samples for proliferation consisted of fibroblasts incubated in
unconditioned RPMI macrophage growth media that was supplemented with 100ng/ml
rhPDGF-bb.
After 24-hour incubation in conditioned media, there were no significant
differences in fibroblast proliferation among any of the treatment groups for 10-minute
conditioned media (p = 0.783, F = 0.608) or 1-hour conditioned media (p = 0.747,
F = 0.641) compared to sham, negative control unconditioned media or positive control,
rhPDGF-bb-supplemented media (Fig. 2.2).
After 48-hour incubation in conditioned media, negative control media or media
supplemented with rhPDGF-bb ANOVAs revealed significant differences in fibroblast
proliferation for the 10-minute conditioned media plus controls comparison (p < 0.001,
F = 7.320) and for the 1-hour conditioned media plus controls comparison (p < 0.001,
F = 17.52). Post hoc analysis revealed that positive control media supplemented with
rhPDGF-bb stimulated significantly increased fibroblast proliferation compared to all other
groups (p < 0.001), while there were no significant differences in fibroblast proliferation
71

among any treatment groups (including sham) for 10-minute and 1-hour conditioned
media. There were also no differences between any treatment groups and the negative
control group. (Fig. 2.3).
WST-1 Proliferation Assay Validation. To validate the ability of the WST-1 assay
to measure increasing cell number, WST-1 assay and direct cell counting on known
concentrations of HGF-1 fibroblasts was performed. To simulate the media conditions of
the experimental fibroblast assay, serum-free, unconditioned, RPMI macrophage growth
media was used for fibroblast incubation for 24-hour and 48-hour incubation periods.
Fibroblasts were seeded at 0, 1, 2, 4 and 8 x 103 cells/well and allowed to incubate for the
corresponding time period. For both time points, linear regression analysis revealed a
direct correlation between increasing cell number and increasing OD measured via WST-1
assay, (24-hour; r2 = 0.907 and 48-hour; r2 = 0.939) (Fig. 2.4).
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Figure 2.2. HGF-1 Fibroblast Proliferation in Macrophage Conditioned Media – 24 hour
incubation. Fibroblast proliferation was assessed using the WST-1 assay following 24hour incubation in macrophage-conditioned media. (A) Fibroblast proliferation in
conditioned media from macrophages incubated for 10 minutes post-TUS, and in negative
and positive control media. Based on one-way ANOVA, there were no significant
differences in fibroblast proliferation among any treatment groups including sham,
negative control unconditioned media and positive control media supplemented with
100ng/ml rhPDGF-bb (p = 0.783, F = 0.608). (B) Fibroblast proliferation in conditioned
media from macrophages incubated for 1 hour post-TUS, and in negative and positive
control media . One-way ANOVA revealed no significant differences in fibroblast
proliferation among any treatment groups including sham, negative control and positive
control media (p = 0.747, F = 0.651). All data reported as the mean SEM of fibroblast
proliferation as percent of sham treatment, n = 5.
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Figure 2.3. HGF-1 Fibroblast Proliferation in Macrophage Conditioned Media – 48
Hour Incubation. Fibroblast proliferation was assessed using the WST-1 assay following
48-hour incubation in macrophage-conditioned media. (A) Fibroblast proliferation in
conditioned media from macrophages incubated for 10 minutes post-TUS and in negative
and positive control media.. Based on one-way ANOVA there were significant differences
in fibroblast proliferation (p < 0.001, F = 7.320) among the conditions. Post hoc analysis
revealed positive control media supplemented with 100ng/ml rhPDGF-bb significantly
increased fibroblast proliferation when compared to all groups including sham and
negative control samples (p < 0.001). (B) Fibroblast proliferation in conditioned media
from macrophages incubated for 1 hour post-TUS and in negative and positive control
media. Significant differences in fibroblast proliferation were found based on one-way
ANOVA (p < 0.001, F = 17.52). Post hoc analysis revealed rhPDGF-bb supplemented
media increased proliferation compared to all treatment groups including sham and
negative control samples (p < 0.001) indicated by *. All data reported as the mean SEM
of fibroblast proliferation as percent of sham treatment, n = 5.
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Figure 2.4
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1.2

Figure 2.4. WST-1 Proliferation Assay Validation. (A) Comparison of direct cell counting
and WST-1 assay for fibroblasts following 24-hour and, (B) 48-hour incubation in
unconditioned, macrophage growth media. Cells were seeded at 0, 1, 2, 4 and 8 x 103/well
and allowed to incubate for the 24 or 48 hours. Optical density values that were obtained
for 0 x 103 cells/ml were used as background measures of the WST-1 assay and were
subtracted from all other values for plated cells at 1, 2, 4, and 8 x 103 cells/well. For both
time points, linear regression analysis revealed a direct correlation between increasing cell
number and increasing optical density measured via WST-1 assay, (24-hour: R2 = 0.907)
and (48-hour: R2 = 0.939).
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Discussion
Since the WST-1 assay measures mitochondrial enzyme activity, it was imperative
to establish validity of the assay for measurement of increased cell number. Similar
validation of this colorimetric assay for assessing cellular proliferation has been reported
181

. In the current investigation, identical serial dilutions of fibroblasts were assessed by

direct counting and with the WST-1 assay. The regression analysis of these variables
showed good correlation (R2 = 0.907 – 0.939) between cell number and optical density,
thus verifying the ability of the WST-1 assay to assess cell number using our experimental
protocol.
In this study, none of the TUS parameter sets (Table 2.1) utilized for macrophage
sonication stimulated the release of fibroblast mitogens into the media that would
subsequently induce fibroblast proliferation. Conditioned media from macrophages
incubated post-TUS for 10-minutes or 1-hour had no effect on fibroblast proliferation
when comparing TUS treatment parameter sets to each other and to sham and negative
control samples, regardless of whether fibroblasts were exposed to the conditioned media
for 24 or 48 hours. The lack of proliferation of fibroblasts exposed to the conditioned
media was not due to the fibroblasts already being at their proliferative maximum, as the
ability of the cells to proliferate in response to mitogenic stimuli was demonstrated by the
fibroblast response to rhPDGF-bb supplementation of unconditioned RPMI macrophage
growth media.
Based on the WST-1 assay, the absence of increased fibroblast proliferation among
the conditioned media samples compared to sham, suggests macrophages may not respond
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to the selected TUS parameters by release of fibroblast mitogens. The lack of mitogen
release is contrary to findings reported by Young and Dyson 161. They reported increased
fibroblast proliferation following incubation in conditioned media from sonicated,
undifferentiated U937 macrophages (0.75 or 3 MHz, 500mW/cm2 SATA, CW, 5-minutes).
They also reported different effects on mitogen release from macrophages, as assessed by
fibroblast proliferation, based on the TUS wavelength frequency (0.75 and 3 MHz)
applied; specifically 0.75 MHz induced release of a fibroblast mitogen within 30 minutes
of sonication, while 3 MHz induced release when the media was sampled at 12 hours
post-TUS, but not when sampled at 30-minutes post-TUS. The current investigation
analyzed media that was conditioned for a maximum of 1-hour post-TUS. Given the
comparatively abbreviated incubation period of the current investigation, it was not
possible to verify or refute the differential response of macrophage release of fibroblast
mitogen at 12 hours post-treatment for 3 MHz TUS.
Methodological differences could be responsible for the variant findings of the
current investigation compared to Young and Dyson. U937 cells in the current
investigation were induced to differentiate toward terminal macrophages, compared to
undifferentiated U937 monocytes. Upon leaving the vasculature, monocytes differentiate
into tissue macrophages that will function in the healing process, which results in changes
in cellular and secretory activity 164,168. Effects of sonication on function of some cells,
specifically chondroblasts and spleenocytes, have been shown to be dependent on the state
of cellular differentiation 83,109,162. The difference in findings noted here, compared to
those of Young and Dyson, may be further evidence of TUS effects being specific to the
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state and/or activity of the treated cell. However, this differential cellular response to TUS
based on the state of cellular differentiation has not been reported in macrophages. Such a
comparison of cellular response to TUS between undifferentiated and differentiated U937
cells would provide insight about this type of response among monocytes and
macrophages.
TUS application in the current investigation was conducted using a 20% duty cycle,
compared to a CW application used by Young and Dyson. Varied TUS duty cycles have
been shown to stimulate different proliferative and secretory responses in sonicated cells
including osteoblasts, fibroblasts, and chondrocytes 7,83. While this effect is a plausible
explanation of the differences in findings noted above, the aim of this investigation was not
to identify the effect of altered TUS duty cycle and its affect on cellular response. As such,
a more detailed, directed experimental protocol designed to address this question would
provide better analysis of this question.
Lastly, the current investigation analyzed media that was conditioned for a
maximum of 1-hour post-TUS. Given this comparatively abbreviated incubation period, it
was not possible to verify or refute the differential response of macrophage release of
fibroblast mitogen at 12 hours post-treatment for 3 MHz TUS, as described by Young and
Dyson.

Conclusion
Overall, TUS at varied, clinically applicable levels had no effect on macrophage
release of fibroblasts mitogens 10 min or 1 hr post TUS. It appears that TUS does not
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affect an immediate release of fibroblast mitogens at the TUS parameters used in this
model. Differences in the state of cellular differentiation and the TUS duty cycle could
explain the lack of effect noted in this study in comparison to the findings of Young and
Dyson. The importance of these two variables in relation to macrophage response to TUS
deserves additional investigation.
Macrophage release of fibroblast mitogens is only one mechanism by which
macrophages could alter tissue healing in response to TUS. Macrophages produce and
release other paracrine factors that are capable of improving tissue healing. For example
IL-1 , TGF- and VEGF are released by macrophages and have beneficial effects on
tissue healing 182,183,184,185. These factors induce important aspects of the inflammatory and
early proliferative phase such as matrix removal 186,187, matrix deposition 188,189,190,191, and
angiogenesis 100,192,193. The macrophage response to TUS may involve these aspects of
tissue healing rather than induction of fibroblast proliferation. Indeed, fibroblasts
themselves respond to TUS by increased proliferation 8, and the TUS action on fibroblast
proliferation may be through direct action on fibroblasts rather than an indirect mitogenic
response mediated via macrophages. Given these other possible mechanisms of healing
enhancement by TUS and the lack of fibroblast proliferation in our experimental model,
we decided to explore the release of IL-1 , TGF- and VEGF from TUS-treated
macrophages.
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Chapter 3
Cytokine and Growth Factor Release From Activated
Macrophages Exposed to Various Levels of Therapeutic
Ultrasound

Abstract
During tissue healing, macrophages release various paracrine mediators, including
cytokines and growth factors. These cytokines and growth factors control various cellular
mechanisms of healing. Therapeutic ultrasound (TUS) is a treatment modality that is used
to enhance healing of injured tissues. In vitro analyses indicate that various levels of TUS
can alter the activity of many different cell types. In vivo investigations suggest that TUS
affects the early phases of tissue repair, at a time point which macrophages are likely to be
active. As such, we explored the effect of TUS on macrophage release of IL-1β, VEGF
and TGFβ1, paracrine factors involved in inflammation, angiogenesis and extracellular
matrix production. Activated U937 human macrophages were treated with 5 or 10-minute
TUS exposures using 1 and 3MHz frequencies at a 20% duty cycle at the intensities of 40,
and 400mW/cm2 SATA. Conditioned media from treated macrophages was collected at 10
minutes or 1 hour post-treatment and analyzed for the presence of IL-1β, VEGF and
TGFβ1 using enzyme-linked immunosorbent assay (ELISA). At 10 minutes posttreatment, TUS exposure for 10-minutes at 1MHz, 400mW/cm2 SATA, 20% duty cycle
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increased the release of IL-1 β and VEGF. However, no levels of TUS exposure affected
the release of TGF-β1from treated macrophages. IL-1β and VEGF are important
regulators of inflammation and angiogenesis, respectively, and the current findings suggest
that TUS may enhance the early phases of tissue healing by stimulating macrophage
release of these paracrine mediators.
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Introduction
Healing of injured tissues involves a complex array of interactions between cells
and cellular processes. When damaged, tissues respond with an orderly sequence of events
that leads to repair of the defect. The healing process is typically divided into four
overlapping phases; hemostasis, inflammation, repair and remodeling (maturation).
Inflammation begins within a few hours after injury and is largely completed by 72
hours 157. This phase of healing involves a dynamic and complex series of vascular,
cellular and biochemical reactions that prepare the wound environment for the reparative
phase in which the extracellular matrix and tissue integrity are restored 163,194.
The presence of macrophages in the inflammatory milieu is critical for tissue
repair. Absence or malfunction of macrophages during wound healing results in
inadequate succession of the reparative and remodeling phases of healing with an outcome
of poor tissue repair 195. In vivo healing models in which macrophage function was
prohibited, have demonstrated delayed and incomplete wound healing 165,166,196.
Macrophages develop from blood-borne precursors, monocytes 164,168. Following
tissue injury, products from activated platelets, prostaglandins from neutrophils, leukocytederived cytokines, protein products from degraded matrix, and chemical factors from
invading microorganisms are capable of inducing monocytes to leave the circulation and
differentiate into macrophages 164. These macrophages are responsible for the coordination
of the inflammatory and subsequent reparative phases of healing.
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Macrophages coordinate many actions of the inflammatory and reparative phases of
healing through the production of a variety of secretory factors, many of which are
cytokines and growth factors 132,194. These paracrine agents stimulate many tissue healing
processes such as phagocytosis, cell recruitment and proliferation, matrix molecule
degradation and production, and angiogenesis 89,100,166,172,197,198. Cytokines and growth
factors, produced by macrophages, that are believed to enhance healing include insulin-like
growth factor-1 (IGF-1), interleukin-1 (IL-1 ), transforming growth factor- 1 (TGF- 1),
vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet
derived growth factor (PDGF), and epidermal growth factor (EGF) 182,199,200.
TGF- 1 has been shown to increase tendon fibroblast collagen production and
result in increased mechanical stiffness of healing ligaments 170. Experimentally
decreased macrophage production of VEGF and bFGF during wound repair resulted in
delayed wound healing 195. PDGF, EGF and bFGF have a mitogenic effect on tendon and
ligament fibroblasts in vitro, and exogenous PDGF (20µg) increased the biomechanical
strength of rabbit ligaments, when it was added to the ligament after experimental ligament
transection 201,202.
Therapeutic ultrasound has been shown to affect the function of cells and tissues
during healing. Based on investigations of enhancement of soft tissue healing, TUS
appears to exert its primary effect on the inflammatory and repair phases of healing 4,1316,26,127,135,136,153

. The specific processes of the inflammatory and repair phases that are

affected by TUS continue to be identified. Given that macrophage function is crucial for
coordinating the inflammatory and early reparative phases of healing, macrophage
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response to TUS should be further explored in an effort to better understand the
mechanism of TUS effects on healing tissue.
Evidence directly concerning monocyte/macrophage secretory response to TUS is
limited to three published investigations 7,161,203. Young and Dyson treated human
monocytes (undifferentiated U937 cells) with TUS (0.75 MHz or 3.0 MHz, 500 mW/cm2
SATA, CW, 5 minutes) and reported the presence of an unidentified fibroblast mitogenic
factor in the culture media at 30 minutes and at 12 hours after TUS exposure 161. The
authors believed that TUS wavelength frequency affected sonicated monocytes
differentially based on the findings that 0.75 MHz caused release of the mitogenic factor
within 30 minutes of TUS application, while 3.0 MHz induced mitogen release by 12
hours post-TUS only.
Doan et al sonicated primary human monocytes at various intensities (20, 80, 140,
and 200 mW/cm2 SATA, 20% duty cycle, 5 minutes) using a 1.0 MHz frequency, and
measured release of cytokines and growth factors thought to be involved in controlling
angiogenesis during wound healing (IL-1 , bFGF, VEGF, IL-6, IL-8, and TNF- ) 7. TUS
at 1 MHz had no effect on monocytes release of IL-1 , bFGF, IL-6, IL-8, and TNF- at 18
hours post-TUS compared to sham-treated monocytes. However, monocytes treated at the
intensities 20, 80 and 200 mW/cm2 released more VEGF compared to sham, when
assessed 18-hours post-TUS. The authors also reported monocytes released IL-1 and
VEGF in response to ultrasound applied at 45 kHz. While this ultrasound wavelength is
much lower than traditional therapeutic ultrasound and continues to be validated for

87

clinical use, this finding provides further evidence that variable ultrasound frequencies
stimulate cytokine/growth factor release.
Iwabuchi et al reported increased release of TNF- from activated rat peritoneal
macrophages within 2 hours of a single TUS exposure at SAFHS, using a macrophageIVD co-culture model 203. The difference in TNF- release post-TUS, compared to Doan
et al (1999), is likely due to the difference in experimental protocols, for example single
cell type vs. co-culture; primary human macrophages vs. activated rat macrophages; and
different TUS treatment parameters.
The within study comparisons of the effect of varied TUS intensity or wavelength
frequency on macrophage function demonstrate differential effects on cellular secretion of
cytokines and growth factors 7,161. Furthermore, these three studies indicate that
monocytes and macrophages respond to both low-intensity TUS (< 100mW/cm2 SATA)
and higher-intensity TUS (500 mW/cm2 SATA) by releasing cytokines and growth factors.
However, comparison of ultrasound delivered at varied therapeutic levels of intensity,
wavelength and duration has not been conducted within one study.
The family of cytokines and growth factors encompasses many different peptides.
In order to investigate how TUS might effect the inflammatory and proliferative phases of
healing via altered macrophage function, we chose to analyze the release of IL-1 , VEGF,
and TGF- 1 from macrophages exposed to TUS. IL-1 is considered to be a proinflammatory mediator that stimulates many cellular actions that occur during
inflammation 204. Angiogenesis and ECM repair are major actions occurring during the
proliferative phase of healing and the growth factors VEGF and TGF- 1, respectively, are
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known mediators of these functions 101,190,192,205,206. Therefore, the purpose of this
investigation is to examine the effects of TUS, applied at varied levels of intensity,
wavelength frequency, and treatment duration, on release of IL-1 , VEGF, and TGF- 1
from activated, human macrophages in an effort to identify the TUS parameters that are
most stimulatory.

Materials and Methods
Materials and Reagents. Phorbol 12-myristate 13-acetate (PMA), dimethyl
sulfoxide (DMSO), and sodium dodecyl sulfate (SDS) were obtained from Sigma
Chemical Co., St. Louis, MO. Tris and DC Protein Assay Kit were from BioRad
Laboratories, Hercules CA. Glycerol, HEPES, sodium hydroxide, hydrochloric acid, heatinactivated fetal calf serum (HIFCS) and sterile pipets were from Fisher Scientific,
Pittsburgh, PA. Bovine serum albumin (BSA) protein standard was obtained from Pierce
Biotechnology Inc., Rockford, IL. Protease inhibitor cocktail was from Roche Applied
Science, Mannheim, Germany (Cat # 11 697 498 001). Human monocytic cells (U937)
were purchased from American Type Culture Collection, Manassas, VA. Sterile tissue
culture plates and centrifuge tubes were from Corning Inc., Corning NY. ELISA antigen
detection kits for IL-1 , VEGF, and TGF- 1 were acquired from R & D Systems,
Minneapolis MN. All other reagents were obtained from Invitrogen Corp., Carlsbad, CA.
U937 Cell Culture. All U937 cell manipulations were conducted using sterile
technique within a standard biological safety cabinet (Forma Scientific, Waltham, MA)
and are described in Chapter 2.
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U937 Macrophage Differentiation and Preparation for TUS Exposure.
Differentiation of U937 cells into macrophages was completed according to the protocol
previously described in Chapter 2 of this document.
TUS Treatment of U937 Macrophages. For all experimental TUS exposures,
culture plates (samples) containing cells were treated using a system similar to that
described by Reher et al, and described in detail in Chapter 2 of this document 177. Each
experimental block was conducted on a single day using cells from the same stock batch to
reduce intra-assay variability. A total of n = 3 experimental blocks were completed.
Cell Lysates post-TUS. Following sonication and incubation, macrophage
conditioned media was collected, centrifuged, dispensed into four aliquots in sterile 1.7 ml
microtubes and stored at -70 C. Cell lysis and total protein extraction was completed for
each sample of sonicated macrophages, in order to determine the total cellular protein from
each sample. Total cellular protein was used to normalize the data for cytokine release into
the media. Immediately after conditioned media collection, macrophages were rinsed three
times with 5 ml of sterile phosphate buffered saline (PBS), and covered with 500 ul of
sterile-filtered, chilled (4 C) Laemmli buffer, pH 6.8 (60 mM Tris-Cl, 5% SDS, 10%
glycerol, and protease inhibitor cocktail including inhibitors of serine, cysteine, metallo
and aspartic proteases). Cells were incubated with lysis buffer for 5 minutes on ice and the
lysates were collected in 1.7 ml microtubes. Lysates were centrifuged (Eppendorf 5804R,
Westbury, NY) at 20,000 g for 20 minutes at 4 C. The supernatant was transferred into a
fresh 1.7 ml microtube and stored at -70 C and the pellet was discarded.
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Total Protein Determination. Cell lysates from sonicated macrophages were
assayed for total protein concentration using the DC Protein Assay System. Protein
residues (tyrosine, tryptophan, cystine, cysteine and histidine) react with copper in alkaline
medium and then reduce a Folin reagent, which generates a blue color with maximal
absorbance at 750 nm. A SpectraMax Plus microplate reader (Molecular Devices,
Sunnyvale, CA) set to measure absorbance at 750 nm was used to analyze all samples.
Bovine serum albumin (BSA) standards were serially diluted in lysate buffer (0.25 mg/ml
to 2.0 mg/ml) to prepare a standard curve of protein concentrations. Total protein
concentrations of the cell lysates were interpolated from the standard curves using
manufacturer software for the microplate reader (Molecular Devices, Sunnyvale, CA).
ELISA assays for IL-1 , VEGF and TGF- 1. Analysis of conditioned media for
these growth factors was completed using commercially available, quantitative, sandwich
enzyme-linked immunosorbent assays (ELISA). Initial assays were completed for each
cytokine ELISA to determine the need to dilute conditioned media samples. Monoclonal
antibodies specific for IL-1 , VEGF and TGF- 1 were pre-coated onto 96-well plates.
Serial dilutions of the appropriate recombinant human antigen and macrophage
conditioned media samples were pipetted into the wells in duplicate and incubated 2-3
hours (per manufacturer directions) to allow antigen-antibody binding. Wells were washed
to remove any unbound material and a secondary polyclonal antibody labeled with
horseradish peroxidase was pipetted into each well. Following an incubation period of 1-2
hrs, wells were washed to remove unbound secondary antibody. A substrate solution
containing hydrogen peroxide and a stabilized chromogen (tetramethylbenzidine) was
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added to each well and incubated in the dark for 20 minutes to allow color development.
The degree of color developed in each well is directly proportional to the amount of bound
polyclonal antibody-enzyme conjugate. Finally, a stop solution, 2N HCl, was added to
each well and the optical densities measured on a SpectraMax Plus microplate reader set at
450 nm with wavelength correction set at 550 nm, per instructions of the ELISA
manufacturer. Detection ranges for the various cytokines growth factors are as follows:
IL-1 3.9 - 250 pg/ml, VEGF 15.6 - 1000 pg/ml, and TGF- 1 31.2 - 2000 pg/ml.
Cytokine/growth factor content was determined using the standard curve and was recorded
as pg/ml of media. The final cytokine growth factor concentrations (pg/ml) were then
normalized to total protein concentration (mg/ml) in the cell lysate, generating values
reported as pg cytokine/mg total cellular protein.

Data Analysis/Statistics
Each experimental block was repeated for n = 3 replicates for each TUS parameter
set tested. All conditioned media assayed for growth factors by ELISA and cell lysates
analyzed for total protein concentration were analyzed in duplicate, with the average being
reported. Values for statistical analysis are reported as mean ± standard error of the mean
(SEM). One-way analysis of variance (ANOVA) was used to evaluate for differences in
growth factor release among various TUS parameter sets for 10-minute and 1-hour
incubations. Tukey’s HSD post hoc analysis was employed to reveal specific differences
among treatment parameters. A p-value of < .05 was considered significant for all values.
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Results
IL-1 Release. One-way ANOVA revealed that IL-1β release was significantly
different among macrophages incubated for 10 minutes (p = 0.012, F= 3.584) and 1 hour
(p = 0.004, F= 4.465) post TUS exposure. Post hoc analysis revealed significant
differences in IL-1β release from macrophages among the TUS parameter sets for each
incubation period. For both incubation periods, 1 MHz, 400mW/cm2 SATA, 10-minute
treatment induced greater IL-1β release compared to all other parameter sets except
1 MHz, 400mW/cm2, 5-minute treatment (Fig. 3.1).
VEGF Release. VEGF release following TUS exposures was significantly different
among macrophages treated with various TUS parameters sets incubated for 10-minutes
(p = 0.003) and 1-hour (p = 0.036) post-TUS. Post hoc analysis revealed significant
differences in VEGF release among the parameters sets for both time periods (Fig. 3.2).
For the 10-minute post-TUS incubation, TUS at 1 MHz, 400mW/cm2 10-minute treatment
induced greater VEGF release than sham (p = 0.006), than 5-minute treatments delivered at
1 MHz, 40mW/cm2 (p= 0.004), 3 MHz, 40 mW/cm2 (p = 0.005), and 3 MHz, 400mW/cm2
(p= 0.007) and than 10-minute treatments delivered at 3MHz, 40mW/cm2 (p = 0.013). For
the 1-hour post-TUS incubation, TUS at 1 MHz, 400mW/cm2 10-minute treatment induced
greater VEGF release compared to sham treatment (p = 0.044) and TUS delivered at
3MHz, 40mW/cm2, 5-minute treatment (p = 0.028).
Unlike IL-1 release, VEGF release increased from 10-minutes to 1-hour post-TUS
for all samples, including shams. To assess these changes, the mean VEGF levels for each
parameter set at 10-minutes and 1-hour were calculated (Fig. 3.3). The difference of the
93

means between sham samples at 10-minutes and 1-hour was 74.522 pg/mg total cellular
protein. In comparison, mean differences between experimental samples ranged from
71.203 to 92.626 pg/mg total cellular protein. One-way ANOVA assessment of means
between incubation periods revealed no difference among any of the experimental or sham
groups (p = 0.989).
TGF- 1 Release. Based on ELISA, TUS exposures had no effect on TGF- 1
release from macrophages. No TGF- 1 was detected in any treated macrophage sample
regardless of TUS parameter selection and post-TUS incubation period. A standard curve
of serially diluted TGF- 1protein demonstrated that the ELISA was capable of measuring
TGF- 1 (Fig. 3.4). To determine whether U937 macrophages were capable of releasing
TGF- 1, cells were differentiated in PMA (50ng/ml) for 24 hours as previously described
and then incubated for 24-hours in serum-free RPMI growth media. U937 macrophages
released TGF-β1 (313.38

16.50 pg/mg total cellular protein, n = 4 samples) into the

conditioned media, as measured by ELISA.
Total cellular protein. Total cellular protein for each TUS parameter set and for
both incubation periods was analyzed by one-way ANOVA (Figs. 3.5 A,B). Cellular
protein amounts ranged from 87.5% to 104.9% of sham protein for 10-minute incubation
samples, and ranged from 97.4% to 109.9% of sham protein for 1-hour incubation samples.
One-way ANOVA revealed that total cellular protein was not significantly different among
any of the TUS parameter sets, including sham treatment, for the 10-minute incubation
(p = 0.612, F= 0.781) or 1-hour incubation (p = 0.940, F= 0.309).
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Figure 3.1. IL-1β release from TUS-treated macrophages incubated 10 minutes or 1 hour
post-TUS in serum-free media. Macrophages were treated with TUS and incubated for 10minutes or 1-hour. Conditioned media was then assayed for the presence of
cytokines/growth factors. One-way ANOVA revealed that IL-1β release was different
among macrophages incubated for 10 minutes (p = 0.012, F= 3.584) and 1 hour (p = 0.004,
F= 4.465) post TUS exposure. Post hoc analysis revealed significant differences in IL-1β
release from macrophages among the TUS parameter sets. For both incubation periods,
1 MHz, 400mW/cm2 SATA, 10-minute treatment induced greater IL-1β release compared to
all other parameter sets except 1 MHz, 400mW/cm2, 5-minute treatment. * and ** indicate
significantly increased IL-1β in conditioned media at 10 minutes and 1 hour post-TUS,
respectively, except where indicated by - and --. Values represent the average picograms
of IL-1β per milligram of total cellular protein for each TUS parameter set ± SEM for n= 3
experiments.
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Figure 3.2. VEGF release from TUS-treated macrophages at 10 minutes and 1 hour posttreatment. Macrophages were treated with TUS and incubated for 10-minutes or 1-hour.
Conditioned media was then assayed for the presence of cytokines/growth factors. Oneway ANOVA revealed significant differences in VEGF release from macrophages treated
with TUS and incubated for 10 minutes (p = 0.003, F= 4.649) and 1 hour (p = 0.036, F =
2.740) post-treatment. Post hoc analysis revealed that TUS at 1MHz, 400mW, 10-minutes
stimulated a significant increase in VEGF release at both post-TUS incubation periods.
For 10-minute incubation, # represents significant differences compared to 1MHz,
400mW/cm2, 10 minutes. For 1-hour incubation, * indicates significant increases in VEGF
release compared to 1MHz, 400mW/cm2, 10 minutes. Values represent the average
picograms of VEGF per milligram of total cellular protein ± SEM for n= 3 experiments.
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Figure 3.3. Difference in VEGF levels following 1-hour compared to 10-minute post-TUS
incubation. VEGF release increased from 10-minutes to 1-hour post-TUS for all samples,
including shams. VEGF levels for each sample at 10-minutes were subtracted from VEGF
levels for the corresponding sample measured at 1-hour. The mean difference between
sham samples was 74.522 pg/mg total cellular protein. Mean differences between
experimental samples ranged from 71.203 to 92.626 pg/mg total cellular protein. Oneway ANOVA revealed no significant differences between VEGF levels from 10-minutes to
1-hour post-TUS for any TUS treatment parameter set (p = 0.989, F= 0.190). Data points
represent the mean difference between VEGF levels from treated macrophages at 10minutes compared to 1-hour post-TUS incubation ± SEM of n = 3 replicates.
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Figure 3.4
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Figure 3.4. ELISA standard curve for TGF- 1. Recombinant human TGF-β1 protein
standard control samples were serially diluted and were added in duplicate to wells of a
microplate coated with a monoclonal antibody to human TGF-β1. Conditioned media
from macrophages treated with TUS and incubated for 10-minutes or 1-hour were also
added in duplicate wells of the microplate. The remainder of the assay was completed as
described in materials and methods. TGF-β1 was not detected in any of the experimental
samples, while the TGF-β1in the serially diluted standard control samples was detected.
R2 value represents the coefficient of determination for the linear regression analysis of
optical density vs. known concentrations of TGF-β1. Data points represent the mean of
two measurements for each TGF-β1 concentration.
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Figure 3.5. Total cellular protein from macrophages following TUS exposure and postTUS incubation for 10 minutes or 1 hour, as percent of sham controls. Cellular protein
content ranged from 87.5% to 104.9% of sham protein for 10-minute incubation samples,
and ranged from 97.4% to 109.9% of sham protein for 1-hour incubation samples. Oneway ANOVA revealed that total cellular protein was not significantly different among the
TUS parameter sets, including sham treatment, for the (A) 10-minute incubation
(p = 0.612, F= 0.781) and (B) 1-hour incubation (p = 0.940, F= 0.309). Values represent
the mean ± SEM of milligrams cellular protein per milliliter as a percent of sham control
milligrams cellular protein per milliliter for n = 3 samples at each parameter set and for
both post-TUS incubation periods.
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Discussion
Cytokines and growth factors play critical roles in the coordinated processes of
tissue repair 89,199 and their release following TUS exposure is one of the hypothesized
mechanisms of TUS-enhanced tissue healing 110,154,161,177. TGF- 1 and VEGF enhance
numerous cellular mechanisms of tissue healing 184,189,192,200,207,208,209, while IL-1 is
known to potentiate inflammation and has been reported to be an important regulator of
some of the cellular mechanisms of healing 183,210.
In the current study, macrophages exposed to TUS for 10 minutes at 1 MHz,
400mW/cm2, responded by releasing IL-1 and VEGF but not TGF-β1. The release of IL1 occurred within 10-minutes of sonication and there was no change when postsonication incubation was extended to 1 hour (Fig. 3.1). Interleukin-1, originally identified
as a leukocyte growth factor, exists in two distinct forms IL-1 and IL-1 . IL-1 is the
predominant form, although the two have very similar functions in controlling local and
systemic inflammation 211.
Mainly a product of monocytes and macrophages, IL-1 is an important regulator of
the inflammatory processes following injury and infection, as well as being noted as a
fibroblast mitogen 171,183,210. Much of its pro-inflammatory properties are derived through
activation of cyclooxygenase-2 (COX2) and subsequent release of prostaglandin-E2
(PGE2) 204,212-214. IL-1 is also involved in ECM catabolism through stimulation of matrix
metalloproteinase (MMP) production by fibroblasts 215 and macrophages 216, and by
promotion of neutrophil degranulation 217. Furthermore, IL-1 induces synthesis of other
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cytokines and growth factors that are involved with tissue healing in a paracrine and
autocrine manner 171,210.
Young and Dyson found an acute macrophage response to TUS similar to the
current investigation 161. They reported that undifferentiated U937 macrophages released a
fibroblast mitogen within 30 minutes of TUS exposure that was applied for 5 minutes (0.75
MHz, 500mW/cm2 SATA, 100% duty cycle). The identity of the mitogen was not
characterized, although IL-1 does exhibit mitogenic effects on fibroblasts 183,210. IL-1 is
capable of providing mitogenic stimulus to fibroblasts in culture 69, and increased levels
could provide a stimulus for fibroblast proliferation as described by Young and Dyson 161.
Increased fibroblast number in the wound milieu could account for the accelerated rate of
healing reported with in vivo investigations. However, we did not find any increase in
fibroblast proliferation, as discussed previously in Chapter 2, which suggest that IL-1
may not have been the mitogen responsible for the fibroblast proliferation reported by
Young and Dyson.
As evidence of a differential effect of TUS parameters on cellular response, Young
and Dyson also reported that no secretory response was found within 30 minutes of
sonication when TUS was applied using 3 MHz frequency for the same duration and at the
same intensity, but they did report that TUS delivered at 3 MHz resulted in mitogen release
at 12-hours post-exposure 161. In agreement with those results, we did not find an increase
in fibroblast mitogen (nor IL-1β or VEGF) release from macrophages within 1-hour of
insonation (Figs. 2.2, 2.3, 3.1 and 3.2) at 3MHz, regardless of the other TUS parameters
(Table 2.1). We did not explore whether U937 macrophages respond at time points
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beyond 1-hour, thus it is not known if treated cells in the current model respond over
longer periods of time post-TUS.
IL-1 release from TUS-treated, primary human monocytes has been previously
reported 7. TUS applied for 5 minutes (1 MHz, 80, 140 and 200mW/cm2 SATA, 20% duty
cycle) stimulated release of IL-1 , 18 hours after sonication. Unfortunately, the exact
timing of the cellular response is not known since no earlier incubation time points were
included. The monocytes also released IL-1 following a 5-minute sonication with a
continuous-wave, 45 kHz wavelength and intensities of 15, 30, and 50mW/cm2 SATA. At
present, this low frequency (45 kHz) is not available on clinical TUS machines and has not
been evaluated by others in relation to cytokine/growth factor release. However, the
stimulation of cellular activity at this alternative ultrasound frequency indicates that a
variety of combinations of wavelength, intensity and duty cycle affect cellular response to
TUS.
VEGF is known to be a regulator of angiogenesis during tissue repair 218 and its
importance to healing has been demonstrated in various models 101,193,193,208. Addition of
VEGF to full-thickness integument wounds accelerates tissue healing in vivo 101, while
decreased levels of VEGF are associated with delayed angiogenesis and delayed healing
219

. Non-union fractures in rabbits were stimulated to heal following addition of VEGF to

the injury site 193. A study on normal fracture repair revealed that inhibition of VEGF at
the fracture site resulted in decreased blood flow and non-union, while addition of VEGF
increased blood flow at the fracture site 208. Macrophages may play a role in VEGF release
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during wound healing as they produce and release VEGF in situations of tissue damage
and hypoxia 165,192,220.
Increased levels of VEGF were detected 10-minutes and 1-hour after applying TUS
for 10 minutes at 1 MHz, 400mW/cm2 (Fig. 3.2). One-hour post-TUS, VEGF levels were
increased in all experimental and sham samples in comparison to the 10-minutes levels,
which indicates that VEGF released between 10-minutes and 1-hour post-TUS was not
dependent on TUS stimulation. The continued increase in VEGF levels was most likely
due to constitutive release. The reasons for this hypothesis are first; the effect occurred
across all of the TUS parameter sets, regardless of whether there was an initial increase in
VEGF release. Also, increased levels of VEGF between 10-minutes and 1-hour incubation
post-TUS were nearly identical to the VEGF increase that was detected in the sham
samples over the same time period (Fig. 3.3). To support this hypothesis, statistical
analysis revealed no differences among the increased levels of VEGF for any TUS
treatment parameter sets over the additional 50 minutes of incubation time. Together with
IL-1 release, these findings indicate that the macrophages responded acutely to TUS.
TUS enhancement of healing has also been associated with enhanced
angiogenesis. TUS application (0.75 MHz, 100mW/cm2 SATA, 20% PW, 5 minutes)
accelerated angiogenesis in wounds in adult rat hind limbs after 5 days of treatment 135.
TUS treatment for 3 days (2 MHz, 50mW/cm2 SATA,CW, 5 minutes) increased VEGF
messenger ribonucleic acid (mRNA), overall vascularity, and blood flow in ischemic hind
limbs of adult rats 154. The cellular source of VEGF following in vivo TUS has not been
reported, but macrophages are a source of VEGF in humans and mice 185,220. The current
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findings that macrophages release of VEGF following sonication, in addition to previously
reported findings that monocytes release VEGF in response to TUS 177, suggest that
monocytes/macrophages are at least partly responsible for the angiogenic response to in
vivo TUS.
The current investigation did not find increased VEGF release from macrophages
treated at 40 mW/cm2 SATA, contrary to the report by Doan et al that primary monocytes
released increased amounts of VEGF when exposed to TUS at intensities within the same
range 20, 80 as well as at 200 mW/cm2 SATA 7. Doan et al utilized primary monocytes
that were not differentiated toward a macrophage phenotype. The state of cellular
differentiation can affect response to TUS 83,84,109 and is a possible explanation of the
variance in findings of the current investigation and Doan et al. Also, no intensities higher
than 200mW/cm2 SATA were assessed in their investigation, thus it cannot be refuted with
any certainty that the monocytes would have also responded to higher TUS intensities by
releasing VEGF.
Roles of TGF- in tissue repair include chemotaxis of reparative cells, stimulation
of release of other cytokines, and enhancement of matrix deposition 130,206,221,222,223. The
addition of TGF- to fibroblast cultures increased collagen production 191. Wound healing
in rats has been accelerated following topical application of TGF- , and decreased in rats
that are deficient in TGF-
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Regarding TUS, in vitro exposure stimulated TGF- secretion from osteoblasts and
chondrocytes 90,110. The increased release of TGF- from chondrocytes was directly
correlated with enhanced matrix molecule production and cellular proliferation 110. In the
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current investigation, TGF- 1 was not detected in the conditioned media of experimental
or sham samples at 10-minutes or 1-hour post-TUS. The inability to detect TGF- 1 was
not due to dysfunction of the ELISA as evidenced by the standard curve (Fig. 3.4) and by
detection of TGF- 1 in the media of untreated, differentiated macrophages incubated for
24 hours in serum-free RPMI growth media (data not shown). As such, it appears that
U937 macrophages do produce and release TGF- 1, but TUS does not stimulate its
immediate release, as is it does for IL-1 and VEGF.
To further evaluate this finding, the presence of TGF- 1 in cell lysates from
differentiated, non-treated U937 macrophages was evaluated. TGF- 1 was not present in
detectable levels, which suggests that U937 macrophages do not readily store TGF- 1
protein intracellularly, and therefore TUS could not stimulate its immediate release.
Supporting this, U937 macrophages have been reported to maintain constant levels of
TGF- 1 mRNA levels, with TGF- 1 protein production occurring upon cell stimulation
184,224,225

. Similarly, TGF- 1 protein has been detected in the cytosol of primary

macrophages, but its presence was dependent on prolonged exposure (24 hours or more) to
cellular activation signals 226,227.
In conjunction with TUS-induced cytokine and growth factor release, acceleration
of the healing process is hypothesized as a mechanism of TUS 32. As evidence of this
effect, in vivo TUS has been reported to enhance the early stages of healing (inflammatory,
proliferative) resulting in replacement tissue that is of better quality than untreated, healing
tissue 4,5,12,13,133. Earlier clearance of macrophages and enhanced angiogenesis in TUS-
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treated wounds also supports the acceleration hypothesis 135. Enhanced angiogenesis
stimulated by VEGF could provide the improved vascular response to healing and
accelerate tissue healing related to TUS exposure. Improved angiogenesis of healing tissue
following TUS has been reported in animal models for soft tissue and bone. The anabolic
and proliferative effects of TGF- 1 on tissue healing are important for completion of the
tissue healing process. Evidence suggests that TUS does not stimulate macrophage release
of TGF- 1, rather its release may be induced from resident cells of the healing tissues as
reported for osteoblasts and chondrocytes.
The mechanism that is responsible for transduction of ultrasound energy into
signals for releasing cytokines and growth factors is not known. Calcium flux across the
cell membrane, indicating increased membrane permeability, has been reported to occur in
TUS-treated cells 50,65,158. This ionic flux has been directly correlated with chondrocytes
release of the ECM protein, aggrecan 49. From this it follows that an increase in membrane
permeability could provide the stimulus for release of intracellular contents from sonicated
cells.
Genetic studies have identified numerous genes and their associated proteins that
are up-regulated by TUS, suggesting that TUS energy was transduced into an intracellular
signal that promotes genetic transcription and translation. This mechanism has been
reported for VEGF and TGF- in chondrocytes, periosteal cells and osteoblasts
10,11,64,90,110,154

. In the current investigation, the nearly immediate release of VEGF and IL-

1 is unlikely to have occurred as a result of genetic transcription, translation and protein
release.
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Another possible mechanism of the release of VEGF and IL-1 in the current
investigation is stimulation of exocytosis. Exocytosis of cytokines/growth factors occurs
as a process of interactions between membrane proteins, cytosolic granules and
cytoskeletal components 228-230. Alteration of proteins associated with the membrane,
vesicles and cytoskeleton following TUS could result in stimulation of exocytosis. As
evidence of this possibility, TUS has been reported to alter membrane proteins (G-proteins
and integrins) and associated second messenger proteins in fibroblasts and osteoblasts
123,125,231

. Thus, it may be that TUS affects exocytosis in addition to the longer-term affects

on genetic transcription and translation. Investigations of a cellular mechanism
responsible for TUS-stimulated release of cytokines and growth factors from macrophages
have not been reported and elucidation of the mechanism is important to aid in the
understanding of TUS affects on macrophage function and tissue healing.
Conclusion
U937 macrophages stimulated with TUS (1MHz, 400mW/cm2, 20% duty cycle, 10minute application) released IL-1 and VEGF into culture media within 10-minutes of
exposure. From the findings of IL-1 and VEGF release, it is apparent that macrophages
respond to TUS in a nearly immediate manner by releasing these molecules. Both IL-1
and VEGF are important paracrine regulators of the early stages of healing and as such,
their release into the wound bed following TUS may very likely be part of the overall
mechanism for TUS-accelerated healing that has been reported elsewhere.
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U937 macrophages are capable of producing and releasing TGF- 1. This response
was not stimulated in the post-TUS period up to 1-hour. The current study did not clarify
whether TUS stimulates TGF- 1 release from macrophages by a mechanism other than
that for IL-1 and VEGF, or if TUS-stimulated immediate release of TGF- 1 is precluded
due to the lack of intracellular stores. In chondrocytes, TUS has been reported to increase
TGF- 1 mRNA within 2 hours of treatment and to increase protein expression of TGF- 1
by 12 hours post-TUS 110. No similar investigations have been reported in relation to
macrophages. Mechanistically, therapeutic ultrasound units ultimately affect some
property of cellular physiology (e.g., membrane permeability, free radical formation, stable
cavitation, alteration of protein conformation, activation of second messenger systems).
For macrophages, this mechanism has been hypothesized to be part immediate release and
part stimulation of secretion. Given the differential expression of the cytokines and growth
factors in response to TUS, reported here and by other investigators as discussed, it is
important to provide a better characterization of the macrophage response to TUS.
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Chapter 4

Mechanism of Interleukin-1 Release From Macrophages
Treated With Specific Levels of Therapeutic Ultrasound

Abstract
Various cell types have been reported to respond to TUS by releasing cytokines and
growth factors. Release of these paracrine mediators is thought to be part of the
mechanism by which TUS enhances tissue healing. TUS exposure for 10-minutes at
1MHz, 400mW/cm2 SATA, 20% pulsed-wave at 37 C stimulates the release of IL-1 from
PMA-differentiated U937 macrophages. The purpose of this study was to investigate the
possible contributions of non-specific increased cell membrane permeabilization and
physiological processes in the release of IL-1 in response to TUS exposure at these
parameters. Based on previous data compared to the total cellular IL-1 in macrophages
not exposed to TUS, more than one-third of the total cellular content of IL-1 (197.648
16.016 vs. 75.774

33.057 pg IL-1 per 1 x 106 cells) was released in response to TUS.

Non-specific cell permeabilization following TUS exposure was analyzed via
measurement of LDH release into the media and microscopic evaluation of cells following
staining with the fluorescent dyes calcein-AM and ethidium homodimer (EthD-1) to
determine the proportion of cells permeabilized post-TUS. LDH release data indicates that
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approximately 10% of the cells were permeabilized. Altered physiological processes were
evaluated by exposing macrophages to TUS at 37 , 25 and 4 C. IL-1 release was
attenuated at the lower temperatures. This attenuation in cytokine release at lowered
temperatures suggests that, in addition to non-specific permeabilization, a specific
mechanism of cell-mediated release of IL-1 was stimulated by TUS. Because there are at
least four proposed mechanisms of IL-1 release from macrophages, further
experimentation is necessary to identify which of these is affected by TUS.
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Introduction
Many cell types, including osteoblasts, chondrocytes, fibroblasts, spleenocytes,
monocytes, and endothelial cells release secretory products following TUS exposure at
intensities ranging from 20 to 500mW/cm2 SATA and exposure durations of 5 to 10
minutes 90,110,161,162,177,232. In the current series of studies, activated macrophages were
induced to release increased amounts of IL-1 and VEGF within 10-minutes with no
further enhancement by 1-hour post-treatment, with TUS delivered for 10 minutes at
1MHz, 400 mW/cm2 SATA, 20% duty cycle. Release of cellular products in response to
TUS has been hypothesized to occur as release of material form preformed vesicles and as
release of products synthesized de novo 11,64,161,162,177. Given the rapid response in this
series of studies, it is likely that TUS stimulated release of preformed material either via a
form of cell-regulated exocytosis or at the result of cellular permeabilization.
TUS-induced cell membrane permeability changes following sonication have been
related to a generalized increase in membrane porosity and to calcium flux across the
membrane, which subsequently affects ion-gated channels 14,33,49,233,234. The increased
membrane porosity and calcium flux have been reported to be transient responses to TUS
and cells have been shown to revert back to normal membrane function soon after
sonication with minimal cell death occurring 235-239.
Changes in cell membrane permeabilization can be studied by measuring the
release of lactate dehydrogenase (LDH) from cells and through visualization of cells
following staining with dyes whose entrance into the cell is dependant on the degree of
permeabilization. LDH is a cytosolic enzyme that is released from cells when their
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membranes are damage 240, and therefore, has frequently been used as a marker of nonspecific permeabilization that occurs as a result of cell membrane damage. The fluorescent
cellular stains acetoxymethylester (calcein-AM) and ethidium homodimer-1 (EthD-1)
provide a reliable method of staining cells with intact membranes (calcein-AM) and cells
whose membranes have been permeabilized (EthD-1) 241,242. Numerous normal
physiological cellular processes are retarded with decreases in temperature away from
normal physiological levels of 37 C. As such, temperature reduction was used to help
delineate whether normal cellular processes were in part or in whole responsible for the
rapid release of IL-1β from the TUS stimulated cells. The purpose of this study was to
investigate the possible contributions of non-specific cell membrane permeabilization and
physiological processes in the release of IL-1 in response to TUS exposure for 10 minutes
at 1MHz, 400 mW/cm2 SATA, 20% duty cycle.

Materials and Methods
Materials. Phorbol 12-myristate 13-acetate (PMA), dimethyl sulfoxide (DMSO),
and lauryl sulfate (SDS) were obtained from Sigma Chemical Co., St. Louis, MO. Tris
and the DC Protein Assay Kit were obtained from BioRad Laboratories, Hercules, CA.
The BSA protein standard was purchased from Pierce Biotechnology Inc, Rockford, IL.
Glycerol, sodium hydroxide, hydrochloric acid, and sterile pipets were purchased from
Fisher Scientific, Pittsburgh, PA. Tissue culture plates and centrifuge tubes were
purchased from Corning Inc., Corning NY. Microtubes were purchased from ISC
Bioexpress, Kaysville, UT. Cell Proliferation Assay Kits were purchased from Chemicon
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Intl., Temecula, CA. Disk sterile filters (0.22 M) were obtained from (Millipore,
Billerica, MA). Human monocytic cells (U937) were purchased from American Type
Culture Collection, Manassas, VA. Cell culture media reagents including RPMI-1640
culture media, sodium pyruvate, sodium bicarbonate, HEPES, L-glutamine, 0.25% trypsin,
fetal calf serum, penicillin/streptomycin/amphotericin B, and phosphate buffered saline
(PBS) were purchased from Invitrogen, Carlsbad, CA. LDH assay kit was obtained from
BioVision Research Products, Mountain View CA. Calcein-AM and EthD-1 fluorescent
stains were obtained from Molecular Probes Inc, Eugene, OR. Visualization and
photography of fluorescent-stained cells was accomplished using a Nikon Eclipse TE300
Inverted microscope fitted with a Nikon DXM1200 digital still camera (Nikon Corp.,
Melville NY). Quantification of stained cells was completed using the Image Pro Plus
Software Program, Silver Spring MD.
Cell Culture (U937 cells). All cell manipulations were conducted using sterile
technique within a standard biological safety cabinet (Forma Scientific, Waltham, MA)
and were described previously in Chapter 2 of this document.
U937 Macrophage Differentiation and Preparation for TUS Exposure.
Differentiation of U937 cells into macrophages was completed according to the protocol
previously described in Chapter 2 of this document.
TUS Treatment of U937 Macrophages for IL-1 and LDH Release at Physiological
Temperature. Plated and differentiated macrophages were treated using a system similar
to that described by Reher et al, and described in detail in Chapter 2 of this document 177.
Each experimental block was conducted on a single day using cells from the same stock
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batch to reduce intra-assay variability (Table 2.1). A total of n = 3 experimental blocks
were completed.
LDH Assay. LDH in the conditioned media was assessed with a commercially
available colorimetric assay kit (Biovision Research Products) in which, LDH is quantified
based on the enzymatic conversion of tetrazolium salt (WST-1) to a formazan dye. LDH
initially catalyzes the oxidation of lactate to NADH (nicotinamide adenine dinucleotide).
The NADH then reacts with WST-1 to produce the formazan dye, a process that results in
the development of a yellow color. An increase in color intensity is directly correlated to
an increase in LDH in the conditioned media samples and this intensity can be measured
by assessing the optical density (OD) of each sample using a spectrophotometer at 450nm.
The assay was completed according to the manufacturer protocol.
Conditioned media samples were thawed in a water bath and immediately placed
on ice. 10ul of each conditioned media sample was added to duplicate wells of a clean 96well microtiter plate. Next 100ul of WST-1 assay solution was added to each well and the
reaction was allowed to proceed for 30 minutes up to 4 hours, until the OD of the 0.1ug/ml
LDH positive control had an OD of approximately 2.0 at 450nm, as recommended by the
manufacturer protocol. Sample plates were read on a microplate spectrophotometer
(SpectraMax Plus, Molecular Device, Sunnyvale, CA) at 450nm with the reference
wavelength set at 650nm. Samples were measured every 30 minutes until the positive
control reached the recommended OD. OD values were then recorded with values
representing the mean value of the sample duplicates. OD was normalized to total cellular
protein.
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For total cellular LDH analysis, macrophages were propagated and differentiated as
previously described in Chapter 2. Following 24-hr serum free incubation, cell lysates
were collected as described in Chapter 3. Analysis of total cellular LDH content was
conducted using the protocol described above in this section. For all LDH analyses, A
total of n = 3 experimental blocks were completed.
Total Protein Determination for Cell Lysates. Cell lysates from sonicated
macrophages were assayed for total protein concentration using DC Protein Assay System
(Bio-Rad Laboratories, Hercules, CA) as previously described in Chapter 3.
Treatment of Macrophages for Fluorescent Cell Staining. Cell staining based on
membrane permeabilization, as a measure of cell viability, was completed using the
Live/Dead Viability/Cytotoxicity Assay that includes the EthD-1 and calcein-AM
fluorescent dyes. The assay allows simultaneous determination of viable and non-viable
cells from one sample. EthD-1 is a cell impermeant dye that stains nucleic acids by
intercalating between base pairs, while calcein-AM is a cell permeant dye that is retained
in cells and fluoresces upon conversion to calcein after interacting with intracellular
esterases 241-243. Calcein-AM produces a bright green fluorescence at ~530nm, and EthD-1
produces a bright red fluorescence at ~635nm. Macrophages were stained following TUS
treatment using parameters sets of 1 MHz, 40mW/cm2SATA 20% PW; 1 MHz, 400mW/cm2
SATA 20% PW; and sham, all of which were applied for 10-minutes. Following
macrophage sonication and incubation for 10-minutes or 1-hour, calcein-AM and EthD-1
were added to the culture plates containing cells and conditioned media at concentrations
0.8µM and 2µM, respectively and incubated with the cells for 30 minutes at room
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temperature. After incubation, the media containing the dyes was decanted and the cells
rinsed three times with 5ml of PBS and then visualized using the Nikon Eclipse TE300
fitted with a high-pressure 75-watt xenon lamp and a 10X objective lens. Each
fluorophore was excited using a 495 nm excitation wavelength with fluorescence viewed at
530 nm for calcein-AM and 605 nm for EthD-1. Digital photographs were captured on the
ACT-1 software (Nikon, Melville NY). Multiple photographic images were required to
insure an adequate sampling of the treated macrophages coated on 60 x 15 mm plates.
Specifically, the plate was divided into 9 equally sized areas within the body of the culture
dish (Fig. 4.1). The 5 areas marked on the figure indicate the areas of each plate in which
the stained cells were photographed. The field of view was manually centered in each area
and three photographs were taken of each field: 1) normal light microscopy, 2)
fluorescence of the calcein-AM, and 3) fluorescence of the EthD-1 (Figs. 4.2-4.4). The
photographs were stored for later image analysis using the Image Pro Plus 4.1 software
program. For the fluorescent photographs, the software identified the area, in pixels, of all
the cells that were stained with calcein or EthD-1 within each field. For each photographic
field, the area of all stained cells, calculated by the image program from the number of
pixels, were summed to generate a total area for each fluorophore. The total areas from
each of the five fields of the culture plate were summed to give a total area of each
fluorophore per plate (the total number of pixels encompassing the stained cells). Thus,
there was a total area for each plate for calcein-AM stained cells and a total area for EthD1 stained cells. For each plate, the total area of the calcein-AM stained and EthD-1 stained
cells were summed to generate a total area of cells analyzed. This total cellular area of the
121

plate was used to generate the percentage of viable cells (calcein-AM stained) by dividing
the total calcein-AM stained area by the total cellular area and multiplying by 100. A total
of n = 3 experimental blocks were completed and each experimental block was conducted
on a single day using cells from the same stock batch.
To determine the ability of the combined calcein-AM and EthD-1 cell staining to
represent the total area of cells present on each analyzed field, total area determination was
also completed from normal light microscopy images. A sample of gray-scaled images of
two randomly selected fields from each of five randomly selected plates were analyzed
using the Image Pro Plus 4.1 software program and total cellular area (number of pixels)
for the fields was recorded (total of ten fields analyzed). These values were then used to
generate a percentage of total cellular area represented by the sum of the calcein-AM and
EthD-1 stained cells compared to the normal light microscopy images (data not shown).
Treatment of Macrophages at Variable Temperatures. Macrophages were
propagated, plated, differentiated and treated with TUS using the custom-designed
apparatus as described in Chapter 2 except; macrophages were exposed to TUS for 10
minutes using sham treatment (0 mW/cm2 SATA) and treatment at 1MHz, 400mW/cm2
SATA, 20% PW at 4 , 25 and 37 C and then incubated for 10-minutes post-treatment at
the respective temperatures. A thermostatically controlled water bath was utilized to
maintain the appropriate exposure temperature. Post-TUS incubations were completed on
ice (4 C), at room temperature (25 C) or in a humidified incubator maintained at 37 C.
Following incubation, conditioned media were collected as described previously, and
analyzed for the presence of IL-1 . A total of n = 3 experimental blocks were completed
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and each experimental block was conducted on a single day using cells from the same
stock batch.
ELISA for IL-1 β in Conditioned Media and Cell Lysates. Analysis of macrophage
conditioned media and cell lysates for IL-1β was completed using commercially available,
quantitative, sandwich enzyme-linked immunosorbent assays (ELISA; R & D Systems,
Minneapolis, MN) as described in Chapter 3. The detection range for IL-1 was 3.9 - 250
pg/ml. IL-1 content was determined using the standard curve and recorded as pg/ml. The
final concentrations (pg/ml) were then normalized to pg/1 x 106 cells/ml, based on the
number of macrophages plated.
IL-1 content in total cell lysates of untreated macrophages. To determine the total
amount of IL-1 in untreated macrophages, macrophages were propagated, plated and
differentiated as described previously. Macrophages at concentrations of 0.5, 0.25 and
0.125 x 106, cells/ml in 5ml of media for a total of 2.5, 1.25 and 0.625 x 106 cells,
respectively, were analyzed for IL-1 . Cell lysates were collected as described previously
and then analyzed by ELISA. Data for IL-1 content in total cell lysates from untreated
cells was normalized as picograms IL-1 per 1 x 106 cells. All macrophage cell lysates
assessed were from the same batch of cells. The data reported represents the mean ± SEM
of n = 3 for each cell concentration analyzed.
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Data analysis/Statistics.
For macrophage sonication and subsequent determination of LDH release, each
experimental block of TUS parameters was repeated for n = 5 replicates. For cell staining,
variable temperature experiments, and ELISAs for IL-1β from treated and untreated
macrophages, the experimental blocks were repeated for n = 3 replicates. All data are
represented as the mean of the replicates ± SEM. Data from all experiments was analyzed
using a one-way ANOVA with significance level set at p < 0.05 with post hoc testing
completed using Tukey’s HSD test.

Results
LDH release from macrophages. TUS exposure induced increased LDH release
from macrophages (p = 0.001, F = 7.734) following 10-minutes post-treatment incubation.
Post hoc analysis revealed that macrophages treated with TUS delivered at 1 MHz,
400mW/cm2, 10 minutes released an increased amount of LDH compared to other levels of
TUS, except TUS delivered at 1MHz, 400mW/cm2, 5 minutes (Fig. 4.5A). At 1-hour posttreatment, TUS also induced increased LDH release (p = 0.002, F= 4.057) (Fig 4.5B).
Based on post hoc testing, LDH release from macrophages treated at 1 MHz, 400mW/cm2,
10 minutes was increased over all other TUS parameter sets except 1MHz, 400mW/cm2, 5
minutes (Fig 4.5 A, B). Data represents the mean values for the optical density for the
LDH assay normalized to the total cellular protein from each treated sample for n = 5
samples at each TUS parameter set.
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Figure 4.6 represents the comparison of the total content of LDH in untreated
macrophages and LDH release from macrophages treated with the stimulatory TUS
parameters. Untreated macrophages plated at the same concentration as TUS-treated
macrophages (2.5 x 106 cells) contained approximately ten-times the amount of LDH
released in response to TUS, evidenced by the total cell lysate of untreated cells requiring a
10-fold dilution of samples to allow measurement of LDH content. This value provided
the estimate that approximately 1/10th of the total LDH was released in response to the
stimulatory TUS parameters.
Macrophage viability as a measure of permeabilization. Macrophages treated with
1MHz TUS for 10-minutes at 0, 40 or 400mW/cm2 SATA, 20% PW incubated for 10minutes or 1-hour post-TUS and stained with the fluorescent dyes, calcein-AM and EthD-1
were analyzed for total area of intact cells (Figs. 4.2-4.4, 4.7). Following 10-minute post
TUS incubation, the percentage of the total area of macrophages that were stained by
calcein-AM was not significantly different when comparing sham, 1 MHz, 40mW/cm2,
and 1 MHz, 400mW/cm2 (10 minute treatments) (p = 0.128, F= 2.952) (Fig. 4.7A).
Following 1-hour post TUS incubation, the percentage of the total area of macrophages
that were stained by calcein was significantly different among the treatment groups (p =
0.002, F= 17.930) (Fig. 4.7B). Post hoc testing revealed that calcein-AM staining was
significantly less for TUS treatment at 1 MHz, 400mW/cm2, 10 minutes compared to sham
(93.805% ± 1.637 vs. 98.433% ± 0.336, p = 0.003) and 1 MHz, 40mW/cm2 , 10 minutes
(93.805% ± 1.637 vs. 97.953 % ± 0.336, p = 0.005). These findings indicate that
approximately 7-8% of the treated cells were permeabilized by the stimulatory TUS
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parameter set and that percentage is comparable to the 10% of total LDH release, which
also characterizes the extent of non-specific permeabilization due to TUS.
The total area of fluorescently stained cells (calcein-AM and EthD-1) was
compared to total area of cells from normal light microscopy images from the same fields
of the culture plates (10 total fields from 5 culture plates) containing treated macrophages.
The total area of all fluorescently stained cells was 94.321% ± 1.578 of the total area of
cells identified in the light microscopy images of n= 10 fields analyzed (data not shown).
IL-1 content in total cell lysates of untreated macrophages. Cell lysates from 2.5,
1.25 and 0.625 x 106 differentiated, untreated macrophages were analyzed for IL-1 using
ELISA with data normalized as IL-1 per 1 x 106 cells. The concentration of IL-1 from
the samples was 197.648 ± 16.016 pg/1 x 106 cells (range 178.161 - 229.408 pg/1 x 106
cells) (Fig. 4.8A). This data was used to compare IL-1 release from macrophages treated
with various TUS parameter sets to the total IL-1 from untreated macrophages.
IL-1 content in conditioned media following TUS exposure. Macrophages
exposed to various levels of TUS (Table 2.1) released significantly increased amounts of
IL-1 at 10-minutes (p= 0.005, F= 4.203) and 1 hour post-TUS (p= 0.004, F= 4.560). Post
hoc analysis revealed that TUS delivered at 1MHz, 400mW/cm2 SATA, 10-minute
treatment induced significantly greater IL-1 release when compared to all other TUS
parameter sets at 10 minutes and 1 hour incubation post-TUS (Fig 4.8B) for n = 3 separate
TUS experiments (p < 0.05). TUS-stimulated macrophages released 75.774

33.057 pg

IL-1 / 1 x 106 cells protein, compared to the total cellular content of 197.648 ± 16.016 pg
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IL-1 /1 x 106 cells (Fig 4.8A,B). These findings indicate that approximately 1/3rd of the
total cellular IL-1 was released by macrophages in response to the stimulatory TUS
parameter set.
Comparison of the release of greater than 30% of the total IL-1 to the 7-10% of
non-specific permeabilization indicated by LDH and fluorescent staining suggests that
another mechanism beyond non-specific membrane permeabilization is likely responsible
for a portion of the IL-1 released by TUS-exposed macrophages.
Temperature effect on IL-1 release from macrophages treated with TUS at 1MHz,
400mW/cm2 SATA, 20% PW, 10-minutes. The release of IL-1 in response to TUS was
affected by temperature during TUS exposure and the post TUS incubation (p < 0.001, F=
15.081) (Fig. 4.9). Post hoc analysis indicated that macrophages released increased
amounts of IL-1 when TUS (1MHz, 400mW/cm2 SATA, 20% PW, 10 minutes) was
carried out at 37 C when compared to all sham treatments and compared to TUS (1 MHz,
400mW/cm2 SATA, 10 minutes) completed at 4 C, as indicated by (p < 0.05). TUS
(1MHz, 400mW/cm2 SATA, 20% PW, 10 minutes) delivered at 25 and 37 increased the
release of IL-1 compared to sham treatments at the respective temperatures (p < 0.05). In
addition, IL-1 release was greater at 37 C compared to 25 C and 25 C compared to 4 C
and but neither trend was not statistically significant (p = 0.08, p = 0.061).
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Figure 4.1
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Figure 4.1. Culture plate areas analyzed for cell staining. Diagram representing the five
selected fields that were photographed and analyzed for calcein-AM and ethidium
homodimer staining of insonated macrophages. All culture plates of stained macrophages
were analyzed from these fields. Data from the five fields were summed and the summed
data was reported as representative of total area of stained cells for each plate.
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Figure 4.2
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Figure 4.2. Images of macrophages stained with calcein-AM, ethidium homodimer or
unstained, following sham TUS exposure, 0 mW/cm2 SATA, 10 minutes and 10-minute or
1-hour post-TUS incubation. Images were captured using a Nikon Eclipse TE300
microscope fitted with a high-pressure 75-watt xenon lamp for fluorescent imaging and a
10X objective lens. A) Macrophages incubated with 0.8 M calcein-AM, a membrane
permeant dye that is converted to a green fluorescence based on intracellular esterase
activity, demonstrating viable cells, B) Macrophages incubated with 2.0 M EthD-1, a dye
which enters cells with damaged membranes and increases fluorescence after binding to
nucleic acids, C) Overlay of images calcein-AM and EthD-1 stained cells, and D)
Unstained macrophages imaged under normal light microscopy conditions. All three
images are of macrophages from the same field and are representative of the images
analyzed for cytotoxicity of the TUS treatment.
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Figure 4.3
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Figure 4.3. Images of macrophages stained with calcein-AM, ethidium homodimer or
unstained, following TUS exposure at 1MHz, 40mW/cm2 SATA, 20% PW 10 minutes and
10-minute or 1-hour post-TUS incubation. Images were captured using a Nikon Eclipse
TE300 microscope fitted with a high-pressure 75-watt xenon lamp for fluorescent imaging
and a 10X objective lens. A) Macrophages incubated with 0.8 M calcein-AM, a
membrane permeant dye that is converted to a green fluorescence based on intracellular
esterase activity, demonstrating viable cells, B) Macrophages incubated with 2.0 M EthD1, a dye which enters cells with damaged membranes and increases fluorescence after
binding to nucleic acids, C) Overlay of images calcein-AM and EthD-1 stained cells and,
D) Unstained macrophages imaged under normal light microscopy conditions. All three
images are of macrophages from the same field and are representative of the images
analyzed for cytotoxicity of the TUS treatment.
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Figure 4.4. Images of macrophages stained with calcein-AM, ethidium homodimer or
unstained, following TUS exposure at 1MHz, 400mW/cm2 SATA, 20% PW 10 minutes and
10-minute or 1-hour post-TUS incubation. Images were captured using a Nikon Eclipse
TE300 microscope fitted with a high-pressure 75-watt xenon lamp for fluorescent imaging
and a 10X objective lens. A) Macrophages incubated with 0.8 M calcein-AM, a
membrane permeant dye that is converted to a green fluorescence based on intracellular
esterase activity, demonstrating viable cells, B) Macrophages incubated with 2.0 M EthD1, a dye which enters cells with damaged membranes and increases fluorescence after
binding to nucleic acids, C) Overlay of images calcein-AM and EthD-1 stained cells, and
D) Unstained macrophages imaged under normal light microscopy conditions. All three
images are of macrophages from the same field and are representative of the images
analyzed for cytotoxicity of the TUS treatment.
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A

2.5

2.0

1.5

*

--

1.0

0.5

0.0

Macrophage Treatment Parameters (mW/cm2 SATA)

B
2.5

2.0

*

1.0

--

0.5

0.0

Figure 4.5. Lactate dehydrogenase release from TUS-treated macrophages incubated for
10-minutes and 1-hour post-treatment. A) TUS exposure induced increased LDH release
from macrophages (p = 0.001, F = 7.734) following 10-minutes post-treatment incubation.
Post hoc analysis revealed that macrophages treated with TUS delivered at 1 MHz,
400mW/cm2, 20% PW, 10 minutes released an increased amount of LDH compared to
other levels of TUS, except TUS delivered at 1MHz, 400mW/cm2, 20% PW, 5 minutes as
indicated by the * and -- symbols. B) Lactate dehydrogenase release from TUS-treated
macrophages incubated for 1-hour post-treatment. At 1-hour post-treatment, LDH release
from macrophages insonated at 1 MHz, 400mW/cm2, 20% PW, 10 minutes were increased
over all other TUS parameter sets except 1MHz, 400mW/cm2, 20% PW 5 minutes, as
indicated by the * and -- symbols (p = 0.002, F= 4.057). Data represents the mean values
the optical density for the LDH assay normalized to the total cellular protein from each
insonated sample for n = 5 samples at each TUS parameter set. All significant differences
were noted with p < 0.05.
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Figure 4.6. Comparison of Lactate Dehydrogenase in Conditioned Media from TUStreated Macrophages and from Total Cell Lysates of Untreated Macrophages. LDH was
measured in conditioned media at 10-minutes and 1-hour post-treatment from
macrophages exposed to TUS (1MHz, 400mW/cm2 SATA, 20% PW, 10-minutes) and also
in total cellular lysates of untreated macrophages. Data represents mean ± SEM of n = 3
separate samples.
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Figure 4.7
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Figure 4.7. Analysis of macrophage staining with fluorophores, following TUS exposure
and 10-minute and 1-hour post-TUS incubation. Macrophages were insonated for 10
minutes, at 1MHz, 40 or 400 mW/cm2 SATA, 20% PW incubated for 10-minutes or 1-hour
post-TUS and then stained with the cell permeant fluorescent dyes, calcein (viable cells)
and EthD-1 (permeabilized cells). Images of the stained cells were analyzed for total area
(total # of pixels) encompassing both calcein and EthD-1 stained cells. A) At the 10minute incubation time point, the percentage of the total area of macrophages that were
stained by calcein were not significantly different when comparing sham, 1 MHz,
40mW/cm2, and 1 MHz, 400mW/cm2. 20% PW (10 minute treatments) (p = 0.128, F=
2.952). B) At the 1-hour incubation time point the percentage of the total area of
macrophages that were stained by calcein was significantly different among treatment
groups (p = 0.002, F= 17.930). Specifically, calcein staining for TUS treatment at 1 MHz,
400mW/cm2, 20% PW, 10-minutes was significantly decreased compared to sham and 1
MHz, 40mW/cm2, 20% PW, 10-minutes (p = 0.003, p = 0.005 respectively). Data
represent mean ± SEM of n = 3 samples at each treatment parameter set.
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Figure 4.8. IL-1 content in total cell lysates of untreated macrophages and conditioned
media from macrophages exposed to various levels of TUS. A) Total cell lysates from
differentiated, untreated macrophages (2.5, 1.25 and 0.625 x 106 cells) were analyzed for
IL-1 using ELISA, which determined pg/ml of IL-1 . The concentration of IL-1 is
reported as IL-1 per 1 x 106 cells. IL-1 concentration ranged from 178.161 to 229.408
pg/1 x 106 cells, with a mean ± SEM of 197.648 ± 16.016. Data represents the mean ±
SEM for n = 3 at each cell concentration. B) IL-1 released from 0.5 x 106 cells/ml (total
of 2.5 x 106 cells plated) exposed to various levels of TUS and incubated for 10 minutes or
1-hour post-TUS. Release of IL-1 was significantly increased by TUS at 10-minutes
post-TUS (p= 0.005, F= 4.203) and at 1 hour (p= 0.004, F= 4.560). Post hoc analysis
revealed that TUS delivered at 1MHz, 400mW/cm2 SATA, 20% PW, 10-minute treatment
induced significantly greater IL-1 release (p < 0.05) when compared to all other TUS
parameter sets at 10-minute and 1-hour incubation post-TUS, as indicated by # and *.
Data represents the mean ± SEM of picograms IL-1 released per 1 x 106 cells for n = 3
separate TUS experiments.
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Figure 4.9. IL-1 release from macrophages treated with TUS at variable temperatures.
Macrophages were treated for 10 minutes with sham TUS or TUS delivered at 1MHz,
400mW/cm2 SATA, 20% PW and incubated for 10-minutes post-exposure at 4 , 25 and
37 C. IL-1 release was compared between the groups of macrophages exposed to TUS at
the variable temperatures. Macrophage release of IL-1 was affected by the TUS exposure
and by the temperature of TUS exposure (p < 0.001, F= 15.081). Post hoc analysis
indicated that macrophages released greater amounts of IL-1 when TUS (1MHz,
400mW/cm2 SATA, 10 minutes) was applied at 37 C compared to sham treatments at each
temperature and compared to TUS applied at 4 C, as indicated by *, p < 0.05. IL-1
release following treatment at 25 was decreased compared 37 C treatment, but the trend
was not statistically significant (p = 0.08). TUS applied at 25 C increased IL-1 release
compared to sham treatments at 4 and 25 C, as indicated by #, p < 0.05. The trend of
increased IL-1 release with TUS applied at 25 C compared to 37 C sham treatment was
not statistically significant (p = 0.055). Data represents the mean ± SEM of n = 3 samples
at each parameter set/temperature of TUS.
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Discussion
TUS stimulates cellular activities that result in the release of various substances
from cells in vitro. Monocytes and macrophages respond to TUS by release of cytokines
and growth factors. Previously, we identified a set of specific TUS parameters (1MHz,
400mW/cm2 SATA, 20% PW, 10-minute treatment) that induced the release of IL-1 from
activated macrophages. In addition, we found that the macrophage response occurred
within 10 minutes post-TUS. The goal of this investigation was to begin to characterize
the possible cellular mechanism(s) responsible for the macrophage response to TUS using
the treatment parameters identified in the earlier aspects of this series of investigations
Release from cells post TUS has been hypothesized to occur as a result of increased
membrane permeability or enhanced metabolic processes of exocytosis or stimulation of
protein synthesis and exocytosis 233. The rapid release of IL-1 following TUS suggests
that the response involved release of pre-formed protein rather than synthesis and release.
This study analyzed TUS-induced release via two mechanisms, non-specific membrane
permeabilization and exocytosis. LDH release and staining of intact and permeabilized
membranes were used to assess non-specific permeabilization of cells. To explore
exocytosis as a mechanism of response, the effect of varied temperature on TUS
stimulation of IL-1 release was assessed. Because lowered temperature reduces many
cellular metabolic processes, including Exocytosis 246, this method of analysis provided
indirect evidence that exocytosis of IL-1 was stimulated by TUS.
LDH is an intracellular enzyme that is released from cells with damaged
membranes and is used to identify cellular treatments that damage cell membranes 240,244.
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Utilizing this marker, we found that membrane damage occurred in macrophages following
exposure to the TUS parameter set (1MHz, 400mW/cm2 SATA, 20% PW, 10-minute
treatment) that stimulated release of IL-1 as evidenced by the increased levels of both
LDH and IL-1 when macrophages were exposed to this TUS parameter set (Figs. 4.5,
4.8). Cell lysates from untreated macrophages plated at the same concentration as TUStreated macrophages contained nearly ten-times the amount of LDH that was released due
to TUS exposure (Fig. 4.6). This suggests that approximately 10% of treated cells had
sufficient membrane damage to allow release of LDH into the culture media. However, it
is possible that the 10% of total LDH release due to TUS represents non-specific
permeabilization of all the cells so as to allow release of only a fraction of intracellular
contents from all cells.
The extent of membrane permeabilization related to TUS exposure was also
explored by directly examining cells following insonation. Using the fluorescent dyes
calcein-AM and EthD-1, which identify healthy and membrane-damaged cells
respectively, we found that TUS (1MHz, 400mW/cm2 SATA, 20% PW, 10-minute
treatment) induced a significant increase in cells with damaged membranes (Figs. 4.7).
Quantification of cells with intact and damaged membranes revealed that approximately
5% more of the total cells treated with TUS using had membrane damage compared to
sham treated cells. The total combined area from intact and damaged cells comprised
approximately 94% of the total cell area measured from the unstained, gray-scaled images
of the fluorescent stained cells. This indicates that there was a 5-6% under-estimation of
the total area from the measurements of the fluorescent images. If the underestimation of
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total area included only damaged cells that were not stained with EthD-1, the total
percentage of damaged cells would approach 10-11% of cells. In this “worst case”
scenario”, this value is in the range of that we found in the analysis of LDH release
compared to total LDH content in the experimental cells, lending further support to the
conclusion that approximately 10% of the insonated cells had membrane damage.
Given the two analyses indicating approximately 10% of treated cells were
permeabilized, we compared the release of IL-1 following TUS exposure to IL-1
content of untreated cells in order to estimate the portion of total IL-1 released from
treated cells. Macrophage cell lysates contained 197.648

16.016 pg IL-1 per 1 x 106

cells, and macrophages treated with the stimulatory TUS parameter set (1MHz,
400mW/cm2 SATA, 20% PW, 10-minute treatment) released 75.774

33.057 pg IL-1

per 1 x 106 cells. Comparing these two values, it appears that greater than one-third of the
available IL-1 was released following TUS exposure (Fig. 4.8). This is substantially
greater than what would be expected based on the permeabilization data that indicated
damage to 10% of the cells. Thus, it appears that only a portion of IL-1 release was
related to permeabilization of the cells, with the remaining portion of IL-1 release was
due to stimulation of a form of cell-controlled exocytosis.
To investigate whether TUS induced metabolic cellular changes that may have
contributed to IL-1 release, macrophages were exposed to TUS (1 MHz, 400 mW/cm2
SATA, 20% PW, 10-minutes) at various temperatures (4 , 25 and 37 C). At
temperatures below 37 C metabolic process are slowed 245,246, therefore, if IL-1 release

148

was in part due to cell-mediated metabolic processes, release following TUS would be
reduced at the lower temperatures. The results confirmed this hypothesis. Compared to
37 C, IL-1 release was significantly reduced at 4 C and there was a trend towards
reduced release at 25 C indicating that decreased temperature attenuated the effects of
TUS on macrophages, most likely due to decreased physiological activity of cells
associated with decreased temperatures (Fig 4.9). In support of this hypothesis, decreased
IL-1 release from LPS-stimulated macrophages after incubation for two hours below
physiological temperatures (32 C) compared to 37 C has been reported 259. LPS is
thought to stimulate several cell signaling mechanisms including tyrosine kinases,
mitogen-activated protein kinase C, protein kinase A, G-proteins, and microtubules which
can induce secretory responses 247-249.
One confounding factor in the data from macrophages exposed to TUS at different
temperature was identified when IL-1 release due to TUS from the two separately
conducted macrophage-TUS experiments was compared. In the normal-temperature TUS
experiments, macrophages released 75.774

33.057 pg IL-1 per 1 x 106 cells IL-1 (Fig.

4.6B), while in the subsequent variable-temperature experiments macrophages stimulated
with the same TUS parameters (1 MHz, 400 mW/cm2 SATA, 20% PW, 10-minutes) at
physiological temperatures (37 C) released 22.889

2.723 pg IL-1 per 1 x 106 cells

(Fig. 4.9). This lower level of release represents nearly 11% of the total cellular IL-1
(Fig. 4.8A), which falls within the range of non-specific permeabilization indicated by
LDH release and cell-staining data (Figs. 4.5, 4.7). There was a minimal difference in
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release of IL-1 from the sham cells in the two experiments 3.096
compared to 1.703

0.566 (mean

SEM)

0.844 pg IL-1 per 1 x 106 cells, suggesting that the macrophages

were overall less responsive to TUS, likely resulting in the decreased IL-1 release noted
for insonated macrophages. Analysis of TUS intensity from the sonication device was
maintained throughout experimentation, thus we concluded that the difference in response
was not related to reduced ultrasound energy. Specifically, the Omnisound 3000 delivered
374.4

4.1 mW/cm2 over the course of the variable temperature experiments compared to

380 ± 3.347 mW/cm2 from normal temperature experiments (Appendix B, Table B3),
demonstrating a minimal reduction of TUS energy delivered for 400mW/cm2.
Based on the results of this study, it appears that TUS exposure at (1 MHz, 400
mW/cm2 SATA, 20% PW, 10-minutes) results in increased release of cytokines via both
increased cellular permeabilization as well as through metabolic mechanisms. At least
four metabolic mechanisms have been proposed for IL-1 release from macrophages, these
include release of multivesicular bodies as exosomes, Ca2+-dependent release of lysosomes
and microvesicle shedding of membrane blebs, and direct release through the membrane
via specific membrane transporters 250. Given that changes in calcium flux in response has
been reported in fibroblasts, chondrocytes, and epithelial cells in response to TUS
exposure 49,50,65, it is reasonable to suspect that calcium-mediated mechanisms may be
involved in IL-1 release from macrophages exposed to TUS. U937 macrophages do
contain cell membrane-gated potassium (K+) channels 251-253. However, additional
research is need to determine whether a Ca2+ mediated process or some other metabolic
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process is responsible for the IL-1 release from macrophages in response to TUS that is
not accounted for by the increased permeability.
Conclusion
IL-1 release from macrophages in response to TUS appears to be due to a
combination of non-specific permeabilization and some form of cell-mediated release
mechanisms. Non-specific permeabilization was directly assessed using metabolic and
cytological assays, while specific cell-mediated mechanisms were indirectly assessed by
decreased response at sub-physiological temperatures. Additional experimentation is
needed to determine the specific cell mediated mechanisms of IL-1 release from
macrophages following exposure to TUS.
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Chapter 5

DISCUSSION and CONCLUSION:
Mechanism of Macrophage Response to TUS
The data presented here indicates that macrophages can play a role in TUSstimulated tissue healing. Macrophages responded to TUS exposure at 1 MHz,
400mW/cm2 SATA, 20% PW, 10-minute treatment by releasing IL-1 and VEGF. These
secretory peptides are paracrine factors involved with control of inflammation and
angiogenesis, which are integral activities for appropriate repair of damaged tissue 163,199.
Release of both mediators occurred within 10-minutes of TUS-exposure, and this
immediate response is most likely due to release of preformed products. Macrophages are
highly secretory cells, especially in the wound-healing milieu 164,168, and stimulation of
mediator release by TUS could provide an acceleration of processes normally controlled by
wound macrophages.
Initially, fibroblast proliferation was measured following incubation in media
conditioned by TUS-stimulated macrophages. TUS did not stimulate any fibroblast
mitogen release at any parameter set tested, as assessed by 24 and 48-hours of fibroblast
incubation in macrophage conditioned media. This is contrary to the findings of Young
and Dyson who reported that TUS-stimulated macrophage release of fibroblast mitogen
within 30-minutes of treatment when TUS was delivered at 1MHz, 500mW/cm2, SATA,
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CW, 5-minutes 161. While we could not confirm macrophage release of fibroblast
mitogens, the findings of IL-1 and VEGF release within 10 minutes of TUS-exposure in
the same cell type (U937 cells) studied by Young and Dyson does appear to support the
idea of TUS-stimulated release of pre-formed products that was posited by Young and
Dyson.
Methodological differences in the use of undifferentiated macrophages and CWTUS compared to use of differentiated macrophages and PW-TUS in the current study may
be the reason for the lack of fibroblast mitogen release noted here. Once differentiated,
macrophages assume a different phenotype from monocyte precursors and their overall
cellular activity is altered 168. Indeed U937 cells differentiated with agents like PMA have
been shown to respond differently to subsequent stimuli 254. Thus, it is plausible that the
PMA-differentiated macrophages assumed a phenotype that was unable to provide a
mitogenic signal for fibroblasts in the short post-TUS time frame. Direct comparison of
the response of U937 macrophages in various stages of differentiation to TUS would
provide significant insight into this aspect of TUS stimulation.
Differences in cellular response to TUS have been attributed to different duty
cycles 118. However, no additional in vitro investigations on duty cycle have been
reported, therefore there is no clear indication of what particular duty cycle is associated
with stimulation of particular cellular functions. It may be that cells respond to PW-TUS
signals differently than CW-TUS, which could result in a different release response. In
support of this hypothesis, a study of the effect of variable TUS duty cycles indicated that
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increased cell permeabilization is directly correlated to increasing duty cycle suggesting
differential cellular response to duty cycle 238.
On the other hand, the difference in response to duty cycle could be a function of
overall TUS energy transmitted to the cells. The fact that 5-minute exposures to TUS at 1
MHz, 400mW/cm2 SATA, 20% PW in the current study did not induce a significant
release supports this hypothesis. The stimulatory TUS at 10-minutes delivered twice as
much energy compared to 5-minute treatment, which suggests that some energy threshold
was required to generate the response reported in this investigation. In vitro investigations
reporting TUS-stimulation have utilized exposure times ranging from 3 to 20 minutes
8,112,162,177

. However, within study comparison of cellular response based on treatment

duration have not yielded consistent results of increased response due to increase energy
applied 7,98,112.
TUS has been reported to induce membrane permeabilization 236,239 which could
result in non-specific dumping of intracellular contents. The current investigation
confirms this hypothesis of TUS action. Given the immediate release response, we
analyzed macrophages for evidence of non-specific membrane permeabilization. To
accomplish this, conditioned media was analyzed for the presence of LDH, and TUStreated macrophages were visualized with fluorescent dyes that identify intact and
membrane-damaged cells. The same stimulatory TUS parameters for IL-1 and VEGF
release also induced LDH release (Figs 3.1, 3.2, 4.5). This finding indicates that nonspecific permeabilization was involved in the macrophage response. Similar to IL-1 ,
significant levels of LDH were released at 10 minutes post-TUS without additional
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measurable release at 1 hour. Further analysis of LDH content in experimental
macrophages revealed that the extent of LDH release stimulated by TUS was
approximately 10% of the total content in untreated macrophages (Fig. 4.6). This indicates
either a low level of LDH release from all cells or a small fraction of the total cells being
permeabilized.
Analysis of fluorescently-stained cells revealed that approximately 5% of cells
were permeabilized by TUS exposure (Figs 4.2-4.4, 4.7). Quantification of stained cells
underestimated the total cell area by nearly 6% (data not shown). As such, the data is
presented with the recognition that up to 11% of the cells were actually permeabilized.
Because that value was nearly the same as the percentage of LDH release, it appears that
the staining data provides confirmation of permeabilization identified by LDH release.
Furthermore, the staining data suggests that a limited number of cells were permeabilized
as opposed to slight permeabilization of all cells.
In efforts to identify the mechanism of the immediate release, we chose to
investigate further the mechanism of IL-1 release. VEGF release also appeared to be
non-specifically increased during the incubation period from 10-minutes to 1-hour
(Fig. 3.3). The fact that VEGF release was induced at the stimulatory parameters, and that
it continued to be released by all samples including sham indicates that TUS can enhance
an already active cell processes. Given the apparent constitutive release of VEGF, further
analysis of this growth factor would likely have been confounded by the constantly active
cells. TUS-induced IL-1 release appeared within 10-minutes and did not change over the
remainder of the incubation period. Like VEGF release, this response indicated that TUS
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induced an immediate cellular response (Figs. 3.1, 4.8). Because IL-1 release did not
continue to any measurable extent over the final 50-minutes of incubation, analysis of
mechanism of this cytokine provided a more discreet avenue of mechanism investigation.
Comparison of IL-1 release stimulated by TUS to total cellular content of IL-1
revealed that approximately one-third of measurable IL-1 was released in response to
TUS (Fig. 4.8). This fraction of the total represents a larger portion than was expected
based on the permeabilization data, and presents the possibility that another mechanism of
release was stimulated by TUS. TUS-exposure at variable temperatures (4 , 25 and 37
C) revealed an inhibition of release that was increasingly pronounced as temperatures were
lowered to 4 C (Fig. 4.9). Since lowered temperatures generally decrease cellular
metabolic processes 245,255, which includes exocytosis, the inhibition at decreased
temperature indicates that some form of exocytosis of IL-1 was likely stimulated by TUS.
Mechanisms of IL-1 exocytosis include release of multivesicular bodies as
exosomes, Ca2+-dependent release of lysosomes, Ca2+-dependent microvesicle shedding of
membrane blebs, and direct release through the membrane via specific membrane
transporters 249,250. TUS-stimulated exocytosis has been reported to be dependent on Ca2+
for chondrocytes and fibroblasts 49,50. Since macrophage exocytosis is partially dependent
on Ca2+, it is reasonable to hypothesize that TUS stimulated either lysosome release or
microvesicular shedding. However, cellular response to TUS is variable among cells,
evidenced by reports of response involving angiotensin II receptors, phosphorylation of
extracellular signal-regulated kinase (ERK) and increased expression of integrins ( 2, 5,
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and 1) in osteoblasts 125,256. As further evidence of the plethora of possible TUS
transducers in cells, fluid shear stress, which is likely the biophysical mechanism of TUS
on cells, activates membrane-bound G-proteins creating second messenger signaling in
endothelial cells 257. Macrophages transduction of TUS energy by any of these
mechanisms has not been directly explored, thus further directed experimentation is needed
to confirm a Ca2+-regulated mechanism of macrophage response.
TUS delivered at 1 MHz, 400mW/cm2 SATA, 20% PW stimulates release of
paracrine factors associated with tissue healing. Mechanistically, macrophages responded
to TUS through at least two mechanisms; non-specific permeabilization and some form of
cell-mediated exocytosis. Cell permeabilization is a well-known result of TUS exposure,
however, immediate cell-mediated exocytosis in response to TUS has not been previously
reported. Flux of calcium ions across the membrane is a possible mechanism of
macrophage response, given previous reports of Ca2+-regulated secretion from fibroblasts,
chondrocytes and keratinocytes. Continued research regarding the mechanism of release
response of macrophages should be focused on identifying the specific mechanism of IL1 release, as well as characterizing the cellular response based on the differentiation state
of the macrophages.
The current investigation explored only one facet of macrophage function during
wound healing, release of cytokines and growth factors. Given the numerous functions of
macrophages during healing (i.e., phagocytosis, release of proteases for matrix
degradation, release of chemokines, induction of neutrophil apoptosis), the effects of TUS
on those other aspects of macrophage activity should be explored. In addition, in vitro
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assay of macrophage response to TUS cannot simulate the wound healing environment
where many environmental factors influence cell activity and function. As such, the
importance of macrophage function in TUS-treated, healing tissue should be explored
using in vivo models where macrophages are depleted or rendered non-functional.
Lastly, since all experimental macrophages were induced to differentiate using
PMA, its role in the current results should be acknowledged. In U937 cells, PMA arrests
cell proliferation and stimulates expression of macrophage-like characteristics, but it does
not completely recapitulate naturally occurring monocyte-to-macrophage
differentiation 175,176. As described in a biochemistry review by Nelson and Alkon (2009),
PMA is one of the most potent of group of compounds that stimulates protein kinase C
activation, which results in various changes in cellular function, including DNA
transcription, protein synthesis, cell growth, cell proliferation and differentiation 260. In
addition, PKC activation leads to temporary down-regulation of PKC within the cell. This
change renders second messenger systems within the cell less responsive to signaling, and
as such can affect the cell’s response to stimuli. Given its potency, it is reasonable to
believe that PMA-induced activation of PKC likely affected cell functions beyond the
intended use in the current investigation for monocyte-to-macrophage differentiation. As
such, it is possible that the response of macrophages to TUS in the current series of
experiments is partially due to alteration in PKC-regulated cell activities. Investigations
using various differentiation agents and comparing macrophage response to TUS are be
important for understanding the possible role PMA-induced activity may have played in
the macrophage response to TUS reported here.
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APPENDIX A
Preliminary Experimentation With Macrophages Exposed to TUS and
Incubated 24-hours Post-Treatment
PREFACE: This appendix includes preliminary experimentation of therapeutic
ultrasound-induced (TUS) growth factor and cytokine release from macrophages. Due to
the limitations of the experimental methodology, the data included herein was not included
as part of the current series of investigations previously describe.

Therapeutic ultrasound has been reported to enhance tissue healing in models including
integument, ligaments, tendons and bones. TUS-enhanced healing is thought to occur via
alteration of cellular activities during the inflammatory and early proliferative phases of
healing. Specific cellular responses to TUS have been investigated in numerous cell types
including osteoblasts, periosteal cells, chondrocytes, fibroblasts, endothelial cells, and
leukocytes. Despite the volume of investigations into TUS effects on healing, few
investigations of TUS effects on macrophages have been reported. Because macrophages
are important mediators of inflammation and early proliferative phase of healing, where
TUS effects are thought to be greatest, the following set of experiments was undertaken to
explore the growth factor and cytokine release response of macrophages treated with TUS.
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Materials and Methods
Materials and Reagents. Phorbol 12-myristate 13-acetate (PMA), dimethyl
sulfoxide (DMSO), and lauryl sulfate (SDS) were obtained from Sigma Chemical Co., St.
Louis, MO. Tris and DC Protein Assay Kit were from BioRad Laboratories, Hercules CA.
Glycerol, HEPES, sodium hydroxide, hydrochloric acid, heat-inactivated fetal calf serum
(HIFCS) and sterile pipets were from Fisher Scientific, Pittsburgh, PA. BSA protein
standard was obtained from Pierce Biotechnology Inc., Rockford, IL. Human monocytic
cells (U937) and human gingival fibroblasts (HGF-1) were purchased from American Type
Culture Collection, Manassas, VA. Sterile tissue culture plates and centrifuge tubes were
from Corning Inc., Corning NY. Cell culture media reagents including: RPMI-1640
culture media and Dulbecco’s Modified Eagle’s Medium (DMEM), sodium pyruvate,
sodium bicarbonate, HEPES, L-glutamine, 0.25% trypsin, fetal calf serum and
penicillin/streptomycin/amphotericin B were purchased from Invitrogen, Carlsbad, CA.
ELISA antigen detection kits for IL-1 , VEGF, and TGF- 1 were acquired from R & D
Systems, Minneapolis MN. All other reagents were obtained from Invitrogen Corp.,
Carlsbad, CA.
U937 Cell Culture. All cell manipulations were conducted using sterile technique
as described in Chapter 2.
Cell differentiation and preparation for sonication. U937 cells induced to
differentiate into macrophages through the addition of phorbol 12-myristate 13-acetate
(PMA) 175. Differentiation of U937 monocytes was conducted as described in Chapter 2,
except: Following 24-hour differentiation in PMA-containing media, cells were incubated
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24hr in RPMI-growth media supplemented with 5% HIFCS. Differentiated macrophages
were subsequently exposed to TUS in RPMI-growth media supplemented with 5% HIFCS.
TUS Treatment of U937 Macrophages. For all experimental TUS exposures,
culture plates (samples) containing cells were treated using a system similar to that
described by Reher et al 177 as described in Chapter 2 (Fig. 2.1). Sham treated samples
were included for 5 and 10-minute exposure times (Table A1). Each experimental block
(set of TUS treatments) included each TUS parameter group (Table A1) for total of 14
parameter sets per experimental block. The order of application of each TUS parameter set
was randomized for each experimental block to reduce the possibility of experimenter bias
as previously described in Chapter 2. A total of n = 6 experimental blocks were
completed.
Preparation of Fibroblasts for Experimentation with Conditioned Media. HGF-1
aliquots were thawed, washed in plain DMEM and resuspended in DMEM growth media
and propagated under humidified incubation conditions as described in Chapter 2. From
each batch of fibroblasts, three separate 96-well plates were seeded with cells (for 24, 48
and 72 hour incubations). Seeded cells were placed in the humidified incubator for 4 hours
to allow adherence to the culture plate as described in Chapter 2. At the end of the
incubation period in serum-free DMEM, media was removed from each well and replaced
with 100 L of macrophage conditioned media and the fibroblasts were returned to the
incubator for 24, 48 or 72 hours. Fibroblast proliferation was assessed at the end of each
incubation period as described in Chapter 2.
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Fibroblast Proliferation Assay. Fibroblast proliferation following incubation in
macrophage conditioned media was analyzed using a Cell Proliferation Assay Kit as
described in Chapter 2.
Validation of WST-1 Assay for Cell Proliferation. The validity of the WST-1 assay
used to assess fibroblast proliferation was examined in relation to direct cell counts as
described in Chapter 2, except: 1) the validation assay included fibroblasts incubated for
72hrs prior to assay. 2) After the 24 hr incubation period in serum-free DMEM growth
media, the media was replaced with 100 l of RPMI growth media supplemented with 5%
HIFCS, which was identical to macrophage RPMI growth media utilized in the TUS
exposures.
ELISA assays for IL-1 , VEGF and TGF- 1. Analysis of conditioned media for
these growth factors was completed using commercially available, quantitative, sandwich
enzyme-linked immunosorbent assays (ELISA; R & D Systems, Minneapolis, MN) as
described in Chapter 3, except: Initial assays were completed for each cytokine ELISA to
determine the need to dilute conditioned media samples (Table A2). Dilution factors were
identified for IL-1 at 1:10 and for VEGF at 1:20 in order to have measurements were
within the detection range of the ELISA. For TGF- 1 samples were assayed undiluted.
Following ELISA, data collected was recorded as pg/ml of media, with final
concentrations in the conditioned media being calculated by multiplying the dilution factor
x ELISA value. The final cytokine growth factor concentrations (pg/ml) were then
normalized to total protein concentration (mg/ml) in the conditioned media, generating
values reported as pg cytokine/mg total protein.
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Data Analysis/Statistics.
Each experiment was repeated for n=6 replicates. Fibroblast proliferation in
response to macrophage conditioned media was assayed in duplicate wells and the mean of
the two values was reported. Conditioned media assayed for growth factors by ELISA,
and conditioned media analyzed for total protein concentration were analyzed in duplicate,
with the average being reported. All values for statistical analysis are reported as mean ±
standard error of the mean (SEM). Three-way analysis of variance (ANOVA) was used to
evaluate for differences in fibroblast proliferation and growth factor release among various
macrophage conditioned media to account for the effect of the independent variables:
treatment intensity (mW SATA), treatment frequency (1MHz, 3MHz) and treatment
duration (5min, 10min) (Sigma Stat version 2.03; Systat Software, Inc., Point Richmond,
CA). Post hoc analysis of significant differences was performed using Tukey’s HSD. A pvalue of < .05 was considered significant for all values. Data analysis for WST-1 assay
validation was completed using a correlation analysis on the variables of OD and cell
counts and was reported as R2 (coefficient of determination).
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Table A1
5 minutes

2

0 mW/cm (sham)

1 MHz
40 mW/cm2

3 MHz
40 mW/cm2

100 mW/cm2

100 mW/cm2

400 mW/cm2

400 mW/cm2

10 minutes
1 MHz
2

0 mW/cm (sham)

3 MHz
2

40 mW/cm

40 mW/cm2

100 mW/cm2

100 mW/cm2

400 mW/cm2

400 mW/cm2
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Table A1. TUS Exposure Parameters for 24-hour post-TUS macrophage incubation.
Exposure parameter combinations utilized for sonication of macrophages. All intensity
values are reported as SATA at 20% duty cycle. Sham treatments were completed for 5
minute and 10-minute exposures, in which the culture plates were secured in the sonication
apparatus but the ultrasound unit was not turned on. For each experimental block, the
order of application of TUS parameter sets to macrophages was randomized.
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Table A2

Growth Factor

Minimum (pg/ml)

Maximum (pg/ml)

IL-1

3.9

250

TGF- 1

31.2

2000

VEGF

15.6

1000
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Table A2. Detection ranges of the ELISA assays. Detection ranges of ELISA assay kits
(pg/ml) that were utilized to determine growth factor release by sonicated macrophages
incubated for 24-hours post-TUS.
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Results
Fibroblast Proliferation in Macrophage Conditioned Media. Proliferation of
fibroblasts was measured following 24, 48, and 72-hour incubation in conditioned media
from TUS-treated macrophages. Three-way ANOVA revealed that TUS intensity, TUS
wavelength frequency, and TUS treatment duration had no effect on fibroblast proliferation
in macrophage conditioned media indicating no release of a fibroblast mitogenic factor at
any level of TUS (Figs. A1 – A3).
Validation of WST-1 assay for Fibroblast Proliferation. Fibroblasts were plated at
serially diluted concentrations (8, 4, 2 and 1 x 103 cells/well) and were incubated for (A)
24 hours, (B) 48 hours or (C) 72 hours in serum-free macrophage growth media. Cell
proliferation assayed by WST-1 assay was compared to direct cell counting. WST-1
proliferation assay was strongly correlated with increasing cell number for (A) 24-hours,
R2 = 0.998, (B) 48 hours, R2 = 0.978, and (C) 72 hours, R2 = 0.939 (Figs. A1.4A-C).
Total protein determination. Total protein concentration of cell lysates was used as
an indirect measure of cell number and was then utilized for normalization of the cytokine
release data. Protein concentrations of samples were pooled based on the TUS treatment
intensity from among the 1 and 3 MHz and the 5 and 10-minute treatments. Total protein
concentrations were slightly less among treatment groups compared to sham control (Fig.
A5), but the difference between groups was not statistically significant in comparison of
any groups (ANOVA, p= 0.985, F = 0.391,).
TUS effects on release of IL-1 . IL-1 was measured by ELISA in the
macrophage-conditioned media 24 hours after TUS exposure. Values on figure A6
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represent mean ± SEM of n = 6 replicates that have been normalized to total protein in
macrophage cell lysate. Three-way ANOVA revealed no significant differences in IL-1
release based on any TUS parameter: intensity, p = 0.176, wavelength frequency, p =
0.471, and duration, p = 0.110.
TUS Effects on VEGF. VEGF was measured in the conditioned media of TUStreated macrophages following 24-hour post-treatment incubation. VEGF in the
conditioned media was normalized to total cellular protein isolated from sonicated
macrophages. Values in figure A7 represent mean ± SEM for n = 6 replicates. Three-way
ANOVA for the effects of TUS parameters revealed no significant effect on VEGF release
based on TUS intensity, p = 0.772, wavelength frequency, p = 0.744, or treatment duration,
p = 0.751.
TUS effects on TGF-β1 release from sonicated macrophages. TGF-β1 was
measured in conditioned media following TUS exposure and 24-hour post-TUS
incubation. TGF-β1 levels were normalized to total cellular protein isolated from lysates
of sonicated macrophages. All values are expressed as mean of n = 6 samples ± SEM.
Similar to IL-1 and VEGF, TGF-β1 was detected in all samples including sham control
(Fig. A8). Three-way ANOVA revealed a significant effect of TUS wavelength frequency,
where 1 MHz exposure was associated with increased TGF-β1 release, when compared to
release in response to 3 MHz exposure (p = 0.025). There was a trend toward increased
TGF-β1 release for 10-minute treatments compared to 5-minute treatments (p = 0.061) and
for treatments administered at 400mW/cm2 (p = 0.082) although those trends did not reach
statistical significance.
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Figure A1. Fibroblast proliferation in response to 24-hour incubation in macrophage
conditioned media. Fibroblast proliferation was assessed using WST-1 assay and reported
as optical density units. Collapsed data across the TUS wavelengths and treatment
durations demonstrates the three-way ANOVA analysis for intensity. (A) No level of TUS
stimulated macrophage release of fibroblast mitogens into the conditioned media (p =
0.577). Effect of TUS wavelength frequency (B). Collapsed data across the TUS intensities
and treatment durations demonstrates the lack of an effect by exposure wavelength (p =
0.176). Effect of TUS treatment duration (C). Collapsed data for TUS treatment duration
demonstrates no effect of treatment time among all the TUS intensities and wavelength
frequencies investigated (p = 0.230). All data represent mean SEM of n = 6 experiments
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Figure A2
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Figure A2 Fibroblast proliferation in response to 48-hour incubation in macrophage
conditioned media. Fibroblast proliferation was assessed using WST-1 assay and reported
as optical density units. Collapsed data across the TUS intensity, wavelengths and
treatment durations demonstrates the three-way ANOVA analysis for each TUS parameter
variable. No intensity, wavelength frequency or treatment duration of TUS-exposure
stimulated macrophage release of fibroblast mitogens into the conditioned media at 48
hours. Collapsed data across (A) TUS Intensity (p = 0.247), (B) TUS wavelength (p =
0.628) and (C) TUS treatment duration (p = 0.862), demonstrates three-way ANOVA
analysis of the effect on each variable on macrophage release of fibroblast mitogens. All
data represent mean SEM of n = 6 experiments.
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Figure A3
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Figure A3. Fibroblast proliferation in response to 72-hour incubation in macrophage
conditioned media. Fibroblast proliferation was assessed using WST-1 assay and reported
as optical density units. Collapsed data across the TUS intensity, wavelengths and
treatment durations demonstrates the three-way ANOVA analysis for each TUS parameter.
Collapsed data across (A) TUS Intensity (p = 0.480), (B) TUS wavelength (p = 0.685) and
(C) TUS treatment duration (p = 0.587), demonstrates three-way ANOVA analysis of the
effect on each variable on macrophage release of fibroblast mitogens. No significant effect
of TUS on release of fibroblast mitogen was found among any of the TUS treatment
parameters at 72 hours. All data represent mean SEM of n = 6 experiments.
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Figure A4
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Figure A4. Validation of WST-1 assay for Fibroblast Proliferation. Comparison of direct
cell counting and WST-1 colorimetric assay for determination of cellular proliferation.
Fibroblasts were plated at serially diluted concentrations (8, 4, 2 and 1 x 103 cells/well) and
were incubated for (A) 24 hours, (B) 48 hours or (C) 72 hours in macrophage growth
media. Cell proliferation assayed by WST-1 assay was compared to direct cell counting.
WST-1 proliferation assay was strongly correlated with increasing cell number for (A) 24hours, R2 = 0.998, (B) 48 hours, R2 = 0.978, and (C) 72 hours, R2 = 0.939.
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Figure A5
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Figure A5. Protein concentration of macrophage cell lysates following TUS exposure and
24 hr incubation period. Experimental samples from the same TUS treatment intensity
were pooled from 1 MHz and 3 MHz frequency and from 5 and 10-minute treatments.
Values are expressed as mg/ml ± SEM. Percentages indicate comparison of the protein
content of sonicated samples compared to protein content of control samples and range
between 97.1 – 97.5% of sham).
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Figure A6
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Figure A6. IL-1 release from macrophages 24-hours after exposure to TUS. IL-1 was
measured by ELISA in the conditioned media 24 hrs after TUS exposure. Values represent
mean ± SEM of n = 6 replicates that have been normalized to total protein in cell lysates.
Three-way ANOVA revealed no significant differences in IL-1 release based on any TUS
parameter: intensity, p = 0.176, wavelength frequency, p = 0.471, and duration, p = 0.110.
Figures A-C exhibit the pooled values for IL-1 release based on TUS intensity, TUS
treatment duration and TUS wavelength frequency. (A) Comparison of TUS Intensity.
Data has been collapsed for each intensity among the 5 and 10 minute treatment durations
and among the 1 MHz and 3 MHz wavelength frequencies. (B) Comparison of TUS
Treatment Duration, Collapsed data for 5 and 10-minute treatments among all intensities
and wavelengths, and (C) Comparison of TUS Wavelength Frequency, Collapsed data for
1 and 3 MHz among all intensities and treatment durations.

205

Figure A7
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Figure A7. VEGF release from macrophages 24-hours after exposure to TUS. VEGF
was measured in the macrophage conditioned media following 24-hour incubation
following sonication. VEGF in the conditioned media was normalized to total cellular
protein isolated from sonicated macrophages; values represent mean ± SEM for n = 6
replicates. (A) Pooled values for each TUS intensity among 5 and 10-minute treatments
and 1 and 3 MHz application. TUS intensity had no effect on VEGF release from treated
macrophages at 24-hours post-TUS (p = 0.772). (B) Pooled values for 1 and 3 MHz
among each TUS intensity and 5 and 10-minute treatments. There was no effect of either
TUS wavelength frequency on VEGF release at 24-hours post-TUS (p=0.744). (C) Pooled
values for 5 and 10-minute treatments among each intensity and wavelength frequency.
Treatment duration had no effect on VEGF release 24-hours post-TUS (p = 0.751).
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Figure A8
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Figure A8. TGF-β1 release from macrophages 24-hours after exposure to TUS. TGF-β1
was measured in conditioned media following TUS exposure and 24-hour post-TUS
incubation. TGF-β1 levels were normalized to total cellular protein isolated from lysates of
sonicated macrophages. All values are expressed as mean of n = 6 samples ± SEM.
Values are pooled for each independent variable (A) TUS intensities among the
wavelength and durations, (B) TUS wavelength among all intensities and durations, and
(C) TUS treatment duration among all intensities and wavelengths. Three-way ANOVA
revealed a significant effect of TUS wavelength frequency indicated by *, where 1 MHz
exposure was associated with increased TGF-β1 release, when compared to release in
response to 3 MHz exposure (p = 0.025). Treatment intensities and treatment duration did
not demonstrate a significant effect on TGF-β1 release (p=0.061 and p=0.082,
respectively). However, there was a trend toward increased TGF-β1 release for 10-minute
treatments compared to 5-minute treatments and for treatments administered at
400mW/cm2.
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Discussion
Three-way ANOVA revealed no differences in fibroblast proliferation following
incubation up to 72 hours in conditioned media from TUS-treated macrophages based on
any TUS variable assessed (Figs. A1-A3). As such, it appeared that macrophages did not
respond to TUS at 20% pulsed-wave, 40-400 mW/cm2 SATA, 5 or 10 minute exposure by
releasing mitogenic factor(s) for fibroblasts.
In addition, TUS parameters did not affect the release of IL-1 (Fig. A6) and
VEGF (Fig. A7) from macrophages exposed to TUS and incubated 24 hours posttreatment. TGF- 1 release from macrophages was affected by TUS wavelength frequency,
where 1 MHz exposure increased release when compared to TUS delivered at 3 MHz.
Despite statistical significance, the difference in release of TGF- 1 induced by TUS at 1
MHz compared to 3 MHz (622.058

46.060 pg/mg total protein vs. 593.205

43.392

pg/mg total protein) is quite small in comparison to total release.
Limitations. The original experimental design included sham-treatments that
provided a negative control against the other experimental samples. However, the
experimental design lacked a positive control for fibroblast proliferation. It is possible that
the fibroblasts in our model were at their peak proliferative ability prior to addition of
macrophage conditioned media. Under those conditions, additional mitogenicity from the
macrophage conditioned media would not enhance proliferation, and no differences among
treatment groups would be identified. Also, it is possible that the growth factors that are
normally contained within the 5% HIFCS contributed to increased fibroblast proliferation
across all samples. This effect may have overridden the effect of any added mitogens
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present in the macrophage conditioned media, resulting in the equal number of fibroblasts
in all experimental groups. Furthermore, a negative control of unconditioned media is
desirable to allow analysis of the experimental media on fibroblast proliferation and
determine any proliferative or inhibitory effects of media alone.
Concerning cytokine and growth factor data, the conditioned media containing 5%
HIFCS may have provided measurable amounts of the proteins assessed. Since no
unconditioned, 5% HIFCS-containing media was analyzed by ELISA, the possibility of
serum/media altering the ELISA assays cannot be refuted.
For all assessments, the incubation period of macrophages following TUS exposure
may have contributed to the non-stimulatory results noted above.

Incubating

macrophages for 24 hr may have allowed a constitutive release of mitogens to overwhelm
the immediate release due to TUS, thereby eliminating the ability to determine whether any
changes in TUS-treated macrophages actually occurred. To insure the validity of the
“negative” proliferative data and cytokine release data, these experimental limitations are
addressed by changes in and additions to the original experimental protocol and resulted in
refinement of methodology described in Chapters 2-4.
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Appendix B

Energy Emission Measurement for the Omnisound 3000 Ultrasound Generator

PREFACE: This appendix describes testing of the energy emission for the TUS generator
utilized for treatment of macrophages in all experiments described in previous chapters.
Testing of energy emission was completed in an effort to ensure repeatable treatments
(based on intensity) throughout experimentation.

TUS Energy Emission Measurement. All ultrasound treatments were completed
using an Omnisound 3000 ultrasound generator with a 5 cm2 transducer containing a lead
zirconate titanate crystal (Accelerated Care Plus Corp, Sparks, NV). The Omnisound 3000
maintains a beam non-uniformity ratio (BNR) < 4:1 and an effective eradiating area (ERA)
of 5.0 cm2, while producing a collimated cylindrical beam when applied. This unit is
commonly used in clinical applications of TUS and permits a wide variety of intensities,
and duty cycles at 1 or 3 MHz.
To insure comparable energy output between experiments, actual TUS energy
emission from the ultrasound generator was measured using an UPM-DT10 ultrasound
power meter (Ohmic Instruments Co., Easton, MD). This instrument uses the radiant force
method to measure the ultrasound power output of diagnostic and therapeutic ultrasound
transducers. Ultrasonic energy is passed through de-gassed water to a submerged conical
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target. The radiant power transmitted to the target during ultrasound exposure is
proportional to the total downward force (weight). An electro-mechanical load cell of the
UPM-DT10 measures this force and converts force measures into power measures using
the following equation: p = Wgc where;
p = power in watts
W = measured force in grams
g = acceleration in dynes
c = velocity of ultrasound in centimeters/second
Ultrasound watt density (mW/cm2) was calculated manually by converting the watt values
into milliwatts and then dividing the milliwatts values by the cross sectional area of the
transducer (Ohmic Instruments, UPM-DT10 operators manual).
Pre-experiment and post-experiment measurements were completed for each TUS
experiment. TUS exposures from the Omnisound 3000 ultrasound generator at various
intensity and frequency levels (Table B1) were applied to the UPM-DT10 and power
measurements recorded. This process was completed immediately prior and immediately
after each sonication experiment to insure intra and inter experiment consistency of
ultrasonic exposure. Testing for 100mW/cm2 was completed only for 24-hour
experimentation as this level of intensity was not utilized in the short-duration
experiments.
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Table B1

TUS Treatment Intensity

Omnisound 3000 settings
1 MHz

3 MHz

40mW/cm2 SATA

200 mW/cm2 at 20%

200 mW/cm2 at 20%

100W/ cm2 SATA

500 mW/cm2 at 20%

500 mW/cm2 at 20%

400mW/ cm2 SATA

2000 mW/cm2 at 20%

2000 mW/cm2 at 20%
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Table B1. Ultrasound Power (Intensity) Analysis Testing Parameters. Ultrasound
intensity and parameter settings for the Omnisound 3000 TUS generator utilized prior to
and immediately after each ultrasound experiment. Analysis consisted of three different
intensities (40, 100, 400 mW/cm2 SATA) delivered using 1 or 3 MHz wavelength
frequency immediately before and immediately following each experimental block of
sonications.
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Data Analysis/Statistics.
Differences between pre-experiment and post experiment measurements were
analyzed for each TUS parameter set (Table A5.1). For 24-hour post-TUS incubation
period, values represent mean

SEM for n = 6 experiments. For short duration

experimentation (10-minute and 1-hour) values represent mean

SEM for n = 5

experiments.

Results
Omnisound 3000 Energy Measurements. TUS energy emittance was assessed
immediately prior to and immediately following each experiment to insure consistent
ultrasound delivery. TUS delivered with 3 MHz at 40, 100 and 400 mW/cm2 and with 1
MHz at 400mW/cm2 showed consistent ultrasound energy emittance throughout the 10minute and 1-hour incubation experiments (Tables B2 and B3). No significant differences
were found among pre and post testing for 24-hour experiment at any level of TUS. For
the short duration experiments, TUS delivered with 1MHz at 40mW/cm2 showed a
statistically significant variation (p = 0.040) when pre and post values were compared
using a t-test (Table B3). Actual energy variation was approximately 4mW/cm2 from pre
to post testing.
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Table B2
40mW/cm2

100mW/cm2

400mW/cm2

1 MHz Pre-TUS

44.64 ± 1.23

105.33 ± 2.23

374.67 ± 6.25

1 MHz Post-TUS

44.00 ± 1.03

105.33 ± 1.69

372.67 ± 4.43

p-value (pre to post)

0.687

1.00

0.799

3 MHz Pre-TUS

44.00 ± 1.03

88.67 ± 1.91

324.67 ± 5.60

3 MHz Post-TUS

46.00 ± 1.71

90.00 ± 1.71

336.00 ± 3.43

p-value (pre to post)

0.341

0.615

0.115
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Table B2. Omnisound 3000 Ultrasound Generator Energy Emission at 1 MHz and 3 MHz
for 24hr post-TUS incubation experiments. Data reported as mean ± SEM of n = 6
replicates for pre-TUS and post-TUS values. Comparison between pre and post
experimental values was completed using a t-test for each pre/post pair. Analysis revealed
no significant differences among any pre-post pair indicating consistent energy emittance
of the Omnisound 3000.
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Table B3
40mW/cm2

400mW/cm2

1 MHz Pre-TUS

36 ± 1.265

378.4 ± 11.496

1 MHz Post-TUS

40.8 ± 1.497

380 ± 3.347

p-value (pre to post)

0.040

0.897

3 MHz Pre-TUS

41 ± 0.980

344 ± 5.215

3 MHz Post-TUS

39.2 ± 1.497

338.4 ± 3.250

p-value (pre to post)

0.217

0.389
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Table B3. Omnisound 3000 Ultrasound Generator Energy Emission at 1 MHz and 3 MHz
for revised experiments with 10-minute and 1-hour incubations. Data was collected using
the UPM DT10 power meter and is reported as mean ± SEM of n = 5 replicates for preTUS and post-TUS energy emittance values. Comparison between pre and post
experimental values was completed using a t-test for each pre/post pair. Analysis revealed
a significant difference between pre and post energy levels when applied using 1MHz at 40
mW/cm2. All other tested parameters were not significantly different from pre to post
experimentation.
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Discussion
Omnisound 3000 Ultrasound Generator: Measurement of Exposure Intensities.
Ultrasound energy emission at the experimental TUS parameters was measured before and
after each sonication experiment. Over the entire course of experimentation, TUS energy
emission remained nearly constant at each intensity level. Student’s t-test comparisons
among intensity levels demonstrated no significant difference between any pre/post
measurements indicating the TUS generator emitted consistent doses throughout the
completion of all ultrasound exposure experiment sets outlined in Table B2. Although
TUS energy delivery remained essentially constant throughout the experimental sets,
differences were recorded when comparing actual TUS energy and the Omnisound 3000
intensity display.
For 1 MHz treatment frequency, intensity settings closely matched with actual
energy emission measured. However, for 3 MHz wavelength, intensity settings at 400
mW/cm2 produced only 324 to 336 mW/cm2. The possibility exists that this decreased
overall energy, compared to 1 MHz, 400mW/cm2 muted the cellular response to this
parameter set of TUS. As such, 3 MHz exposure at 400mW/cm2 could have induce
macrophage release with an intensity comparable to that at 1 MHz. Additional
experimentation using 3 MHz wavelength and fully comparable output intensities should
be performed to clarify this issue.
In addition to the intensity difference noted at 1 and 3 MHz, pre to post testing for
1 MHz, 40 mW/cm2 SATA was found to be significantly greater at post-testing (Table
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B3). The measured difference in intensity before and after experimentation indicates a
slight increase (4.0

1.497 mW/cm2) in TUS intensity from beginning to end of a daily

experiment set for the short duration (10-minute and 1-hour) experiments. To prevent any
bias in treatment parameter set usage, delivery of specific parameters sets were randomized
for each daily experiment such that the order of parameter exposures were varied among
the experiments. This treatment randomization should have reduced any effect of
increasing TUS intensity from beginning to end of each experiment. In addition, no effects
occurred with TUS exposure at 40 mW/cm2 regardless of wavelength frequency, or
treatment duration assessed. Thus, the difference noted in those pre-post intensity testing
do not appear to have influenced the findings described in this investigation.
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